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CHAPTER I 
 
INTRODUCTION 
 
1.1 Problem Statement 
     Oral inflammatory disease in the United States is widespread, with the vast majority 
of adults exhibiting clinical manifestations of gingivitis or periodontitis.1  It is well known 
that microbial pathogens are an integral component of the pathogenesis of periodontal 
diseases.2  Approximately forty years ago, the concept that bacteria functions as a 
biofilm community began to emerge.1  Further evidence has revealed the complex 
organization of biofilm and the corresponding relationship between the colonies.1  Oral 
plaque biofilm balance is attributed to the transition from oral health to disease, and the 
pathogenicity of biofilm is inherently reduced through effective oral hygiene.3  
     Gingivitis is typically diagnosed through the observance of inflammation in the 
gingival tissue with the absence of clinical attachment loss.4  Inflammation is the innate 
reaction of the human body to cellular injury, and oral inflammation is characterized by 
changes in gingival color, contour, and consistency.5  If gingival inflammation is not 
reversed through improved oral hygiene or professional prophylaxis, coronal alveolar 
bone resorption and damage to the junctional epithelium resulting from the apical shift 
and breakdown of collagen fibers develops, and the subsequent development of 
periodontal disease occurs.4 
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     Similar to natural gingivitis, experimental gingivitis is the result of microbial plaque 
formation.6,7  In clinical research, the experimental gingivitis model is used to evaluate 
the resultant inflammatory response to the oral microflora as the process of moving from 
gingival health to gingivitis occurs in a controlled environment.7   
     Emergent evidence of a relationship between biofilm, inflammation, oral health, and 
systemic diseases such as cardiovascular disease, diabetes, and chronic respiratory 
disease  affirms the importance of maintaining proper oral health.5   Colgate Total® 
toothpaste contains triclosan, which is a broad spectrum antimicrobial, and a 
polyvinylmethyl ether maleic acid copolymer (PVM / MA) binder to increase the uptake 
and retention of triclosan to the enamel and buccal epithelium.8  This unique formulation 
has been shown to provide up to 12 hours of antimicrobial protection, invariably 
inhibiting biofilm growth.5,8  Furthermore, it has also been shown to be effective at 
reducing plaque accumulation and subsequent gingival inflammation, potentially 
restricting bacterial infection and the progression of periodontal disease.5,8   At the 
present time, Colgate Total® is the only dentifrice formulated with triclosan that is 
available for use in the United States.8 
     A comprehensive review of the literature revealed several previous clinical studies 
that have focused on the effects of triclosan containing dentifrices on the oral 
microflora.9–12   A meta-analysis of 16 studies comparing Colgate Total® to a fluoride 
toothpaste determined that Colgate Total® did significantly reduce gingival bleeding and 
improve gingival health.10  However, there is a lack of evidence in the literature to 
support the effects of Colgate Total® toothpaste on microbial pathogens in the total 
absence of mechanical interruption of plaque biofilm.  The results of this research are 
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important because they provide evidence of the reduction of pathogenic microbes in the 
oral cavity in the absence of mechanical plaque removal.  The results of this study may 
improve the oral health of those who are incompliant with oral hygiene 
recommendations, and those with compromised manual dexterity such as the elderly, 
arthritic, or the developmentally disabled.   
1.2 Goal Statement 
     The goal of this proposed study was to conduct a pilot, randomized, controlled, 
clinical trial to determine the effect of Colgate Total® toothpaste on microbial pathogens 
in plaque biofilm samples during an experimental gingivitis model.   
1.3 Specific Aims 
The purpose of this clinical research study was to:  
1) Determine the effect of Colgate Total® toothpaste on microbial pathogens in plaque 
biofilm samples during an experimental gingivitis model in the absence of mechanical 
interruption of plaque biofilm.  
With respect to the study objective, the following alternative hypothesis was 
constructed: 
1a) Colgate Total® toothpaste, as compared to a standard of care toothpaste, will be 
more effective in reducing microbial pathogens in plaque biofilm samples during the 
experimental gingivitis model.   
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1.4 Significance 
     Although evidence exists to support the clinical efficacy of Colgate Total® toothpaste, 
little is known of the effect of this dentifrice on microbial pathogens.  The results of this 
study provide evidence of the true effect of Colgate Total® toothpaste on gingival health 
and plaque biofilm samples in the absence of mechanical plaque biofilm removal during 
an experimental gingivitis model, and substantiate the need for further research on this 
topic. 
1.5 Thesis Overview 
     A detailed overview is presented to facilitate insight of this thesis.  A comprehensive 
Review of the Literature is depicted in Chapter II, and is divided into twelve primary 
subsections, including the history of microbial pathogens, the concept of bacteria as 
biofilm, biofilm development in the oral cavity, oral diseases associated with biofilm, 
natural vs. experimental gingivitis, indices for assessing plaque and gingival 
inflammation, microbial analysis, Colgate Total® toothpaste, triclosan, polyvinylmethyl 
ether maleic acid copolymer, clinical efficacy of Colgate Total® toothpaste, and triclosan 
dentifrice / mouthrinse formulations available in other countries.  Chapter III outlines the 
Materials and Methods utilized during the study, and the subsequent Results of the 
statistical analysis are presented in Chapter IV.  This section is followed by Chapter V, 
the Discussion and interpretation of the study results, and the thesis Conclusion is 
portrayed in Chapter VI.
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
2.1 History of Microbial Pathogens 
           Microbial pathogens are a fundamental component of the pathogenesis of 
periodontal disease.2 The initial concept of a relationship between microbial pathogens 
and infectious disease occurred more than 480 years ago through the work of the Italian 
physician Girolamo Fracastoro.13  His theories involving the source of syphilis infections 
set the precedent for one of the critical junctures in the history of microbes, the germ 
theory of disease.13  
     The distinctive and pervasive nature of microbes was affirmed through the invention 
and advancement of microscopy.14  Plaque microorganisms were first observed 
microscopically in the late 17th century by the Dutch botanist Anton van Leeuwenhoek, 
initiating the concept of a relationship between microbes and infectious disease.1,2,14   
His primitive microscope was similar to the performance of present day light 
microscopy, and provided unique visualization which sustained the first evidence of the 
etiologic determinants of infectious disease.14  Furthermore, this advance in technology 
provided a rationale for scientists to establish the etiology of several systemic 
diseases.15
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      The next century yielded the development of the vaccination process by William 
Jenner, when he discovered that milkmaids in contact with cowpox were immune to 
smallpox infection.13   Although he lacked knowledge of the biological means of 
withstanding disease, or the host’s immune response to another disease agent, what 
began as an experiment emerged as an enduring method of preventing disease 
transmission.2   In the 1970’s, the last cases of smallpox were reported, and this disease 
became the first infection to be completely eliminated from humanity.13   
     In the late 19th century, the germ theory of disease was developed through the work 
of Louis Pasteur, a chemist, and Robert Koch, a German professor of public health, 
providing a novel approach for observing and combatting disease, and yielding 
confirmation that bacteria indeed induces disease.13  Through his scientific work, 
Pasteur unveiled the broad existence of microbiology, and invented the process of 
pasteurization, which destroyed microbes in milk, and prevented the spread of 
infectious disease.13  His determination that bacteria is the etiology of disease led to the 
breakthrough of surgeon Joseph Lister’s use of carbolic acid as an antiseptic during 
procedures.13,15  In addition, he is credited with the development of new vaccines, 
including those to treat rabies and anthrax.13  Koch’s primary contribution was through a 
process he developed known as “Koch’s Postulates,”  which were composed of four 
developmental and analytical measures to determine if a microbe was related to a 
specific disease.13,15  His assumption was that through eliminating or decreasing 
pathogens, the disease progression may cease or at a minimum be reduced.15  He also 
formulated the development of solid nutrient media, which unveiled the use of pure 
culture to isolate organisms.16  His work led to the identification of the bacteria known to 
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cause tuberculosis, anthrax, wound infections, and cholera, which increased awareness 
among his students and competitors in the quest for relating microbes to their resultant 
disease.13,14    
     The turn of the century marked the continued emergence of the existence of 
microbiology.13  In the late 1890’s, Dmitri Ivanowski, a Russian microbiologist, and 
Martinus Beijerinck, a Dutch botanist, detected unknown microbes uninhibited by filters 
used to block the passage of bacteria, which were named “filtrable viruses”.13  The 
study of microbiology then embarked on a new  path, with many researchers using 
scientific theory to determine the pathogenesis of disease and modes of prevention.13  
However, many biologist were skeptical due to the tiny size of the microbes.13  In the 
1930’s, advancements in microscopy revealed the complex structure of bacterial cells, 
and biologists began to show interest in microbiology; consequently, these separate 
entities began to unite.13   
     In 1929, the discovery of penicillin in mold by Alexander Fleming provided an 
innovative approach to combat bacterial disease.13  During the 1960’s, advances in 
medicine due to new antibiotics and vaccines increased  the presumption of infectious 
disease control and treatment through the subjugation of microbial pathogens.13  
Expanded knowledge of bacteria and viruses led to the determination of pathogenic 
versus probiotic microbes, and the notable increase in life expectancy was largely 
attributed to these microbiological advances and the development of antibiotics.13  
However, the discovery new infectious diseases such as the Acquired Immune 
Deficiency Virus, Human Immunodeficiency Virus, and Hepatitis Virus revealed this was 
not the case.13  These viruses expanded further the field of biomedical and 
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microbiological research, and have led to a close and continual evaluation of our 
existence with microbes.13 
2.2 Concept of Bacteria as Biofilm 
    In the 1970’s, the concept of bacteria functioning as biofilm began to emerge.1  The 
next two decades conveyed evidence of the complex organization of attached bacteria, 
and how the combination of different microbes constitutes bacterial plaque.1  
Approximately ninety-five percent of all bacteria in nature constitutes as biofilm.17  A 
biofilm is described as an aggregation of microbiological cells encompassed in a sessile 
matrix community, that thrives on neighboring accessible nutrients for survival and 
growth.5,6   Different microbes are known to frequently combine with one another, and 
then further combine with additional microbes to generate a substantial bacterial mass.1  
Microscopic evidence has revealed the intricate organization of biofilms, with small 
surface colonies proliferating into structured, larger colonies that collaborate with one 
another.1   
     Numerous chronic bacterial infections are composed of biofilms, and are often not 
readily treated through conventional antibiotic therapy. 1  In addition, approximately half 
of all infectious diseases that are found in slightly compromised hosts can be related to 
organisms that are located in the environment or the human body.1  Different biofilms 
share common clinical characteristics, including a preference for inert surface or dead 
tissue, but can also form on living tissue.1  Furthermore, biofilms tend to grow at a slow 
rate in multiple locations, and can be slow to produce symptoms; as a result,  biofilms 
are uncommonly resolved through the host defense mechanisms, and this is true even 
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for individuals with healthy immune systems.1  Although antibiotics have been shown to 
decrease the planktonic cells released from the biofilm, they fail to completely destroy 
the bacteria by failing to completely penetrate the biofilm, resulting in recurring 
symptoms until the biofilm is detached from the body.1   
2.3 Biofilm Development in the Oral Cavity 
     Once supragingival plaque accumulates, a unique biofilm consisting of motile 
organisms and gram-negative, anaerobic microbes, manifests subgingivally.18   The 
biofilm is by definition attached to a surface, whether it be a tooth, host-mediated 
material adjacent to the tooth, the epithelium, or other microbes that have adhered to 
these areas.18  The interactions between these organisms have a vital function to their 
survival and growth.18 Emergent evidence has shown through recent microbial 
ecosystem diversity analysis, a new perspective of the transition from health to disease 
is related to a change in the overall balance of the oral microflora, instead of the 
presence of specific individual periodontal pathogens.19  Increased understanding of the 
oral microbiome is important to dentistry because through improved diagnosis, clinicians 
may be able to determine if periodontal disease is present before clinical signs are 
manifested.19  Although it is undesirable and impossible to completely eliminate dental 
biofilm, the pathogenicity can be diminished through bioburden reduction and proper 
oral hygiene.17  Current research is focusing on the molecular and genetic structure of 
biofilm formation, and comprehensive systems-level analysis of the relationship 
between the host and the microbiome.19  Classification of the putative pathogens 
associated with oral biofilm has been arduous, despite thorough analysis of the 
microbes affiliated with oral disease.20  Oral biofilms are distinguished, readily 
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attainable, and contain a paramount affiliation with disease and health in humans.20  
Although approximately half of the oral microbial flora can be cultured through standard 
means, there are many organisms that are impossible to culture, which inhibits 
comprehensive discernment of oral biofilm compostition.20  Once the oral biofilm 
attaches to a surface, the flora endures in a dynamic, “microbial homeostasis.”20 The 
biofilm customarily exists together with its host, encouraging the host defense against 
invading pathogenic microbes, and creating the subsequent physiologic host 
response.20  Periodically, there may be a disruption in the biofilm-host association due 
to environmental conditions including poor oral hygiene, dietary intake, salivary flow 
rate, and the host defense mechanisms, resulting in oral disease.20,21 
2.4 Oral Diseases Associated with Biofilm 
     The most prolific oral diseases, including enamel caries, periodontitis, and gingivitis, 
are associated in part with biofilm formation.16  The progression of oral disease 
development is episodic, and is detrimental to the social, economic, and physical well-
being of those afflicted with these diseases. 22 Oral disease is widespread, with 
socioeconomic status  inherently related to oral disease risk, and those living in poverty 
disproportionately affected.22,23    
     Globally, the World Health Organization estimates that dental caries effects between 
sixty and ninety percent of all school aged children, and the vast majority of adults.23  
Furthermore, severe forms of periodontal disease affect fifteen to twenty percent of 
adults between the ages of 35 and 44, and approximately thirty percent of individuals 
between the ages of 65 and 74 are completely edentulous.23   
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     In the United States, almost all adults demonstrate clinical symptoms of gingivitis or  
periodontitis, with severe forms of periodontitis affecting about fourteen percent of those 
between the ages of 45 to 54, and increasing to twenty-three percent for those between 
the ages of 65 and 74.22  Although decreasing, the number of edentulous U.S. adults is 
approximately thirty percent.22   Dental caries is the most common disease in American 
children, and is five times more common than asthma.22   
     Maintaining oral health is crucial to overall health and well-being.22,23  Dental caries, 
periodontal disease, and gingivitis are preventable through patient education, proper 
oral hygiene, a healthy diet of fruits and vegetables, decreasing sugar consumption, 
fluoride exposure, and avoidance of alcohol and tobacco use.22,23  In addition, the use of 
a dentifrice with anticaries and antigingivits properties such as Colgate Total® may 
prove beneficial for oral disease prevention and overall health promotion. 
a. Dental Caries 
     Dental caries is the most common childhood disease, with more than seventy 
percent of children in the United States diagnosed with caries by the age of 
seventeen.24  Caries development is multifactorial, and results from acidic products of 
bacterial fermentation of carbohydrates, leading to the breakdown of enamel and 
dentin.25  This breakdown occurs through a combination of established oral bacterial 
biofilm on a tooth surface, and the oral environment balance.25  The oral environment is 
dependent on several aspects of the oral cavity, including the individuals dietary intake 
(particularly sugar), amount of fluoride in plaque and enamel,  buffer capacity, flow rate 
and viscosity of saliva, and the quantity and types of microbes present.25  Once the pH 
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reaches a critical level, demineralization of the tooth structure begins, and can invariably 
progress through enamel, the dentin, and reach the pulp.25  If left untreated, the 
infection can subsequently spread to the oral tissues and alveolar bone.25 
Microbes Affiliated with Dental Caries 
     The most prominent pathogenic microbes associated with dental caries are 
Streptococcus mutans and Lactobacillus.25  S. mutans is theorized to be the primary 
etiologic microbe associated with dental caries, with Lactobacillus more prominent in 
secondary development, including dentinal caries.25   Both of these microorganisms 
thrive in acidic environments, and have the capability to quickly metabolize sugars to 
acid.25  As the caries proliferate into dentin, the microbial composition becomes more 
complex, and includes species from Bifidobacterium, Parvimonas, Rothia, Actinomyces, 
Eubacterium, and Lactobacillus.25    
     16S rRNA molecular studies of advanced caries revealed a preponderance of S. 
mutans and Lactobacillus organisms, with the presence of Selenomonas, 
Fusobacterium, Psuedoramibacter, Prevotella, Dialister, and Bifidobacterium also 
noted.25  Caries progression is dependent on the amount and frequency of carbohydrate 
exposure, in particular dietary glucose and sucrose, and the tooth’s vulnerability to 
caries development, such as the occlusal surface of molars.25  Furthermore, the amount 
of Lactobacillus organisms found in the oral flora is relative to carbohydrate exposure.25   
Current research has also focused on detecting possible genetic links relative to caries 
development.25    
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b. Periodontal Disease 
      Periodontal disease is a common oral infection characterized by clinical attachment 
loss, alveolar bone breakdown, and chronic inflammation associated with an increased 
systemic inflammatory response.26  Gram-negative, anaerobic oral bacterial biofilms are 
often found in individuals with periodontal disease.1   Over the past three to four 
decades, extensive research has provided evidence that the etiology of periodontal 
disease is predominantly related to plaque pathogens.18,27   In addition to these 
pathogens, the observable traits and the rate of disease progression are dependent on 
both genetic, lifestyle, and acquired components, which are important determinants of 
developing plaque induced periodontal disease infection.4   
Classifications of Periodontal Disease 
     There are seven classifications of periodontal disease, including: 1) gingivitis, 2) 
chronic periodontitis, 3) aggressive periodontitis, 4) periodontitis as a manifestation of 
systemic disease, 5) necrotizing periodontal disease, 6) abscesses of the periodontium, 
and 7) periodontitis associated with endodontic lesions.4   Each of these classifications 
has the potential to progress, albeit acutely or chronically, and be unresponsive to 
active treatment.4  Because the mode of progression from gingivitis to periodontitis has 
not been substantiated,  the exact mechanism of initial periodontal disease induction is 
unknown.28   However, environmental and lifestyle factors such as smoking, 
uncontrolled diabetes, and lack of patient compliance have been shown to contribute to 
disease recurrence.29   Furthermore, it has been established that symptoms of gingivitis 
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can manifest in individuals previously diagnosed with periodontal disease that currently 
appear to be stable.4 
Non-Specific vs. Specific Plaque Hypothesis  
     There are two theories for determining the etiology of periodontal disease 
progression, the non-specific and specific plaque hypothesis.15  Initially, the non-specific 
plaque hypothesis was widely accepted.18  The essence of this theory is that all 
microorganisms are inherently associated with periodontal disease, oral diseases are 
the result of plaque mass accumulation, and inflammation is prevented and eliminated 
through the complete mechanical removal of plaque bacteria.30  In addition, this theory 
disregards any possibility that the diverse structure of bacterial colonies is relative to 
pathogenicity, and fails to substantiate why some areas of gingival inflammation fail to 
progress into periodontitis.30  This hypothesis fell out of favor as evidence emerged of 
the qualitative differences between oral plaque during periodontal health and disease.18    
     The specific plaque hypothesis is based on the concept that certain plaque 
pathogens are the etiologic agents of periodontal disease, with the individual 
inflammatory and systemic immune response as the basis for cellular difficulty.15  As the 
specific plaque hypothesis became apparent, emergent measures for determining 
periodontal pathogens were incorporated, and include the host immune response, 
virulence, association, elimination of pathogens, risk assessment, and animal studies.18   
     Once it was determined that the oral microbial community primarily consisted of 
gram-positive microorganisms, and then shift to primarily gram-negative composition as 
the plaque accumulates and inflammatory processes proliferate, Socransky and 
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associates developed the concept of five “complexes” for the subgingival microflora, 
based on associations of specific groups of bacteria with each other and with disease 
status.15  This approach ascertained that the microbiological environment is generated 
by the individual microbes, and that the relationship between the microbes determines 
the extent of disease.15 
Host Immune Response 
     The host immune response is beneficial due to the production of antibodies aimed at 
the species, which function distinctly with the putative pathogen.18  In addition, the ability 
of the pathogen to initiate disease may also be useful in determining pathogenicity.18  
The response of the human immune system is generally classified as either innate or 
adaptive (acquired) immunity.31  Both of these immune responses, combined with 
physiological and anatomical barriers (such as salivary lysozymes and intact skin), 
protect the human host from invading pathogens.31   
     The innate immune system begins the inflammatory response shortly after the 
invading pathogen attacks the host.31  The innate response utilizes a minor amount of 
invariant receptors to locate infectious pathogens, and offsets this by focusing on large 
numbers of pathogens with common microbial elements.31  In addition to the pivotal role 
it plays in the host defense mechanism to invading infectious pathogens, innate 
immunity has a decisive role in the regulation of the inflammatory response due to 
human disease, and enhances the defense provided by the physiological and 
anatomical barriers.31   
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     The adaptive immune response is generated after the initial innate immune response 
to the invading pathogen.31  Antigen exposure forms antibodies and the subsequent 
adaptive response, with T- and B- lymphocytes functioning as the primary defense 
mechanisms.31  A large variety of randomly chosen receptors allow the adaptive 
immune response to identify numerous antigens, which differs from the small amount of 
receptors used in the innate response.31  Although innate immunity occurs in all 
multicellular species, adaptive immunity is formed only in complex vertebrates and 
jawed fish.31  The host’s defense to the invading pathogen is accomplished through 
collaboration of both the innate and adaptive immune systems.31 
Microbes Affiliated with Periodontal Disease 
     The microbes affiliated with periodontal disease include A. actinomycetemcomitans, 
B. forsythus, P. micros, P. gingivalis, S. intermedius, C. rectus, P. intermedia, E. 
nodatum, and Treponema sp.2,18  These organisms are prevalent in both gingivitis and 
periodontitis, but are more prolific in subjects with advanced periodontitis.32   Ramseier 
and colleagues conducted a clinical study to determine if putative host- and microbially 
derived biomarkers are capable of identifying the presence of periodontal disease using 
plaque biofilm and whole saliva.33  Ninety-nine human subjects were equally recruited 
into a healthy/gingivitis group or a periodontitis group and divided into four subgroups 
prior to data analysis.33  Subgingival plaque biofilm species were analyzed including A. 
actinomycetemcomitans, C. rectus, F. nucleatum, P. intermedia, P. gingivalis, T. 
forsythia, E. corrodens, and T. denticola.33  When comparing the healthy/gingivitis group 
to the periodontal pathogen group, biomarker data derived from the plaque pathogen 
samples revealed that  T. denticola, P. gingivalis, T. forsythia, P. intermedia, and C. 
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rectus demonstrated significant differences (p <0.001), whereas F. nucleatum and E. 
corrodens did not.33 The ability of these pathogens to identify periodontal disease was 
greater when paired with the salivary biomarkers, which included MMP-8, MMP-9, 
Calprotectin, IL-Iβ, ICTP, IL-6, and TNF-α, among others.33  In addition to the 
pathogenic microbes in the oral flora, the individual systemic immune response, 
smoking status, and systemic disease are vital components in the development and 
progression of gingivitis and periodontitis.34   
     There is limited knowledge to date of microbial succession in supra and sub gingival 
plaque in both healthy and diseased subjects, and the identification of specific time 
periods of bacterial pathogen colonization and growth would aid clinicians in the 
prevention and management of periodontal disease.35 A recent study by Teles and 
colleagues evaluated the early ecological succession of bacterial organisms throughout 
seven days of abstinence from oral hygiene after professional removal of sub and 
supragingival plaque from both healthy subjects and subjects with periodontal disease,  
to determine if the species return at similar rates in both groups.35  Overall, the 
subgingival plaque samples demonstrated fewer significant differences in the 
proportions of the organisms, which suggests that the subgingival ecosystem may take 
more time to redevelop, which may be due in part to the bacterial cells that were not 
removed during professional cleaning.35  Significant changes in subgingival biofilm 
development were noted at later time points in the periodontal patients when compared 
to the healthy patients, but by day seven, more significant changes were observed in 
the periodontitis group.35  Although the biofilm mass returned within days following the 
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cleaning, the climax community customary of the supra and subgingival tooth surfaces 
was not fully reestablished over the course of this study.35  
The Relationship between Periodontal Disease and Systemic Disease 
    The detrimental effect of periodontal disease in the oral cavity is well documented.  
The prevalence of periodontal disease is widespread, with approximately 80 percent of 
people in the United States exhibiting some form of periodontal disease.24  Emergent 
evidence of a relationship between oral health and systemic diseases such as 
cardiovascular disease, diabetes mellitus, and chronic respiratory disease affirms the 
importance of maintaining proper oral health.3,5,36,  Currently, over 27 million adults in 
the United States are diagnosed with cardiovascular disease, 26 million are diagnosed 
with diabetes mellitus, and 15 million are diagnosed with chronic obstructive pulmonary 
disease.37–39   Inflammatory mediators including interlukin-1 (IL-1), IL-6, and C-reactive 
protein have a suspected role in generating systemic inflammation.3   Researchers 
continue to explore the relationship between periodontal disease and systemic disease, 
and additional information may yield an explanation to substantiate the extent of the 
biological basis of this association.5    
Cardiovascular Disease       
     Cardiovascular disease is defined as the accumulation of inflammatory plaques that 
can lead to thrombosis and future myocardial infarction.5  There are several theories to 
explain the statistical association between cardiovascular disease and periodontal 
disease, and include risk factors common to both conditions (such as tobacco use), or a 
specific consequence related to periodontal disease.40  In addition, evidence has 
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implicated inflammation, systemic infection, and autoimmunity induction as potential 
components of the pathophysiology relative to these two diseases.40  Atherosclerosis is 
an inflammatory condition that results from plaque accumulation in the arteries from 
cardiovascular disease.5  Initial atherosclerotic plaques are comprised of neutrophils, 
monocytes and lymphocytes.5  Once monocytes become macrophages, inflammation is 
generated by inflammatory mediators, and the plaque enlarges, possibly causing 
thrombosis or myocardial infarction.5   Analysis of atherosclerotic plaque lesions found 
in carotid arteries revealed that 40 percent demonstrated antigens consistent with 
periodontal pathogens including P. gingivalis, P. intermedia, and T. forsythia.5  
Furthermore,  platelet aggregation can be induced by  P. gingivalis, suggesting a 
possible mechanistic relationship between oral microbial pathogens and 
atherosclerosis.5   
     Joshipura et al conducted a cross-sectional evaluation of data taken from the  
prospectional Health Professional Follow-up Study (HPFS) investigation of 468 men to 
evaluate the relationship between periodontal disease, tooth loss, and specific 
biomarkers in blood.26 The results revealed an association between periodontal disease 
and elevated serum levels of biomarkers of endothelial dysfunction and dyslipidemia 
including CRP, t-PA, and LDL-C, which are known to be risk factors for cardiovascular 
disease.26  Men without periodontal disease had a 30 percent lower level of CRP, and 
the biomarkers t-PA, vWF, and LDL-C were 11 percent lower when compared to men 
with periodontal disease.26  A meta-analysis of 29 observational studies found that 
subjects with periodontal disease had a 34 percent higher risk of developing 
cardiovascular disease than those without diagnosed periodontal disease.40  This 
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analysis provides further evidence of a relationship between oral health and systemic 
disease. 
Diabetes Mellitus 
     Diabetes mellitus is described as a group of systemic conditions defined by a 
heightened quantity of blood glucose, which are associated with periodontal disease.5,41  
The relationship between these conditions is two-fold, with periodontitis shown to 
exacerbate poor glycemic control in diabetics when compared to subjects without 
diabetes, and diabetes increasing the risk of periodontitis.5,41   It is theorized that 
because of an increase in systemic inflammation, diabetics are prone to infection, and 
bactericidal cell activity is inhibited; therefore, the prevalence and extent of periodontal 
disease devastation in diabetic subjects is elevated.5  In addition, the inflammatory 
reaction to periodontal pathogens in diabetics is thought to encourage the development 
of periodontal disease.41    
     There have been numerous studies that provide evidence of the oral-systemic link 
between diabetes and periodontitis.  In a meta-analysis of 48 clinical studies by Taylor, 
44 studies (seven prospective and 37 cross-sectional) revealed evidence of diabetes as 
a risk factor for periodontal disease.42  Furthermore, an examination of the data from the 
National Health and Nutrition Examination Survey (NHANES) III by Tsai et al of 4,343 
individuals found that those with poorly controlled diabetes mellitus had a significantly 
greater prevalence of severe periodontal disease than those without diabetes.43   The 
results of these studies provide further evidence of the relationship between periodontal 
disease, inflammation, and systemic disease.   
21 
 
Chronic Respiratory Disease 
     In addition to cardiovascular disease and diabetes mellitus, systemic lung diseases 
such as chronic obstructive pulmonary disease (COPD) and nosocomial pneumonia 
infection have also been associated with periodontal disease.5,36  COPD is widespread,  
ranking third on the list of death causes in the United States in 2011, and resulting in the 
loss of over 120,000 lives annually.22,39   The resultant airflow obstruction is irrevocable, 
and leads to the disability of many individuals.22  
     Several recent studies have found a connection between oral health and chronic 
respiratory disease.3,44   Scannapieco and Ho reviewed data from the NHANES III study 
and found a possible relationship between periodontal clinical attachment loss severity 
and individuals with COPD, with those having both periodontal disease and COPD 
exhibiting greater attachment loss when compared to those with periodontal disease 
without COPD.45  In addition, the results appeared to reveal a decrease in lung function 
in those with COPD relative to the degree of clinical attachment loss.45   A case-control 
study of 634 individuals conducted  by Wang and colleagues determined a significant 
association between periodontal health and COPD.3,44   An additional cross-sectional 
study of 392 subjects by Liu et al revealed an association between some indicators of 
periodontal health and COPD exacerbations.3  Furthermore, a 25 year longitudinal of 
1,118 men found that alveolar bone loss significantly elevated the risk of COPD, and the 
degree of severity of alveolar bone loss increased the risk of COPD throughout the 
follow-up period.46  The results of these studies substantiate the need for further 
exploration of the relationship between periodontal disease as it compares to known 
causes of chronic respiratory disease such as smoking.36 
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c. Gingivitis 
    Gingivitis is the initial inflammatory response to microbial plaque accumulation, and is 
the only reversible classification of periodontal disease. 4  Gingivitis is widespread; it is 
estimated that more than fifty percent of all Americans exhibit clinical signs of 
gingivitis.36  Plaque accumulation occurs within hours of the absence of oral hygiene, 
and the process of moving from gingival health to disease occurs within a matter of 
days.36   Once adequate oral hygiene resumes, the clinical signs of gingivitis rapidly 
diminish.47   
     Gingivitis is diagnosed during a periodontal examination by the observance of 
inflammation in the gingival tissue with the absence of clinical attachment loss.4  
Inflammation is the innate reaction of the human body to cellular injury, and is marked 
by changes in color (redness), contour (swelling) and consistency, often exhibiting heat 
and pain.5  Gingival inflammation can then progress, resulting in coronal alveolar bone 
resorption, which, combined with the breakdown and apical shift of collagen fibers from 
the junctional epithelium and cementum, leads to periodontal disease.4 
2.5 Natural vs. Experimental Gingivitis 
     Both natural and experimental gingivitis develop due to an aggregation of microbial 
plaque.6,7  The experimental gingivitis model differentiates from natural gingivitis in that 
it was established to evaluate both the initiation and resolving of gingival inflammation 
during a limited period of time, while being monitored by trained and calibrated 
examiners.7  Subjects are chosen from a pool of volunteers who are free of periodontal 
and systemic disease, and meet the inclusion and exclusion criteria.7  The treatment 
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area is covered with a fabricated stent similar to an occlusal guard, and the subjects 
refrain from brushing this area during the 21 day study period.7  Clinical measurements 
including plaque and gingival crevicular fluid samples, gingival and plaque indices, and 
saliva samples are assessed at baseline, on specific days throughout the 21 day study 
period, and on the day 35 follow up visit.7  After the 21 day test period is complete, the 
subject receives a thorough prophylaxis to remove the plaque and calculus 
accumulation.7  Although the composition of microbes affiliated with natural gingivitis 
differ from experimental gingivitis (see sections 2.5 a. and 2.5 d.), the experimental 
gingivitis model is useful for studying inflammation as it reacts to the increase in 
microbial plaque accumulation, without causing permanent adverse effects to 
periodontium.7   
a. Natural Gingivitis 
     As microbial plaque aggregates, colonization begins and the flora becomes more 
complex, and gingivitis is induced.6  Clinical characteristics of gingivitis are intermittent, 
consisting of bouts of acute inflammation, which are a precursor to periodontitis.6  
Inflammation protects the host from potential infection by delivering antibacterial 
components from adjacent cells, restoring tissue function, and shielding the body from 
the detrimental effects of this damage.5   
     Gingival  health is considerably affected by the inflammatory process.5  Acute 
inflammation develops quickly and does not perpetuate, whereas chronic inflammation 
found in periodontal disease persists over an extended period of time.5  Histologically, 
inflamed tissue contains large numbers of leukocytes, macrophages and lymphocytes, 
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which manifest as tissue necrosis and fibrosis, and result in both local and systemic 
damage.5   
     As a component of gingivitis diagnosis, microbial pathogens and gingival crevicular 
fluid (GCF) samples may also be analyzed.4   Research has shown that inflammatory 
mediators in GCF including prostaglandin E2 and cytokines such as IL-1α and IL-1β 
have been associated with gingival disease.4,5,48  Plaque biofilms emit several biologic 
components, which in turn generate micro-environments in which the organisms must 
adapt for survival.5,17  The gram- positive and gram-negative bacteria in the biofilm 
subsequently colonize interproximally and near the gingival margin, resulting in  pro-
inflammatory byproducts such as protein toxins and endotoxins.5  These byproducts 
permeate the epithelium and trigger the host immune response, which ultimately induce 
gingivits.5   As the  inflammation continues to progress, further mediators such as pro-
inflammatory cytokines are created, which incite the movement of monocytes, T-cells, 
and neutrophils to the region.5  Elevated serum levels of chemical mediators such as IL-
1, IL-6, fibrinogen, and C-reactive protein are found in individuals with chronic gingivitis, 
as well as those with periodontitis.5  Once active periodontal therapy is completed, 
clinical inflammation diminishes, and the levels of these chemical mediators decline.5    
b. Microbes Affiliated with Natural Gingivitis 
     There are several components related to the progression from gingival health to 
gingival inflammation, including the presence and colonization of microorganisms, and 
the host response to this process.18  When compared to samples taken from healthy 
subjects and those with periodontal disease, microbial plaque samples in subjects with 
25 
 
gingivitis differ in composition.18  Microanalysis of oral plaque pathogens found in 
gingivitis demonstrates elevated quantities of microbes, including gram-negative 
organisms, filaments, and motile rods.18  In a study conducted regarding the 
microbiology of gingivitis, Moore and colleagues discovered that a high preponderance 
of organisms found in periodontitis were present in smaller quantities in subjects with 
gingivitis.49 
     The microorganisms most commonly associated with gingivitis include those from 
the Prevotella, Capnocytophaga, Streptococcus, Fusobacterium, and Actinomyces 
species.18,49  In addition, Eikenella corrodens, Eubacterium nodatum, Campylobacter 
gracilis, Peptostreptococcus micros, and Campylobacter concisus are also frequently 
found in subjects with gingivitis.18,49   Certain organisms, including Treponema species, 
Bacteroides forsythus, Campylobacter rectus, Veillonella parvula, Porphyromonas 
gingivalis, Prevotella intermedia, and Actinobacillus actinomycetemcomitans serotype a 
are present in both gingivitis and periodontitis, with smaller quantities of organisms 
noted in subjects with gingivits.18  Furthermore, the quantity of organisms found in 
periodontal disease is significantly higher than those found in periodontal health.18   
c. History of the Experimental Gingivitis Model 
     The experimental gingivitis model was introduced in the 1960’s by Dr. Harald Loe, 
Dr. Else Theilade, and Dr. S. Borglum Jensen.50  Their groundbreaking clinical 
experiment to induce gingivitis in subjects with healthy gingiva through the absence of 
oral hygiene allowed them to analyze the succession of oral microbes and subsequent 
gingival inflammation.50  Currently, the experimental gingivitis model is used in clinical 
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research to evaluate the resultant inflammatory response to the oral microflora as the 
process of moving from gingival health to gingivitis occurs.   
     For their first experimental gingivitis study, Loe and colleagues used twelve subjects 
who were either students or employees at their dental school.50   The subjects were 
initially examined and scored with the Gingival and Plaque Index System, and were 
assessed for periodontal disease with the Periodontal Index System.50  After the initial 
examination, the subjects were instructed to refrain from all oral hygiene practices for 
the duration of the study.50  The subjects were reexamined with the same criteria at 
different time intervals based on the each individual’s experimental period length .50  
Once a microbiological evaluation and a complete index was documented, and an 
inflammatory response was evident, the subjects were given explicit instructions on the 
use of wood and brush massage sticks to use for oral hygiene twice daily for rest of  the 
experiment.50   The examiner continued to evaluate the gingival and plaque scores 
during the oral hygiene phase, and the experiment concluded once the scores neared 
zero.50  Microbial analysis of all subjects occurred in a range of six to ten intervals 
ranging  from baseline until gingivitis was induced.50  The final microbial analysis 
occurred once gingival health was restored.50  The microbial types included gram 
positive cocci, spirochetes, filaments, short rods, fusobacteria, and vibrios.50  In 
addition, the location and size of leukocyte existence was noted at each time interval.50   
The results of the study showed generalized plaque accumulation for all study subjects 
during the absence of oral hygiene, with a mean plaque index increase from 0.43 to 
1.67, and a mean gingival index increase from 0. 27 to 1.05.50  Once oral hygiene 
resumed, the scores decreased significantly.50  The number of days for gingivitis to 
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clinically manifest varied; for three subjects, it took ten days, and the remaining nine 
subjects ranged from fifteen to twenty one days.50  The gingival change assessment 
revealed increased inflammation interproximally when compared to the buccal gingiva, 
with the lingual gingival index demonstrating  the lowest scores.50  The interproximal site 
of maxillary molars exhibited the highest gingival index scores, and the lingual site of 
the mandibular premolars had the lowest scores.50  One week after oral hygiene 
resumed,  the entire group saw a marked decrease in inflammation and gingival index 
scores, from 1.05 to 0.11.50 The initial microbial sample analysis revealed few 
microorganisms; however, once oral hygiene ceased, the microbial count expanded 
significantly, and was similar amongst all subjects with the exception of one.50   There 
were three marked stages in microbial colonization during this experiment.50  The initial 
phase  was distinguished by large amounts of desquamated epithelial cells 
encompassed by coccal organisms, and a few leukocytes.50  Approximately two to four 
days after oral hygiene ceased, the second phase began, and revealed large amounts 
of slender rods and filamentous shaped organisms in addition to the still abundant 
cocci.50  In addition, the second phase also saw an increase in leukocyte aggregation.50  
It is noteworthy that one of the twelve subjects began the experiment with phase two 
microbial composition.50  The microbial shift from phase two to three was not as 
discernible, as it progressed more slowly and at different points of time.50  The transition 
to phase three typically occurred six to ten days after oral hygiene had ceased, and was 
marked by the addition of spirochetes and vibrios to the cocci, rods and filaments 
present in the flora.50   Two of the subjects did not have visible spirochetes in their 
microscopic samples, but they displayed numerous vibros.50  Leukocyte aggregation 
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was considerably abundant during phase three, and remained until the diagnosis of 
gingivitis was delegated.50  Upon resumption of oral hygiene and return of gingival 
health, the final bacterial samples were taken, and ten of twelve subject’s samples 
displayed a majority of short rods and cocci.50  The other two samples showed an 
abundance of filamentous microbes, but vibrios or spirochetes were not observed in any 
of the twelve samples.50  Although there were limitations to this study, the authors were 
able to establish the abundant increase and change in plaque microorganisms during 
the absence of mechanical plaque removal, and subsequent degree of change in 
gingival health.50   
     As a follow up to their initial experiment, Theilade and colleagues again embarked on 
another study, this time utilizing a longitudinal approach.51  Initially, all of the subjects 
demonstrated excellent oral hygiene and gingival health, similar to the first study.51  
Once oral hygiene practices ceased, the plaque began to accumulate significantly, and 
the gingival index scores increased significantly as well, until they reached 1.0, which 
was considered mild gingivitis.51  The amount of time it took to develop gingivitis within 
the group of subjects was relatively the same, and corresponded to the amount of 
plaque accumulation.  Three subjects developed gingivitis in nine to thirteen days, five 
subjects developed gingivitis in fifteen days, and three subjects developed gingivitis in 
seventeen to twenty-one days.51  The group that took the longest time to develop 
gingivitis also developed plaque accumulation slower than the other two groups. 51 
However, for the time to reach a gingival index score of 1.0, the total plaque 
accumulation amongst the subjects was the same.51  Additionally, the total plaque 
accumulation did not variate significantly between the maxillary and mandibular arches; 
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however, the interproximal areas exhibited the highest accumulation, while the oral 
surfaces (excluding the mandibular molars) displayed the lowest.51  Incisor teeth 
showed the highest variability, with the interproximal areas showing heavy plaque 
accumulation, and the oral surfaces exhibiting significantly less amounts.51  In regard to 
the gingival index scores, there was not as much variability as the plaque index scores, 
with the interproximal scores being the highest, and the oral areas of the incisors the 
lowest.51  In addition, the facial and lingual scores of the maxillary molars were a bit 
lower than the corresponding mandibular molars.51  Once oral hygiene was reinstated, 
the plaque and gingival index scores quickly returned to their original numbers, and the 
time to return to gingival health was roughly the same for all subjects.51  Examination of 
the Periodontal Index System revealed no adverse effects of the gingival changes 
during the experimental period.51  The change from a coccal flora to a filamentous flora 
took about 2 days (range one to four days) after oral hygiene ceased, and spirilla and 
spirochetes were observed after about seven days (range four to nine days) after oral 
hygiene ceased.51  Visible characteristics of gingivitis clinically coincided with the 
development of the more complex flora in the areas.51  However, it usually took seven 
or eight days from the time when total complex oral flora was developed in the area of 
the two maxillary left premolars until the participants had manifested generalized 
gingivitis.51  When oral hygiene practices resumed, the change in the oral flora quickly 
returned to baseline levels.51  Nine of eleven subjects’ spirochetes and spirilla vanished 
within 24 hours of resuming tooth brushing, and in seven of eleven, the fusobacteria 
and leptotrichia were undetectable after 24 hours.51  In ten of eleven cases, cocciform 
bacteria were the only ones visible once gingival health had returned.51  Leukocytes 
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were undetected in the initial samples, but after four days of abstaining from hygiene, 
they were present in almost all samples, and continued to increase in amount and 
throughout the duration of the oral hygiene abstinence period.51  
      The purpose of this experimental gingivitis study was to attempt to establish a 
relationship between the bacterial oral flora of certain tooth surfaces, and the gingival 
condition of same tooth surfaces.51  The results demonstrated that in these areas, the 
gingival index score corresponded to the oral flora in the plaque, and  that slight 
gingivitis could be diagnosed at the approximate time the flora began to proliferate.51  
Furthermore, sub clinical inflammation was demonstrated earlier through the presence 
of leukocytes, and may be related to the initial phase of plaque formation.51 The authors 
speculated their findings may implicate that the induction of gingivitis is related to the 
early changes in bacteria in the oral flora, expanding the findings of their initial study.51 
    There have been numerous other experimental gingivitis studies since these time-
honored experiments, which have further substantiated the evidence between bacterial 
plaque accumulation and gingival health.52   A study by Trombelli and colleagues 
utilized a randomized, split mouth localized experimental gingivitis trial to determine if 
and the extent to which the clinical parameters assessed during an experimental 
gingivitis model (such as plaque and gingival index scores) can be duplicated at 
separate times within certain populations (such as groups from previous studies who 
were identified as having different gingival inflammatory response to plaque 
accumulation).53  Second, the consistency to develop a high or low gingival 
inflammatory response within these groups was evaluated.53   
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     The results of this study reveal that a proportion of the subjects (50-59%), regardless 
of their initial classification of low or high responder, had a consistent high or low 
inflammatory response to the plaque accumulation during the repeat trial, and that this 
gingivitis model can be somewhat reproduced in selected populations when using well 
controlled, experimental conditions.53  There was a statistically significant difference in 
regard to time and quadrant for the plaque index and cumulative plaque exposure.53 
The plaque index and cumulative plaque exposure scores in the test quadrants 
increased from day zero to day twenty-one.53  In the control quadrants, the plaque index 
and cumulative plaque exposure scores remained similar to baseline, and were 
significantly different from the test-quadrant measurements at days seven, fourteen, and 
twenty-one.53  In addition, statistically significant increases in the gingival index and the 
angulated bleeding score were observed in the test quadrants over the course of the 
trial.53  The control quadrant gingival index and angulated bleeding score stayed close 
to zero throughout the trial, and were significantly different from the test parameters on 
days seven, fourteen, and twenty-one for both the angulated bleeding score and the 
gingival index.53  When comparing the data from the two trials, no significant differences 
in the plaque index and angulated bleeding score were noted.53  Gingival index scores 
were higher in the second trial, and were consistent in terms of the temporal changes 
throughout both trials in both groups.53 Ten out of seventeen low responder subjects 
showed low susceptibility to inflammation after the second trial, and ten of twenty high 
responder subjects showed a high susceptibility to inflammation.53   The results of this 
study reveal that the plaque and inflammation parameters during this experimental 
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gingivitis model are somewhat reproducible, and that a certain proportion of subjects 
are consistent with their response to plaque accumulation.53 
     A recent study by Lee et al used the experimental gingivitis model in a randomized, 
controlled, clinical trial of thirty subjects to ascertain how periodontal pathogens and 
biomarkers are modulated during bacterially induced gingival inflammation, and 
determine if they can use these results to coin individuals with a high response to 
gingivitis.54  Mean gingival index, plaque index, and papillary bleeding score showed a 
significant increase during the experimental gingivitis induction, and decreased during 
the resolution when assessed at Day 35; however, no differences were observed in the 
IL-1 groups.54  Participants were classified as either high or low responders depending 
on their inflammatory response, with a high gingival index >1.5 and a low gingival index 
< 1.5.54  The baseline levels of salivary IL-6 and IL-8 revealed the highest capability to 
ascertain between the high and low responders.54  Salivary biomarkers, MMP’s, and 
bacterial biofilm were combined to develop receiver operating characteristic curves.54 In 
this study, Fusobacterium species appeared to predispose subjects to an elevated 
inflammatory response, with high responders possessing a microbiological profile that 
could elevate colonization of periodontal pathogens.54  The results of this study 
substantiate previous findings by demonstrating the use of saliva as an effective way to 
monitor critical gingivitis biomarkers, and that the combination of objective baseline 
parameters is very predictive of high responders related to the acute bacterial challenge 
during the experimental gingivitis model.54  The microbial and clinical responses to the 
abstinence of oral hygiene were relatively consistent with previous experimental 
gingivitis studies.54  This study also demonstrates that subjects with elevated baseline 
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levels of IL-6 and MMP-1 are at a higher risk of developing an elevated gingival 
inflammatory response when compared to subjects with low levels of these 
biomarkers.54 Consequently, the results of this study could determine the microbiologic 
profile and biologic host response in the acute phase of gingival inflammation.54  
d. Microbes Affiliated With the Experimental Gingivitis Model 
     A significant increase in the plaque accumulation during an experimental gingivitis 
model differs from traditional gingivitis, with the plaque accumulation demonstrating  
elevated quantities of Actinomyces organisms, which represents fifty percent or more of 
the microbes.27  Furthermore, when compared to traditional gingivitis, experimental 
gingivitis plaques generally consist of gram-positive organisms consistent with those 
observed in subjects with healthy gingiva.27   
     Syed and Loesche performed a study to determine the effect of plaque age on 
microbes during an experimental gingivitis model.55  The results demonstrated that 
succession of microbes is noted in oral plaque, and that Actinomyces were the  
predominant  species throughout the three week study period.55  Once the subjects 
reached the second and third week time interval, there was a significant increase in the 
both the relative amount and number of gram-positive rods, which occurred to the 
detriment of the gram-positive cocci.55  The relative amount and number of the gram-
negative species was consistent, but at the three week interval, the percentage of 
Campylobacter (Vibrio) sputorum isolates demonstrated a significant percentage of 
growth.55  When compared to the quantity of Streptococcus and Actinomyces noted, the 
vibrios comprised a very small amount (1.2%) of the total organisms present.55  The 
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most significant quantity of succession in the early (zero and one week) plaques was 
observed with Streptococcus organisms, and the Actinomyces organisms were 
predominant in the later plaques (two and three week), and increased not only 
absolutely, but also relatively, with Actinomyces israelii the most observed organism.55  
Veillonella species comprised fifteen to twenty percent of all colony forming units 
throughout the entire three week study period.55  In addition, the amounts of other gram-
negative organisms proliferated throughout the study, but at week three, they accounted 
for less than five percent of the total colony forming units.55  These findings indicate that 
if total plaque accumulation is relative to gingivitis formation, then Actinomyces 
organisms had a significant role in the development of gingival inflammation in this 
experimental gingivitis study.55 
2.6 Indices for Assessing Plaque and Gingival Inflammation 
      Indices to characterize gingival inflammation and plaque accumulation are often 
used in clinical research to provide parameters for clinicians to delineate the difference 
between health and disease.56  The majority of gingival indices are comprised of 
minimum and maximum criteria scores on a ranked system, and utilize either bleeding, 
contour, color, crevicular fluid measures, or degree of involvement.56  Numerical indices 
are relatively simple to use in epidemiological surveys and clinical trials, but are 
constrained by the lack of a ratio scale.56  In addition, gingival indices are used to 
examine gingival appearance, which is not necessarily indicative of periodontal 
devastation.56   
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a. PMA Index 
     In the 1950’s, the PMA index was developed to assess gingival health, and has been 
modified and used in clinical research repeatedly over the past few decades, with a 
particular benefit to pediatric research.56  In this approach, the gingiva is divided into 
sections and is founded on the assertion that the interdental papilla (P) is the initiation 
site of inflammation, the inflammation then progresses to the marginal site (M), and in 
extreme circumstances, affects the attached gingiva (A).56  Each area (P,M,A) is scored 
between zero and four, and it is hypothesized that the inflammatory location could be 
indicative of the degree of inflammation.56   
b. Gingival and Plaque Index Systems 
     In the 1960’s, renowned clinical oral health researchers Harald Löe and John Silness 
developed criteria for a gingival and plaque assessment, known as the Gingival Index 
System and Plaque Index System.57,58  In their study of periodontal disease in pregnant 
and postpartum woman, these systems proved effective for evaluation of the degree of 
gingival inflammation and plaque accumulation.57,58  The primary goal of developing 
these systems was to incorporate standards by which to evaluate gingival health 
relative to location, and provide uniform criteria by which to assess the location and 
degree of plaque accumulation.56,59    
     The clinical characteristics relative to the level of gingival inflammation were 
evaluated through four specific criteria, and are described as follows: 
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Criteria for the Gingival Index System 57 
0 = Absence of inflammation. 
1 = Mild inflammation – slight change in color and little change in 
texture. 
2 = Moderate inflammation – moderate glazing, redness, oedema, and   
      hypertrophy. Bleeding on pressure.             
3 = Severe inflammation – marked redness and hypertrophy. 
      Tendency to spontaneous bleeding.  Ulceration. 
 
     The clinical characteristics relative to the level of plaque accumulation were 
evaluated through four specific criteria, and are described as follows: 
Plaque Index System Criteria58 
0 = No plaque 
1 = A film of plaque adhering to the free gingival margin and adjacent 
area of the tooth. The plaque may be seen in situ only after application 
of disclosing solution or by using the probe on the tooth surface. 
2 = Moderate accumulation of soft deposits within the gingival pocket, 
or on the tooth and gingival margin which can be seen with the naked 
eye. 
3 = Abundance of soft matter within the gingival pocket and/or on the 
tooth and gingival margin. 
 
     Prior to examination, either cotton rolls or a blast of air were used to dry the area.57  
One tooth from each sextant was selected for examination, including the maxillary right 
first molar and lateral incisor, the maxillary left first bicuspid, the mandibular left first 
molar and lateral incisor, and the mandibular right first bicuspid.57  Four surfaces of 
each tooth (mesial, distal, buccal, and lingual) were given a score from 0-3, and the 
scores from the four surfaces were added together, and then divided by four, which 
yielded the gingival or plaque index score for the tooth.57  The scores from individual 
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teeth could then be grouped together for a gingival or plaque index for that specific 
group of teeth.57  Furthermore, the gingival index for the patient was assessed as an 
average of the surfaces evaluated, through adding the indices of the teeth and dividing 
by six.57  The Gingival Index does not incorporate probing depth, clinical attachment 
level, bone loss, or any additional periodontal changes; the index is specific to gingival 
qualitative change.59   
c. Retention Index System 
      In the late 1960’s Löe modified these indices slightly, which included the use of 
entire dentition if preferred, and incorporated a new Retention Index System to evaluate 
the primary retentive measures through the quality of tooth surface near the gingival 
margin, which are described as follows: 
Criteria for the Retention Index System59 
0 = No caries, no calculus, no imperfect margin of dental restoration in a 
gingival location. 
1 = Supragingival cavity, calculus, or imperfect margin of dental 
restoration. 
2 = Subgingival cavity, calculus, or imperfect margin of dental 
restoration. 
3 = Large cavity, abundance of calculus or grossly insufficient marginal 
fit of dental restoration in a supra- and/ or sub-gingival location. 
 
       
     The Retention Index System is similar to the Plaque and Gingival Index.  All three of 
these indices provide reversible criteria for clinicians to utilize when screening subjects 
of all ages.59  The adjustable nature of the criteria allows the clinician to select a specific 
number of teeth, or the entire dentition for evaluation.59  These indices have proved to 
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be invaluable tools in clinical research, and modified versions of these indices are still in 
use today.59 
d. Ramfjord Index / Russell Periodontal Index 
     Similar to the Löe and Silness indices, Ramfjord developed a periodontal disease 
index combined with a gingivitis index to assess gingival inflammation.56  The gingiva of 
each tooth is scored between a zero and three.56  In addition, Russell utilized a similar 
system with a range of zero to two.56  Both Russell and Ramfjord’s criteria do not 
specify different sites, and the results are subsequently more generalized than the 
approach used by Silness and Löe.56   
e. O’Leary and Colleagues Gingival and Periodontal Index 
     The index developed by O’Leary and colleagues combines a gingival and 
periodontal index which separates the periodontium into two anterior and four posterior 
components.56   The scores range from zero to three, with zero being slight to moderate 
inflammation that did not surround any single tooth, one being similar to one but entirely 
surrounding one or more teeth, two exhibiting notable inflammation, and three the 
presence of buccal or lingual recession.56    
f. Suomi and Barbano Index 
     A index gauged on a three point scale (0-2) was created by Suomi and Barbano, and 
was comprised of assessing both lingual and facial surfaces of twelve areas of the 
periodontium including an anterior, premolar, and molar tooth from each quadrant.56   
To evaluate gingivitis, Fischman and colleagues developed an “end point” framework 
using the Löe Index, but measured gingival disease exclusively instead of 
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improvement.56   This method was thought to be useful to ascertain effectiveness of 
therapeutic products in subjects currently diagnosed with gingivitis.56 
g. Bleeding on Probing 
     An additional indice that is commonly used to assess gingival inflammation is 
bleeding on probing.  Bleeding on probing presence is a reliable assessment of 
periodontal health that is easily evaluated clinically, and is a potential initial sign of 
gingivitis.56,60  
     In the 1970’s, Ainamo and Bay developed a bleeding on probing index that was 
characterized by gentle probing of the gingival sulcus.56  After a period of ten seconds, if 
bleeding was observed, it was recorded as positive, and the amount of positive sites 
were documented as a proportion of the total number of probed sites.56  This method 
seemed feasible for both clinical dental practice and clinical research purposes.56  
h. Sulcus Bleeding Index 
      In the 1950’s, the Sulcus Bleeding Index was created, and bleeding on probing was 
the most prominent criteria.56  The scoring criteria for this index is as follows: 
Sulcus Bleeding Index56 
0 = Healthy looking papillary and marginal gingiva, no bleeding on 
probing 
1 = Healthy looking papillary and marginal gingiva, bleeding on probing 
2 = Bleeding on probing and color change in gingiva 
3 = Bleeding on probing, color change, slight edema 
4 = Bleeding on probing, color change, obvious edema 
5 = Spontaneous bleeding, color change, marked edema, ulceration 
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 i. Papillary Bleeding Index       
     The Sulcus Bleeding Index was then modified and renamed the Papillary Bleeding 
Index, and was documented as the bleeding of gingiva after careful probing, and was 
classified as follows: 
Papillary Bleeding Index56 
0 = No bleeding 
1 = Only one bleeding point present 
2 = Several isolated bleeding points on a small area of blood 
3 = Interdental triangle filled with blood 
4 = Profuse bleeding spreading toward the marginal gingiva 
 
j. Modified Papillary Bleeding Index      
     The Papillary Bleeding Index was then modified by Barnett and colleagues by 
depicting specific positioning of the periodontal probe using a light movement toward 
the mesial papilla from the mesial line angle of the tooth.56  The appearance of bleeding 
was timed from the moment of probing, and was scored as follows: 
Modified Papillary Bleeding Index56 
0 = No bleeding within thirty seconds of probing 
1 = Bleeding between three and thirty seconds of probing 
2 = Bleeding within two seconds of probing 
3 = Bleeding immediately upon probe placement 
 
k.   Edwards Bleeding Index    
      A bleeding index was created by Edwards in which dental tape was wrapped around 
a buccal or lingual proximal surface and placed into the base of the sulcus, then 
repeated twice.56  Bleeding on probing was assessed using a dichotomous scale, with 
zero designated for absence of bleeding after fifteen seconds, and one if bleeding was 
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visible.56  A similar approach was used by Loesche, and Caton and Polson, where a 
triangular shaped wooden wedge was used to generate interproximal gingival bleeding 
and assess the health of the papillae.56 
2.7 Microbial Analysis  
     Traditional methods of microbial analysis have been limited by the narrow focal point 
on specific pathogens relative to a disease, and the capability to expedite the 
examination and identification of significant quantities of intricate microbes.61  In the 
1990’s, alternative methods of examination were developed, which facilitated 
accelerated execution of subgingival plaque microbe classification, and further 
enhanced understanding of periodontal pathogens.61  Furthermore, these methods 
allowed for the observation of the direct effect of therapeutic procedures on microbial 
plaque composition, and are useful in both diseased and healthy plaque samples.61  In 
addition, these methods are also used in research to assess the relationship between 
microbial plaque and systemic disease.61 
a. DNA Probes      
     Microbial subgingival plaque aggregation and the source of endodontic lesions have 
both been assessed by researchers with the use of whole genomic DNA probes, which 
are developed with the complete genome of a microbial classification as the goal.61  
Although this method is beneficial for the discovery of certain species, it is not free of 
limitations.61  For example, the use of the complete genome yields the potential of 
cross-reactions amongst species, due to the mutual DNA shared between similar 
species.61  In addition, it is possible that all types of a particular species may be 
undetectable by the probes, and result in a subsequent low sensitivity in regard to the 
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amount of cell detection.61  However, these limitations have been disparaged to an 
extent by researchers at the Forsyth Institute, whose efforts have revealed these 
limitations can be refuted.61   
     Although the customary use of DNA probes has been successful for the 
establishment of specific microbes, very few are advantageous for assessing large 
numbers of microbial species.61  On the other hand, regardless of direct or reverse 
procedure, checkerboard systems procure a significant increase in sample assessment 
for many species.61  Because microbial plaque sample analysis has revealed the 
simultaneous occurrence of particular microbes, knowledge of the association between 
microbes could prove beneficial for disease control and prevention.62   
b. “Checkerboard” DNA-DNA Hybridization  
     The “checkerboard” DNA-DNA hybridization method was initially described in 1994 
by Socransky and colleagues.61,63  In the past, techniques such as “reverse 
hybridization” were used, which assessed large quantities of target DNAs in relation to 
small samples.63  The “checkerboard” technique was developed to utilize a sole support 
membrane to assess large quantities of DNA samples relative to large quantities of 
DNA probes, specifically with the aim of analysis of the vast bacterial complexes found 
in dental plaque samples.63  This technique was modeled after previous use of the 
MiniBlotter™ and MiniSlot™ instruments during the preceding “checkerboard” method 
used for multiple antigen anti-body reactions assessed on a sole solid-support 
membrane.63   In this study, the technique described previously by Smith and 
colleagues was used by Socransky and colleagues to isolate DNA from seven 
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references and thirty-six fresh isolates of Campylobacter and associated species.63  
This technique also allows the analysis of up to more than 100 experimental samples 
each day, creating further economic savings.63  This “checkerboard” hybridization 
technique was used for the microbial plaque sample analysis in this experimental 
gingivitis study. 
2.8 Colgate Total® Toothpaste 
     The emergent evidence indicating a relationship between oral and general health 
provides a need for safe, effective, clinically proven preventive oral health care 
products.  In the 1985, the first dentifrice containing triclosan was introduced in 
Europe.64  More than twenty years ago, the Colgate-Palmolive Company developed an 
exclusive toothpaste formulated with the well-known anti-microbial ingredient triclosan 
and a copoylmer.8 In July 1997, the Food and Drug Administration (FDA) approved 
Colgate Total® for use as a preventive dentifrice for gingivitis, plaque and caries.65  
Colgate Total® contains 0.3% triclosan, which is a broad spectrum antimicrobial found in 
soaps, deodorants, and oral products, and 2% polyvinylmethyl ether maleic acid 
copolymer (PVM / MA), which increases the retention and uptake of triclosan to the 
buccal epithelium and enamel.8  Use of this dentifrice can provide up to 12 hours of 
antimicrobial protection and subsequent control of biofilm.8  Currently, Colgate Total® is 
the only dentifrice with triclosan available in the United States.8  Triclosan containing 
toothpaste and mouth rinses without the copolymer formulation are available for use in 
other countries.8   
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2.9 Triclosan  
     Triclosan is a broad spectrum, synthetic antimicrobial compound that has been 
safely used for almost 40 years in deodorants and soaps with no noted adverse 
events.8,66  In 1969, triclosan was registered for use as a pesticide, and is used in this 
capacity for industrial, commercial, and institutional purposes.66  Triclosan is also used 
as a preservative in many materials including plastics, fabrics, and adhesives.66  The 
chemical structure of Triclosan (2ˊ-hydroxy-2,4,4ˊ-tricholrodiphenyl ether) fundamentally 
resembles thyroid hormones.66,67  Triclosan is considered to be non-toxic in mammals, 
and research studies of up to four years of triclosan containing dentifrice use revealed 
no change in the hematological, clinical, or biochemical measurements assessed in the 
subjects.67  However, concentrations of triclosan relative to the use of consumer 
products with triclosan have been detected in urine, breast milk, and human plasma.67  
As a result, researchers evaluated the effect of 14 days of triclosan dentifrice use on 
thyroid hormone levels found in plasma to determine if there was a significant effect.67  
Although there was no notable difference in thyroid hormone levels, the plasma 
concentration of triclosan was higher than what was described previously.67   
     The Environmental Protection Agency (EPA) reregistered triclosan for pesticide use 
in 2008 based on the results of animal studies, and a portion of the  urinary 
concentration data obtained from the 2003-2004 NHANES survey.66   A human health 
risk assessment was performed to analyze available animal study data on the residue 
and product chemistry, residential and occupational exposure, toxicology, and additional 
readily obtained literature to substantiate the reregistration.66  Evidence in regard to 
carcinogenicity, reproductive and developmental toxicity, endocrine effects, and chronic 
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toxicity of triclosan was evaluated.66  Because the 2003-2004 NHANES data was also 
utilized, the 2008 assessment is regarded to be inclusive of regulatory uses of both EPA 
and FDA  exposures of triclosan.66  The EPA is in the process of updating this 
assessment based on the urinary results of the 2005-2006 NHANES data, and will 
revise this assessment if deemed scientifically necessary.66  In addition, recent animal 
study data on the effect of triclosan on estrogen and thyroid hormones has prompted 
further research on the potential risk of triclosan exposure and use in humans.66  In 
2013, the EPA will continue to monitor endocrine research, and conduct an additional 
widespread assessment of triclosan, and will modify their regulatory decision if 
warranted.66  Furthermore, the EPA will maintain involvement in the Interagency Task 
Force on Antimicrobial Resistance, collaborate with the FDA to coordinate data on 
triclosan, and confer requirements for additional research studies that will benefit both 
the FDA and EPA in determining if triclosan is safe for human use.66 
        Several studies have confirmed the safety and lack of microbial resistance due to 
long-term triclosan dentifrice use.8,67,68  The 1986 American Dental Association 
Guidelines for Acceptance of Chemotherapeutic Products for the Control of 
Supragingival Dental Plaque and Gingivitis contains a stipulation pertaining to 
microbiological monitoring.69  In order to fulfill this stipulation, monitoring of the oral 
microflora was incorporated into four long-term clinical efficacy studies on plaque and 
gingivitis, and each of these studies substantiated that long-term use of triclosan 
copolymer dentifrice did not induce changes in the microbial composition of 
supragingival plaque to favor development of pathogenic, opportunistic, or resistant 
microorganisms.69  The lack of adverse effects in these studies were further 
46 
 
substantiated by six additional long-term studies that were constructed solely to assess 
the effect of triclosan copolymer dentifrice on the oral microbes reviewed in these 
studies.69  
     Cullinan et al conducted a sub-study of 132 subjects from their Cardiovascular and 
Periodontal Study, which was investigating the effect of 0.3% triclosan toothpaste on the 
progression of chronic periodontal disease in subjects with cardiovascular disease.67  
This sub- study was conducted to specifically evaluate the use of triclosan dentifrice on 
thyroid function over a four year period.67  Paired serum samples from year one and five 
of the levels of thyroid stimulating hormone (TSH), free thyroxine (fT4), free 
triiodothyronine (fT3), antithyroglobulin antibody (anti-TGab), and antithyroid peroxidase 
antibody (TPOab) were assessed.67  At the conclusion of the four year study, there was 
no significant noted effect of triclosan toothpaste use on thyroid function.67  The results 
support the opinion that 0.3% triclosan in toothpaste is safe for long term use, without 
the risk of adverse effect on thyroid function.67  In addition, the subjects in the triclosan 
group had been using the toothpaste for a year before the first serum samples were 
taken, and the results were similar in both groups, yielding evidence that the triclosan 
dentifrice had no effect on thyroid function during the intervening time period.67  
     Cullinan et al conducted an additional sub-study of 40 subjects from their 
Cardiovascular and Periodontal study to determine triclosan resistance in oral plaque 
samples after a long-term period of triclosan dentifrice use (five years).68  This study 
revealed that using a concentration of 0.3% triclosan, there was no growth of bacteria in 
either group during anaerobic or microaerophilic conditions.68  Lower triclosan 
concentrations showed similar growth in both groups, and the vast majority of 
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identifiable bacteria were common among both of the groups.68   In addition, the 
triclosan and minimum inhibitory concentrations of bacterial isolates in both groups were 
similar, revealing that use of triclosan dentifrice over the five year period did not yield an 
increase in the minimum inhibitory concentration from dental plaque.68  The results of 
this study have provided evidence that triclosan dentifrice use does not lead to oral 
plaque bacterial resistance over a long period of time.68 
2.10 Polyvinylmethyl Ether Maleic Acid Copolymer 
    PVM/MA copolymer and its related salts and esters are used primarily as binders in a 
variety of products, including soaps, deodorants, oral health products (including Colgate 
Total®), cosmetics, hair care products, and film formers.70 A 1993 safety assessment of 
ethyl and butyl ester of PVM/MA copolymer was conducted by the Cosmetic Ingredient 
Review Expert Panel, and this data revealed evidence of the safety of the salts and 
esters of the following PVM/MA copolymers:  calcium/sodium, potassium ethyl ester, 
sodium ethyl ester, potassium butyl ester, sodium butyl ester, and isopropyl ester.70     
     PVM/MA copolymer is included in the Code of Federal Regulations for its use in 
dental products, with calcium/sodium PVM/MA copolymer for its use in dental 
adhesives.70  In addition, PVM/MA copolymer and butyl ester are listed for use in dental 
paste and a topical solution at 30% on the Food and Drug Administration inactive 
database.70  Several published clinical studies on the efficacy of toothpaste containing 
PVM/MA copolymer were evaluated, and no adverse effects were noted from PVM/MA 
copolymer.70  Although there is a lack of data on the reproductive and developmental 
toxicity and the carcinogenicity of PVM/MA copolymer, due to the large molecular 
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weight structure, it was concluded that the skin would not readily absorb PVM/MA.70  In 
addition, there was no information located on the distribution, elimination, metabolism, 
absorption, or general biology of PVM/MA and its related salts and esters in the 
literature.70  The panel concluded that PVM/MA copolymer and its related salts and 
esters are safe to use in cosmetic products.70 
2.11 Clinical Efficacy of Colgate Total® Toothpaste 
     The outcomes of several studies have demonstrated the reduction in gingivitis and 
subsequent benefit to periodontal health due to the anti-inflammatory and antimicrobial 
action of Colgate Total® toothpaste with triclosan copolymer when compared to 
placebo.8  These results convey that Colgate Total® may be used as an evidence-based 
recommendation to improve and sustain periodontal status, and inhibit further disease 
devastation.8 
     There have been several studies and systematic reviews on the clinical efficacy of 
triclosan containing toothpaste (with and without copolymer) on plaque control and 
gingivitis.9–12  Davies an colleagues conducted a systematic review of 16 studies 
comparing Colgate Total® to a fluoride dentifrice for their effect on plaque and 
gingivitis.10   In 13 of the 16 studies, the subjects received a prophylaxis prior to the 
beginning of the studies, which reveals the capability of Colgate Total® to control new 
plaque formation.10  In the three studies without initial prophylaxis, there was indication 
of the effectiveness of existing plaque removal of the two study toothpastes.10  The 
more prominent clinical significance revealed through the meta-analysis was the 
reduction in gingival bleeding and overall improvement in gingival health.10  The results 
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of this systematic review suggest that unsupervised use of a triclosan /copolymer 
containing dentifrice (Colgate Total®) showed a significant improvement in supragingival 
plaque removal and improvement of gingival health when compared to a fluoride 
dentifrice.10  
     A recent study by Fine et al evaluated the antimicrobial effects of triclosan containing 
toothpaste compared with two other dentifrices on Streptococci, Actinomyces, 
hydrogen-sulphide (H(2) S)-producing bacteria, Fusobacteria, anaerobes, and 
Veillonella samples on four oral sites.71  The results of this study showed that the 
subjects using Colgate Total® had statistically significant reductions at all sites and with 
all evaluated organisms, when compared to the two other test dentifrices, up to twelve 
hours post brushing.71  In addition, intergroup comparisons also revealed greater 
efficacy of Colgate Total® when compared to the SnF2/SHMP or NaF groups.71    
     An additional crossover study by Fine and colleagues evaluated the in vivo effect of 
triclosan/copolymer toothpaste compared with a control fluoride toothpaste, and 
included Veillonella species, Fusobacteria species, total cultivable anaerobes and 
hydrogen sulfide (H(2)S)-producing bacteria.72  The results demonstrated that the 
subjects brushing with the triclosan-copolymer toothpaste has statistically significant 
reductions (90 percent or higher)  in both tongue and plaque anaerobic microflora, and 
an 88-89 percent reduction in salivary anaerobic bacteria at both the 6 and12 hour time 
points, when compared to the control dentifrice.72  The results of the Veillonella, 
Fusobacteria, and H2S producing oral bacteria also showed statically significant 
reductions at both time points when compared to the control dentifrice.72  The results of 
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this study show the clinical efficacy of triclosan-copolymer toothpaste on oral 
microorganisms for up to twelve hours.72 
     A randomized, controlled, clinical trial was conducted by Ozaki et al to determine the 
efficacy of a herbal dentifrice (Parodontax®) in the reduction of plaque and gingivitis.73  
The researchers used Colgate Total® toothpaste as the control, and tested the 
dentifrices on subjects with established gingivitis, which provides evidence of the true 
effect of an antimicrobial ingredient on gingivitis.73  The results showed both toothpastes 
were significantly effective at reducing plaque and gingival index scores over a 28 day 
period.73  At baseline, there was no significant difference between the plaque scores 
and GI of the two groups.73   At the day 28 evaluation, the treatment group showed a 
19.9% reduction in buccal and lingual plaque, and the control group demonstrated an 
18.3% reduction.73   In regard to the plaque on the proximal surfaces, the treatment 
group showed a 19.3 percent reduction, and the control group 15.4 percent redcution.73  
Although both groups showed a significant decrease in plaque score, the difference was 
not statistically significant between the groups.  The day 28 gingival index scores 
showed a mean reduction of 28.4 percent in the buccal and lingual surfaces in the 
treatment group, and 36.3 percent reduction in the control group.73  In regard to the 
proximal surfaces, the test group showed a 23.5 percent reduction, and the control 
group 32.5 percent.  Although both groups showed a significant decrease in the gingival 
index, there was no statistical difference between the groups.73  In addition,  no adverse 
events were reported among either group.73  Furthermore, the results revealed that the 
Parodontax® herbal dentifrice was as effective as Colgate Total® at reducing plaque and 
gingivitis.73  
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2.12 Triclosan Dentifrice /Mouthrinse Formulations Available in Other Countries 
     There are several triclosan dentifrice / mouthrinse formulations available for 
consumer use in other countries.  A study was carried out by Prasanth to determine the 
effect of several toothpastes, including triclosan containing toothpaste, on 
Streptococcus mutans, Escherichia coli, and Candida albicans.64  The results of this 
study show that the triclosan containing dentifrice (toothpaste A) had the highest zones 
of inhibition against E. coli (p< 0.001) when compared to all of the other toothpaste 
formations.64  For S. mutans and C. albicans, the zones of inhibition were less than E. 
coli, but were significantly different at higher dilutions (1:8, 1:16, p< 0.05) for the 
triclosan containing dentifrice.64  In addition, all of the mouthrinses (mouthrinse 
formulation F and J contain triclosan) tested showed significant differences against E. 
coli, but Chlorohexidine Gluconate, Sodium Fluoride, and Zinc Chloride mouthrinse had 
the greatest significance.64   In addition, mouthrinses F, G, and J showed significant 
differences when compared to formulations H and I for their effect on S. mutans.64  The 
effect on C. albicans showed the zones of inhibition were significant for mouthrinse F.64   
      A clinical trial was performed by Pradeep and colleagues to assess the effect on 
Streptococcus and Actinomyces species with the use of triclosan co-polymer and amine 
containing dentifrices.74  After 24 weeks, the results of this study demonstrated the 
clinical efficacy of both the triclosan-copolymer and amine fluoride dentifrices when 
compared to the placebo dentifrice.74     
     Otten et al conducted an unblinded, clinical substantivity study of 74 subjects to 
analyze the effect of plaque and saliva on the prolonged substantivity of three 
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antibacterial dentifrices when compared to a non-antibacterial control dentifrice, and to 
compare the potential changes of bacterial composition of saliva and plaque post 
brushing with different dentifrices.75  The authors hypothesized that plaque remaining 
post-brushing could function as a reservoir for antibacterial dentifrice components, and 
increase their substantivity (continual therapeutic benefits although brushing has 
ceased).75  Although both Colgate Total® and Crest Pro-Health® decreased bacterial 
viability in plaque samples up to 12 hours post brushing, only remaining plaque from the 
subjects who brushed with Crest Pro-Health® had significant residual antibacterial 
activity 12 hours post brushing that could contribute to killing bacteria in unexposed 
plaque over a long period of time.75  Additionally, there was a lack of statically significant 
evidence of the direct effect of bacterial viability in saliva across all samples.75  Overall, 
plaques samples obtained post use of both the Crest and Colgate dentifrices 
demonstrated lower viabilities than the control plaques, while the use of Zendium 
showed similar viability when compared to the control plaque.75 
     A crossover in vivo study by Sreenivasan et al was designed to evaluate early dental 
plaque formation in the human oral cavity, and to assess the effects of dietary and oral 
hygiene practices on the formation of biofilm.76   A custom butterfly device made from 
dental acrylic was constructed from mandibular impressions of the subjects.76  After a 
one week “washout” period, the subjects placed the device in their mouth, with the goal 
of microbial accumulation in mind.76  Several treatments, including mouthrinses and 
dentifrices, were tested for their effects on the microbial colonization on the device.76  
The results showed that large amounts of oral microbes colonized the device by two 
hours, and they increased significantly by four hours.76  Colonization of bacteria 
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increased significantly after rinsing with the 10 % sucrose solution, but remained 
unaltered after rinsing with potable water, the fluoride rinse without antimicrobial 
properties, or brushing with the fluoride toothpaste.76  However, rinsing with the 
chlorohexidine gluconate, cetylpyridinium chloride, or triclosan copolymer mouthrinse 
demonstrated significant colonization inhibition, with a dose dependent inhibition  noted 
with the chlorohexidine  rinses.76   In addition, brushing with Colgate Total® also 
significantly inhibited colonization of the microbes when compared to the control 
dentifrice.76 
2.13 Study Objectives and Overview 
    The purpose of this pilot study was to determine the effect of Colgate Total® Clean 
Mint toothpaste on microbial pathogens during an experimental gingivitis model in the 
total absence of mechanical interruption of plaque biofilm.  Previous studies have 
focused on the effects of triclosan containing dentifrices on oral microflora; however, 
few studies have examined the effects of triclosan dentifrice on microbial pathogens in 
the total absence of mechanical interruption of plaque biofilm. If the biofilm is not 
removed through the mechanical effects of brushing, flossing, or other oral hygiene 
aids, the biologically active by-products released from the biofilm infiltrate the gingival 
epithelium, inducing gingivitis.5  The intent of this research was to study the effects of 
Colgate Total® toothpaste in the absence of mechanical plaque biofilm removal during 
an experimental gingivitis model.  The elimination of mechanical plaque removal 
determined the sole effect of Colgate Total® toothpaste on microbial pathogens and 
gingival health. 
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     Potential outcomes of this study could prove to be invaluable for dental hygienists.  
The foundation of dental hygiene is prevention, and a dentifrice known to inhibit 
microbial plaque proliferation and improve gingival health could be an essential 
component of homecare product recommendation.  The goal of this study was to 
determine if Colgate Total® toothpaste is effective at reducing microbial pathogens that 
are prevalent in plaque biofilm samples. Lack of proper oral hygiene is common among 
patients, and insufficient plaque control increases the potential for gingivitis to progress 
into periodontitis.  The emerging relationship between periodontal disease and systemic 
disease validates the need for further research on the preventive capability of Colgate 
Total® toothpaste. The results of this study are beneficial for dentifrice 
recommendations in clinical dental hygiene practice, and may potentially improve 
patient’s oral and general health. 
a. Specific Aim / Hypothesis 
Specific Aim: 
The specific aim of this study is to determine the effect of Colgate Total® 
toothpaste on microbial pathogens in plaque biofilm samples during an 
experimental gingivitis model in the absence of mechanical interruption of plaque 
biofilm.  
Hypothesis: Colgate Total® toothpaste, as compared to a standard of care toothpaste, 
will be more effective in reducing microbial pathogens in plaque biofilm samples during 
the experimental gingivitis model. 
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CHAPTER III 
 MATERIALS AND METHODS  
     This research study was conducted during a randomized, controlled, clinical trial at 
the University of Michigan Center for Oral Health Research (MCOHR).  This was a pilot 
study, with the goal of acquiring data to support a future study on a larger scale.  The 
total number of subjects enrolled for participation was thirty, with fifteen subjects in each 
arm of the study.   
3.1 Examiner Calibration 
     Prior to enrollment of study subjects, all study examiners were required to participate 
in a training and calibration exercise for clinical parameters, intra-oral photos, and 
sample collection at MCOHR.   
3.2 Clinical Periodontal Measurements 
     The clinical periodontal measurements were assessed using a Hu-Friedy (Chicago) 
North Carolina Probe.  Six measurements were recorded on all teeth (except third 
molars), rounding down to the nearest millimeter.  Assessed periodontal parameters 
included clinical attachment level (CAL), free gingival margin (FGM), and probing pocket
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depth (PPD).  The calculation of total clinical attachment level was from the CEJ or an 
additional fixed reference point to the base of the sulcus.  Bleeding on probing (BOP) 
was assessed using a dichotomous scale, with “0” indicated absence of BOP, and “1” 
indicating the presence of BOP. 
3.3 Sample Collection 
     All samples were collected in accordance with the study protocol.   
3.4 Saliva Collection 
     Unstimulated whole saliva was obtained at the beginning of each study appointment, 
and stored at -80° Celsius until it was ready for analysis as described previously.33,77,78   
To remove gross debris, the subjects were informed to rinse their mouth vigorously with 
water for 20 seconds, then expectorate.  After a two minute waiting period to establish 
baseline levels of saliva, the subjects tipped their head toward the graduated test tube 
and expectorated whole saliva in the plastic funnel inserted in the plastic, sterile tubes, 
labeled with the subject’s initials, sample name, and date of harvest. The subject had a 
maximum of 15 minutes to expectorate 2 ml of whole saliva. Following completion of 
sample collection, the sample was immediately placed on ice, aliquoted, and 
supplemented with a proteinase inhibitor combination of 1% aprotinin (1mg/ml) and 
0.5% phenylmethylsulphonyl fluoride (PMSF) (200mM in MeOH) (Sigma Chemical 
Company, St-Louis, MO) prior to storage at -80°C.     
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3.5 Gingival Index 
     Gingival Index was determined as previously described by Loe and Sillness.57   
TABLE 1 
Gingival Index 
Scores Criteria Bleeding 
0 Absence of inflammation No bleeding on probing 
1 Mild inflammation  
Slight change in color and 
texture 
No bleeding on probing 
2 Moderate inflammation, glazing, 
redness, edema and 
hypertrophy  
Bleeding on probing 
3 Severe inflammation, redness 
and hypertrophy. Ulceration. 
Tendency to spontaneous 
bleeding 
 
3.6 Plaque Index 
      Plaque Index was determined as previously described by Silness & Loe.58  
TABLE 2 
Plaque Index 
Scores Criteria 
0 No plaque 
1 A film of plaque adhering to free gingival margin and adjacent 
area of tooth.  The plaque may be seen in situ only after 
application of disclosing solution or by using the probe on the 
tooth surface 
2 Moderate accumulation of soft deposits within the gingival 
pocket, or on the tooth and gingival margin, which can be seen 
with the naked eye 
3 Abundance of soft matter within the gingival pocket and/or on 
the tooth and gingival margin 
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3.7 Gingival Crevicular Fluid Sampling 
     Gingival crevicular fluid samples were collected and analyzed as previously defined 
by Lampster and Ahlo (77) and Giannobile et al (78). 79,80   GCF samples were obtained 
from the mesiobuccal or distobuccal site of two mandibular teeth assigned through 
randomization.  The sample did not contain plaque, blood, or saliva.  If supragingival 
plaque was visible, it was removed gently with a curette prior to sampling.  Cotton roll 
isolation was used around the sample site, and then the site was dried with gauze and a 
small amount of air from the air/water syringe.  Care was taken to not direct any air flow 
into the gingival sulcus.  Forceps were used to insert the white cellulose portion of the 
methylcellulose strip (Periopaper®, Pro flow, Inc. Amityville, NY) into the sulcus until a 
gentle resistance was felt, similar to periodontal probing.  The strip remained in position 
for 30 seconds until it was removed.  Care was taken to ensure the area remained 
isolated. If a site required re-sampling, a minimum of 90 seconds elapsed before 
resampling occurred.  After the GCF sample collection was completed, each strip was 
inserted into a microfuge tube and labeled with the subject’s initials, study number, date, 
and tooth location. The tube was then placed onto dry ice for transportation to the 
laboratory, and is then stored in a -80° Celsius freezer until analysis.  Because the strips 
were not stored with protease inhibitors or stabilizers, it was recommended that 
subsequent analysis be conducted as soon as possible to minimize protein degradation.  
3.8 Gingival Crevicular Fluid Analysis 
     Harvested crevicular fluid proteins were extracted from the GCF strips utilizing an 
elution method adapted from Giannobile et al.80  This process involves a series of 
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washes and centrifugations.  To inhibit protease activity, the elution buffer used during 
the GCF protein extraction was made fresh and kept on wet ice during the entire 
extraction process. The ingredients in the GCF buffer include 24.5mL Phosphate 
Buffered Saline, pH 7.4, 125 µl phenylmethylsulphonyl fluoride (PMSF; Sigma 
Chemical, St. Louis, MO); 200mM in MeOH, 250  µl Aprotinin (Sigma Chemical, St. 
Louis, MO); 1 mg/ml in water,  and 83.5 µl of 30% Human Serum Albumin (Sigma 
Chemical, St. Louis, MO).  The GCF strips were placed on wet ice from the -80° Celsius 
freezer, and kept there for the duration of the procedure.  20 µl of the extraction buffer 
was then pipetted onto the white (cellulose) area of the GCF strips.  The strip was then 
secured at the top of a 12 X 75 ml polypropylene tube labeled with the subject’s initials 
and study number, tooth location, and harvest date. A cap was used to keep the orange 
area of the strip in the correct place.  The tubes were then centrifuged at 2000 rpm at 4 
degrees Celsius for 5 minutes. This centrifugation process was repeated an additional 
four times until a total volume of 100 µl was achieved.  The entire product (100 µl) was 
then placed into a sterile microfuge tube, and stored at -80° Celsius until used.   
3.9 Plaque Biofilm Collection 
     To obtain supra and subgingival plaque samples, a sterile Gracey 11/12 or 13/14 
curette instrument was used.  Samples were collected from the mesiobuccal or 
distobuccal surface of the allocated study appointment teeth, and stored at -20° Celsius 
until processing occurs.  A different tooth was selected for sampling at each visit.  This 
allowed the quantitative and qualitative changes from plaque maturity to be noted. The 
tooth was dried with air, and then the Gracey curette was inserted into the sulcus until 
resistance was felt.  A stroke with light pressure similar to scaling was used to remove 
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the plaque sample. Immediately after obtaining the sample, it was placed into a vial 
labeled with the subject’s initials, study number and sample type, and harvest date, that 
contained 150 µl of TE (10mM Tris-HCl, 1 mM EDTA, 500 ml Distilled Water, pH 7.6).  
The curette was then rotated for 5 seconds to immerse the plaque bacteria sample into 
the solution.  100 µl of 0.5 M NaOH was added into each vial, and the samples were 
stored at -20° Celsius until they were processed.     
3.10 Biomarker and Microbial Analysis 
     Ten biomarkers were analyzed in the gingival crevicular fluid and saliva samples, 
including IL-˦α, IL-˦β, IL-6, IL-8, IL-10, MCP-˦, MMP-8, MMP-9, TIMP-˦, and TIMP-2.  
Forty bacterial microbes were analyzed using the checkerboard DNA-DNA hybridization 
technique as previously described by Socransky et al, including Streptococcus mutans, 
Streptococcus gordonii, Actinomyces viscosus, Veillonella parvula,  Campylobacter 
rectus,  Prevotella intermedia, Porphyromonas gingivalis, Tannerella forsythia, 
Treponema denticola and  Candida albicans.63 The microbial analysis was conducted at 
Dr. Ricardo Teles’ Lab at the Forsyth Institute in Boston, Massachusetts. 
3.11 “Checkerboard” DNA-DNA Hybridization 
     The samples were first boiled for a period of 5 minutes.  Once cooled, 800 µl of 5M 
ammonium acetate was placed in each vial.  The contents of the vials were 
subsequently pipetted into the Miniblot apparatus.  Next, DNA was isolated from the 
individual bacteria and then quantified with a spectrophotometer.  Each DNA sample 
was adjusted to 1 ng/ml and loaded inside the channels of the Miniblotter 45 and placed 
onto Hybond-N+ nylon membrane.  The nylon membranes were then incubated at 4° 
61 
 
Celsius overnight.  Next, the membranes were removed from the device, and the DNA 
was denatured and fixed in a solution of 0.4M NaOH and 1.5M NaCl. The membranes 
were then rinsed in 2X SSC (1x = 0.15M NaCl, 0.015M sodium citrate, pH 7.0). The 
membranes were pre-hybridized at 42° Celsius for 1 hour in 50ml of a solution 
consisting of 50% formamide, 5x SSC, 1% casein, 5x Denhardt’s solution (1x = 0.02% 
Ficoll, 0.02% polyvinylpyrrolidone, 0.02% bovine serum albumin), 25mM sodium 
phosphate (pH 6.5), and 0.5 mg/ml denatured salmon sperm DNA. Then, the 
membranes were placed in the Miniblotter 45, and rotated 90 degrees from the original 
location.  Digoxigenin-labeled whole chromosomal DNA probes were made from the 
individual test strains utilizing the random primer method.  The probes and hybridization 
buffer were mixed and injected into separate lanes of the Miniblotter.  Saran Wrap was 
used to wrap the entire apparatus and it was stored in a Ziploc bag to prevent 
evaporation.  The membranes were then hybridized by gentle shaking overnight at 42° 
Celsius using a hybridizing solution containing 20ng/ml of labeled probe, 45% 
formamide, 5x SSC, 1x Denhardt’s solution, 20mM sodium phosphate (pH 6.5), 
0.2mg/ml denatured herring sperm DNA, 10% dextran sulfate, and 1% casein. The 
membranes were then washed twice at low stringency (25° Celsius in 200ml 2x SSC, 
0.1% SDS for 5 min.), and then twice at high stringency (65° Celsius in 6L of 0.1x SSC, 
0.1% SDS for20 min). For hybrid detection, membranes were blocked with 1% casein in 
maleate buffer (100mM maleic acid, 150mM NaCl, and pH 7.5).  Next, they were 
incubated with anti-digoxigenin antibody conjugated with alkaline phosphatase, and 
diluted with a 1:20,000 in maleic buffer. Once washing was completed, the membranes 
were incubated for 1 hour at 37° Celsius in 4-methoxy-4-(3-phosphatephenyl)-spiro 
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(1,2-dioxetane-3,2’-adamantane) disodium salt, and exposed to x-ray film for time 
periods ranging from 1-30 min. 
3.12 Timeline of Study Procedures 
 
3.13 Screening Phase: Day -14 Study Appointment 
     Informed consent was read, comprehended, and signed by the subject (see 
Appendix B).  A comprehensive medical history was obtained.  Clinical measures 
including an oral and periodontal exam were performed, including probing pocket depth, 
recession, clinical attachment level, and bleeding on probing (see Appendix H).  If the 
subject met the clinical eligibility requirements for study participation, urinary analysis 
was conducted of cotinine levels to determine smoking status.  The subjects were given 
a prophylaxis, including polishing and oral hygiene instructions.  Colgate Regular 
Flavor® toothpaste and Colgate floss was dispensed to each subject. Subjects were 
instructed to not rinse with anti-microbial mouth rinses or brush with anti-inflammatory 
toothpastes.  An impression of the subject’s mandibular arch was taken for stent 
fabrication. A thin layer of silicone material was applied to block out undercuts on the 
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poured model.  In addition, a 1mm thick layer of silicone that extends from 3mm below 
the free gingival margin up to the cervical half of the teeth was applied to provide 
sufficient space for the allocated toothpaste to remain in the appropriate site. The 
purpose was to minimize loss of allocated toothpaste out of the stent while ensuring the 
maximum amount stayed accumulated between the stent, teeth, and gingiva. A 
thermoelastic material comparable to Durasoft (3mm thick), was used for stent 
fabrication.  The material was heated and vacuum formed to the prepared study 
models. The fabricated stent covered one-half of the mandibular arch, and was trimmed 
until it extended 1mm short of the mucobuccal and mucolingual folds in the buccal and 
lingual vestibule.   
3.14 Experimental Gingivitis Phase – Day 0 Study Appointment (Baseline) 
     The subjects returned fourteen days after the initial screening visit to evaluate their 
BOP score (see Appendix I).  The medical history and accompanying medications were 
reviewed and updated if necessary, and reported adverse events were documented.  
Subjects presenting with a BOP score < to 10 percent began the experimental gingivitis 
phase at this appointment.  Those with a BOP > 10 percent received further oral 
hygiene instructions, and were requested to return for an additional appointment in two 
weeks.  Subjects who failed to achieve a BOP score < 10 percent at the second 
appointment were deemed ineligible to participate in the study.  
     Eligible subjects were randomized into an arm of the study.  The assignment of study 
arm (treatment or control) and mandibular stent (right or left) was done through 
randomization (see Appendix E).  The study coordinators had sole access to the 
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randomization chart.  The examiners and subjects were both blinded to the assignment 
of study arm.  The treatment group was allocated Colgate Total Clean Mint® toothpaste.  
The active ingredients of this dentifrice are sodium fluoride 1100 ppm  0.243% (0.14% 
w/v fluoride ion), and triclosan 0.3%.81  The inactive ingredients are water, hydrated 
silica, glycerin, sorbitol, PVM/MA copolymer, sodium lauryl sulfate, cellulose gum, 
flavor, sodium hydroxide, propylene glycol, carrageenan, sodium saccharin, mica, 
titanium dioxide, and FD&C Blue 1.81 The control group was allocated Colgate Great 
Regular Flavor® with 1000 ppm MPF.  The active ingredient of this dentifrice per tube is 
sodium monofluorophosphate 0.76% (0.15% w/v fluoride ion).82  The inactive 
ingredients per tube include dicalcium phosphate dihydrate, water, glycerin, sorbitol, 
sodium lauryl sulfate, cellulose gum, flavor, tetrapotassium pyrophosphate, and sodium 
saccharin.82  The same style of toothbrush was dispensed to all study participants, and 
they were informed to cease usage of all oral home care products except for those 
received as part of the study.  To ensure the absence of all mechanical plaque removal 
in the stent area, subjects were instructed to refrain from flossing their entire dentition 
for the duration of the study. 
     Each subject had six intra-oral photos taken of the mandibular arch.  Collection of 
whole saliva occurred as previously described by Mandel.78  The Plaque Index (PI) and 
Gingival Index (GI) of the mandibular arch was assessed.  Gingival crevicular fluid 
samples (GCF) were acquired from the mesiobuccal or distobuccal surface of two 
mandibular teeth.  Saliva and GCF samples were taken at Day 0, 14, 21, and 35 of the 
study appointments.  Determination of the two sites (teeth and surface) that were 
selected at the study visits to collect the plaque and GCF samples was done using a 
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randomization chart (see Appendix E).  If the subject was missing a posterior tooth, the 
canine was chosen in replacement.   Implants were excluded from selection for plaque 
and GCF samples.  Repeat GCF samples were collected on Day 14 and 21 of the 
study. 
     The subjects received specific home care instructions (see Appendices J and K).  
Each subject was advised to brush their teeth with their allocated study toothpaste twice 
daily for two minutes.  Prior to brushing, the subjects were instructed to place 2ml / 2.6 g 
of their allocated toothpaste into the stent, and then place the stent in the assigned 
area. The toothpaste was filled into a 6ml plastic syringe by placing the open toothpaste 
tube against the barrel of the syringe, and pulling with gentle pressure to fill the syringe 
to the 2ml demarcation.83 The subjects then evenly distributed this quantity of 
toothpaste into the indentations in the stent.83  The stent remained in place until the two 
minutes of brushing was completed.  The stent was then removed, rinsed with water, 
and stored in an appliance case until the next brushing period. 
3.15 Experimental Gingivitis Phase - Day 7 Study E-mail or Phone Call 
     Each subject was contacted by one of the research team members to ascertain their 
compliance of the study protocol and determine if they had any concerns that need to 
be addressed (see Appendix D). The research team member reaffirmed the study 
protocol for stent use and discontinuance of oral hygiene.  If any concerns were noted, 
a follow up appointment was scheduled with the principal investigator of the study and 
the subject.   
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3.16 Experimental Gingivitis Phase – Day 14 Study Appointment 
     Prior to this appointment, the subjects were informed to abstain from brushing their 
teeth for 10-12 hours.  The medical history and accompanying medications were 
reviewed and updated if necessary, and reported adverse events were documented.  
Intra-oral photos, saliva samples, plaque index, gingival index, gingival crevicular fluid 
samples, and plaque samples were obtained.  Prior to brushing, the subjects were 
instructed to place 2ml / 2.6 g of their allocated toothpaste into the stent, and then place 
the stent in the assigned area.  The stent remained in place until the two minutes of 
brushing was completed.  Repeat samples of gingival crevicular fluid were obtained at 
1, 2, 4, and 6 hours after the initial brushing.  The subjects were informed to sustain 
their study home care regimen until the next appointment.  At this time, the subjects 
received an incentive payment of $100. 
3.17 Experimental Gingivitis Phase – Day 21 Study Appointment 
    Prior to this appointment, the subjects were informed to abstain from brushing their 
teeth for 10-12 hours.  The medical history and accompanying medications were 
reviewed and updated if necessary, and report of adverse events was documented.  
Intra-oral photos, saliva samples, plaque index, gingival index, gingival crevicular fluid 
samples, and plaque samples were obtained.  Prior to brushing, the subjects were 
instructed to place 2ml / 2.6 g of their allocated toothpaste into the stent, and then place 
the stent in the assigned area.  The stent remained in place until the two minutes of 
brushing was completed.  Repeat samples of gingival crevicular fluid were obtained at 
1, 2, 4, and 6 hours after the initial brushing.   
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     The subjects were given a prophylaxis of their entire dentition, and their stents were 
collected.   To determine the level of study compliance, unused toothpaste was 
collected.  If more than 60 percent of the assigned toothpaste remained, the subject 
was considered non-compliant, and faced dismissal from the study.84   Participants who 
exhibited compliance with their allocated toothpaste received an additional $100 
incentive payment. 
3.18 Recovery Phase – Day 35 Follow up Contract 
     Prior to this final appointment, the subjects were informed to abstain from brushing 
their teeth for 10-12 hours.  The medical history and accompanying medications were 
reviewed and updated if necessary, and reported adverse events were documented.  
Intra-oral photos, saliva samples, plaque index, gingival index, gingival crevicular fluid 
samples, and plaque samples were obtained.  A sole gingival crevicular fluid sample 
was obtained from the mesiobuccal or distobuccal surface of two mandibular teeth, and 
the plaque samples were acquired from the same areas that the GCF samples were 
obtained.  Participants were given a $300 incentive payment. 
3.19 Study Limitations 
     Although the design and methodology of this study were carefully considered by the 
investigators, there were potential limitations and obstacles of this study.  The inclusion 
and exclusion criteria narrowed the pool of eligible candidates due to various reasons. 
The time commitment required at MCOHR on Study Appointment Days 14 and 21 may 
have eliminated potential subjects who could not commit due to school, work, family, or 
other obligations.  A sample size calculation was not completed for this study; the 
68 
 
estimate of thirty subjects was determined from results founded from a previous 
experimental gingivitis study.  Therefore, if a difference existed, it may not  have been 
detected because it could not be assured that there was a large enough sample for 
adequate statistical power.85  Although the sample size of thirty subjects was reached, 
there was no guarantee that the subjects would remain for the entire duration of the 
study, or comply with the home care protocol. Additionally, subjects could have missed 
a scheduled appointment, began a new medication, developed an adverse reaction, or 
underwent emergency medical or dental treatment. All of these circumstances could 
have interfered with the study parameters and outcomes. To increase subject 
compliance, substantial effort was made to ensure the subjects were informed of the 
study requirements, and an incentive payment was given. 
3.20 Statistical Analysis 
     Statistical analysis was conducted using SPSS.  Descriptive statistics were 
constructed from the demographic data, and included the average age of the subjects, 
gender, the male to female ratio, and ethnicity.  The descriptive statistics were then 
broken down, and basic statistical analyses using both independent samples t-tests  
and paired t-tests were conducted to determine if there was a difference between the 
two groups in this data.  Additional tests were conducted for analysis of the effect of 
Colgate Total® toothpaste on microbial pathogens in the plaque biofilm samples as 
compared to the Colgate® Cavity Protection.  Both independent t-tests and paired 
samples t-tests were used to assess each phase of the research study, including 
Baseline, Day 14, 21, and 35. Finally, a full linear mixed model analysis was performed 
to combine all of the time points and control variables in one model. 
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     The forty microbial pathogens were analyzed using the Wilcoxon Signed Rank test.  
This test was used to examine differences in each pathogen from Day 0 to Day 14, Day 
0 to Day 21, Day 14 to Day 21, and Day 21 to Day 35 in both the Colgate Total® and 
Colgate Great Regular Flavor groups.  The Wilcoxon Rank Sum test was used to 
evaluate if the changes at each of these four paired time points revealed significant 
differences between the two groups.  
3.21 Human Subjects 
     Thirty human subjects were recruited for this study. All subjects were randomly 
assigned into an arm of the study (treatment or control) and side of mandibular stent 
(right or left).  
3.22 IRB Approval 
     This study was approved by the University of Michigan Medical School Internal 
Review Board (IRBMED).  The current approval period is from 10/22/2013 - 10/21/2014.  
There was more than minimal risk to the subjects, and no direct benefit was obtained 
from study participation.  Certain research team members were required to complete 
the PEERRS mandatory training on the protection of human subjects before 
participating in the study. 
3.23 Inclusion Criteria 
     • Race –all races were included in the study 
     • Gender – male or female 
     • Age – between 18 and 40 years 
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     • Dentition – a minimum of twenty permanent teeth was required for participation 
     • Probing Pocket Depth must be < 4 mm in all sites 
     • Mean Clinical Attachment Level must be < 2 mm on each tooth 
     • Bleeding on Probing must be > 30% at Day 14 Study Visit 
     • Consent form must be read, comprehended, and signed 
     • Subjects must be willing to comply with all study procedures 
     Eligible study subjects must present with BOP of < 10% at Day 0 Study Visit. Those 
who did not meet eligibility requirements were requested to return in 2 weeks for a 
follow up assessment appointment.  If they did not meet the requirement of BOP of < 
10% at the subsequent appointment, they were excluded from participation in the study. 
3.24 Exclusion Criteria 
• Medical history exclusions - subjects with immune system diseases, conditions    
that may have affected the study outcome such as systemic infections, unstable 
psychiatric or neurological disorders, and a history of drug abuse or alcoholism 
• Subjects taking certain medications such as those that are known to affect  
periodontal status including immunosuppressives, Depo-Provera contraceptive 
injection, phenytoin, anti-inflammatory medications, and calcium antagonists anti-
convulsives will be excluded, as well as subjects who have begun oral contraceptive 
use in the past three months, or plan to begin using them during the study time 
period  
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• Known hypersensitivity to or an oral allergy to any of the ingredients in the 
dentifrices used in the study 
• Subjects with a history of recent antibiotic therapy (within 3 months of the baseline 
appointment), and those requiring pre-medication for total joint replacement or 
infective endocarditis prophylaxis 
• Subjects who had used antiseptics to control the formation of dental plaque within 
30 days of the baseline visit 
• Current smokers,  previous smokers who quit smoking less than one year ago, or 
those with a pack year history of greater than or equal to 10 (the pack year 
calculation will be assessed by multiplying the average number of cigarette packs 
smoked per day by the number of years smoked) 
    • Subjects with a positive urinalysis results of Cotinine 
    • Subjects undergoing current periodontal or orthodontic treatment 
    • Subjects with unrestored carious lesions or defective restorations that could  
      deteriorate due to the absence of mechanical plaque removal                    
    • Women who were pregnant or lactating 
3.25 Sources of Research Material 
     The sources of research material acquired from the study subjects included clinical 
periodontal measurements (PPD, CAL, and FGM), saliva samples, gingival index, 
plaque index, gingival crevicular fluid samples, plaque samples, biomarker analysis, and 
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microbial analysis. The measurements, samples, and analysis results were specifically 
used for research purposes pertaining to this study. 
3.26 Recruitment of Study Subjects 
     Recruitment of subjects began after study approval was obtained.  Recruitment was 
done through public advertising on the MCOHR website and at the MCOHR office 
location, the UM Human Research Recruiting Registry (UMClinicalStudies.org), and 
posted IRB approved flyers at various locations on the University of Michigan Campus, 
including the Dental School (Appendix A).  Indexed cards were attached to the flyers 
with contact information for interested participants. Previous MCOHR clinical research 
study participants were contacted and informed of the opportunity to participate in this 
study (Appendix F). All interested participants were initially screened by phone 
(Appendix C).  Study recruitment approach was impartial, and represented the sample 
population needed for the study because of the diverse University community in which 
the advertisement occurred.  All ethnicities, and both males and females, were 
coequally eligible for participation, and included a percentage of individuals from the 
University of Michigan School of Dentistry.    
3.27 Consent Procedures 
     A comprehensive written informed consent was obtained from all study subjects. A 
research study team member such as the Principal Investigator, Co-Investigator, Study 
Coordinator, or Research Assistant explained the study objective, all information 
pertaining to the study, and informed consent to the participants (Appendix B).   
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     All subjects were informed that their participation was voluntary, and they were free 
to exit the study at any point.  Subjects were informed that if they decide to leave the 
study prior to completion, there would be no penalty inflicted upon them, and no entitled 
benefits would be lost. Subjects that discontinued participation received a free 
prophylaxis and follow up appointment for evaluation of their gingival tissues.  
      Subjects were informed of the required number of appointments, the inclusion and 
exclusion criteria, what procedures would be conducted at each day of the study, the 
amount of time the study would require, when their participation would end, information 
about the benefits and risks of their participation, what to do if adverse events occurred, 
their options if they decide not to participate, what to do if they decided to discontinue 
participation in the study, reasons why the researchers may remove them from the 
study, financial information related to the study including incentive payment, and who 
may profit from the study (Colgate-Palmolive Company).  
     Time was allotted to answer all questions the potential subjects may have had.  All 
subjects were required to sign the Consent to be Part of a Research Study document.  
All subjects were given a copy of the signed informed consent document.  The informed 
consent document was approved by the University of Michigan IRBMED, and the 
documentation of consent was required for participation. 
3.28 Potential Risks 
     The primary risk of conducting research with specimen samples or secondary data is 
breach of privacy or confidentiality.  This presents the potential to result in financial, 
legal, social/reputation, or psychological harm to the study participant. 
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     The experimental gingivitis model has been used safely with generally minimal risks 
to participants.  Discontinuation of oral hygiene can result in bleeding gingiva, 
accumulation of plaque biofilm, and halitosis.  The results of previous studies 
demonstrate that these effects can be completely reversed once proper oral hygiene 
has resumed.  Gingival health can be restored within seven days of completing a 21 day 
period of absence of oral hygiene during a research study.   
     There are minimal risks involved with collection of saliva, plaque, and gingival 
crevicular fluid samples, and assessment of clinical periodontal parameters.  There may 
be minor discomfort with probing and plaque collection during the gingivitis phase of the 
study, and from scaling and polishing during the prophylaxis.  Additionally, gingival 
bleeding may occur during sample collection or the prophylaxis. Because of the adverse 
effect of discontinuing oral hygiene on decayed teeth or periodontal disease, subjects 
with existing dental needs will be excluded from the study. 
     Study participants could have developed side effects or adverse reactions to the 
allocated study toothpaste, including irritation in the oral cavity.  Participants were 
questioned at each appointment to determine the occurrence of any such events.  
Additionally, the subjects were informed that all research studies have the potential for 
unknown or unexpected risks, and that every effort would be made to prevent or 
minimize these risks. 
3.29 Protection Against Risks 
     This research study involved the access, collection, use, and disclosure of the 
University of Michigan protected health information (PHI), which is a UM HIPAA covered 
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component. The study had a Data and Safety Monitoring Plan. Risks to participants 
were minimized by meticulous screening and observation of the subjects by the 
investigators and research staff throughout the duration of the study.  The study 
investigators were responsible for the documentation of all adverse events or reactions 
during the study.  This documentation was then be forwarded to the Product Safety 
Assurance Department.  Colgate-Palmolive Company was responsible for the costs 
related to medical treatment if the subject sought treatment as required by the 
investigator or sponsoring company.  If an adverse event occurred, the subjects were 
informed to contact the Principal Investigator, or MCOHR staff, and in case of a medical 
emergency, their physician or local poison control center.  Adverse events that were 
serious or had the potential to become serious required additional documentation and 
follow-up.  The investigators were responsible for remaining abreast of all adverse 
events until they were resolved.  
     To protect the subject’s privacy and confidentiality, all eligible participants received 
an assigned study number, which will be used for the entire study.  For additional 
protection, all CRF form and sample labels exhibited the study number and subject’s 
initials. The data and records acquired from this study were protected against 
inappropriate disclosure or use by being kept in a locked office with a locked storage 
unit or cabinet. This area had restricted access to limited number of individuals.  
Computer information was kept on a secure laptop that required individual ID and 
password protection.  Routine electronic backup was performed to ensure computerized 
data was not lost, and network restrictions were in place. At the conclusion of the study, 
the data will be retained for the purpose of record keeping for two years after the 
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completion of the study.  All subjects study binders will be stored, including those that 
discontinue participation in the study.   
 
3.30 Potential Benefits 
     The risks to the study participants were reasonable in relation to the anticipated 
benefits of this study.  The procedures defined in this study were documented in several 
other studies with the same design.  The results of this study provided evidence in 
regard to the effect of Colgate Total® toothpaste on the gingival inflammatory response, 
and this information could invariably be used to improve the public’s oral health.  Plaque 
induced gingivitis has the potential to progress into periodontitis, which is a chronic, oral 
disease that affects millions of adults.26   The emergent relationship between periodontal 
disease and systemic health supports the potential benefits and outweighs the risks of 
this research.   
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CHAPTER IV 
RESULTS 
 
4.1 Enrollment Retention and Adverse Events 
     A CONSORT diagram of study participants is presented (Figure 4.1).  Of the 580 
subjects who were interested in the study, 175 completed the phone screen.  Seventy-
eight of the subjects who completed the phone screen presented to the Michigan Center 
for Oral Health Research for the initial screening appointment.  After informed consent 
was obtained, the subjects completed the screening appointment.  At the screening 
appointment, thirty-eight subjects failed to meet the inclusion / exclusion criteria, and 
forty moved to baseline.  Of the forty subjects who moved to baseline, one failed to 
show for the baseline appointment, one failed to qualify, two failed to show at the re-
baseline, and six failed to qualify for the study at re-baseline.  One subject developed a 
carious lesion during the experimental gingivitis phase (Day 21), and no longer qualified 
for participation.  The subject was advised to schedule an appointment with her dentist 
for restorative care, and was dismissed from the study.  An additional subject withdrew 
after the baseline appointment due to personal reasons.  Two more subjects were then 
recruited, and a total of thirty subjects were randomized into the experimental or control 
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groups following the randomization chart (see Appendix E), and proceeded to complete 
the study. 
     In addition to the carious lesion, other insignificant adverse events were reported 
(see Appendix G), including tissue sloughing (two subjects in the Colgate Great Regular 
Flavor arm), herpetic lesions (two subjects in the Colgate Total® arm), apthous ulcers 
(one in the Colgate Great Regular Flavor arm and three subjects in the Colgate Total® 
arm), TMJ soreness (one subject in the Colgate Total® arm), tingling sensation in the 
tongue (one subject in the Colgate Total® arm, the same subject also developed an 
apthous ulcer), and toothbrush trauma (one subject in the Colgate Total® arm).   All of 
the reported adverse events were resolved by the end of the study.  The outcome of the 
dismissed subject with the carious lesion remains unknown. 
4.2 Compliance 
     To determine the level of subject compliance, the initial weight of each toothpaste 
tube was documented in the subject’s chart at the Baseline (Day 0) appointment. At the 
Day 21 Study Visit, unused toothpaste was collected and re-weighed.  If more than 60 
percent of the assigned toothpaste remained, the subject would be considered non-
compliant, and face dismissal from the study.  Based on the weight of the unused 
toothpaste, all thirty subjects demonstrated compliance with the study protocol. 
 4.3 Background Characteristics 
     Descriptive statistics for the thirty study participants are provided in Table 1, with the 
demographic information of the subjects at baseline classified according to dentifrice 
group. Of the thirty subjects who qualified for the study, 16 subjects were randomized 
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into the Colgate Total® group (seven males (43.8%) and nine females (56.3%), mean 
age: 26.1 ± 5.2 years old), and fourteen subjects were randomized into the Colgate 
Great Regular Flavor group (two males (14.3%) and twelve females (85.7%), mean age:  
27.1 ± 5.2 years old).  Independent samples t-tests were performed to investigate if a 
significant difference in age existed between the two groups, and no significant 
differences were observed between groups (p= .600) (Table 1).  Furthermore, the 
results of Fisher’s Exact Test revealed no significant differences between groups with 
respect to gender (p=.118) (Table 1).   
     Caucasians comprised the largest ethnicity in each group, with N=11 (68.8%) in the 
Colgate Total® group, and N = 9 (64.3%) in the Colgate Great Regular Flavor group.  
Asians constituted the next largest ethnic group, with N =2 (12.5%) in the Colgate Total® 
group, and N= 2 (14.3%) in the Colgate Great Regular Flavor group.  The remaining 
ethnicities, African American, Hispanic, and Other Race had N =1 subject of each 
ethnicity in both groups, with the Colgate Total® sample 6.3% of each ethnicity, and the 
Colgate Great Regular Flavor sample 7.1% of each ethnicity.  The results of Fisher’s 
Exact Test revealed no significant differences between the groups with respect to 
ethnicity (p= 1.00) (Table 1). 
4.4 Clinical Measures 
     At the screening appointment (Day -14), the subjects in the Colgate Total® group 
demonstrated a mean CAL ± SD of 0.76 mm ± 0.25 mm, and a mean BOP ± SD score 
of 0.47 percent ± 0.11 percent.  Comparatively, the subjects in the Colgate Great 
Regular Flavor group had a mean CAL ± SD 0.75 mm ± 0.34 mm, and a mean BOP ± 
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SD score of .49 percent ± 0.13 percent at the screening appointment.  Independent 
samples t-tests were performed to investigate if significant differences in CAL and BOP 
existed between the two groups, and no significant differences were noted between 
groups (p=.931 for CAL and p=.656 for BOP) (Table 1).  
     The study inclusion criteria required the subjects in both groups to demonstrate a 
BOP score of greater than or equal to 30 percent at Day -14, and a BOP score of less 
than or equal to10 percent at Day 0.  A paired samples t-test was performed to 
determine if overall significant differences existed between the BOP scores on Day -14 
and Day 0 pooling both the Colgate Total® and Colgate Great Regular Flavor groups 
together, and a significant difference was noted (p<.001) (Table 2).  A series of paired 
samples t-tests were conducted to determine if significant differences existed in the 
BOP scores at Day -14 and Day 0 within both groups (Table 2).  A significant decrease 
was noted in both the Colgate Total® group (p <.001) and the Colgate Great Regular 
Flavor group (p < .001) (Table 2). 
     Descriptive statistics of the Gingival and Plaque Indices are provided in Table 3, with 
the data classified according to dentifrice group and study appointment. At baseline 
(Day 0), the subjects in the Colgate Total® group demonstrated a mean GI score of 0.32 
± SD 0.13, and a mean PI score of 0.44 ± SD 0.29 (Table 3). Comparatively, subjects in 
the Colgate Great Regular Flavor Group demonstrated a mean GI score of 0.24 ± SD 
0.16, and a mean PI score of 0.38 ± SD 0.26 at baseline (Table 3).  On Day 14, the 
Colgate Total® groups GI also increased to a mean score of 1.40 ± SD 0.29, and the PI 
increased to a mean score of 1.51 ± SD 0.31 (Table 3).  Similarly, the Colgate Great 
Regular flavor groups scores increased, with the mean GI score 1.30 ± SD 0.25, and 
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the mean PI score 1.19 ± SD 0.26 (Table 3).  The GI and PI scores in both groups 
culminated on Day 21, with the mean GI score of Colgate Total® group 1.54 ± SD 0.30, 
and a mean PI score of 1.85 ± SD 0.43 (Table 3). The Colgate Great Regular Flavor 
group presented a mean GI score of 1.53 ± SD 0.30, and a mean PI score1.76 ± SD 
0.41 on Day 21 (Table 3).  By the Day 35 follow up appointment, both groups 
demonstrated a marked decrease in both GI and PI, with slightly higher scores than the 
Day 0 appointment.  The mean GI of the Colgate Total® group was 0.48 ± SD 0.27, and 
the mean PI score was 0.56 ± SD 0.19 (Table 3). The Colgate Great Regular Flavor 
group had corresponding GI scores of 0.40 ± SD 0.28, and a mean PI score of 0.44 ± 
SD 0.24 at the Day 35 study appointment (Table 3).  Longitudinal plots of the GI and PI 
measurements are depicted in Figure 4.2 and Figure 4.3, respectively. 
          A series of independent samples t-tests were conducted to ascertain if significant 
differences existed between the two groups in relation to the Gingival Index and Plaque 
Index scores at each time point.  No significant differences were noted between groups 
in regard to the GI and PI (p >0.05) at each time point with the exception of the Day 14 
Plaque Index (p=.005), with the Colgate Total® group demonstrating more plaque 
accumulation at this study time point (Table 3). 
     Paired samples t-tests were conducted to determine if significant overall differences 
existed in the Plaque and Gingival Index scores for both groups (merged data) over time 
(Table 4).  The Plaque and Gingival Index scores were compared by paired study visit 
(Day 0 to Day 14, Day 0 to Day 21, Day 0 to Day 35, Day 14 to Day 21, and Day 21 to 
Day 35) (Table 4).  The results of the paired samples test revealed that the GI and PI 
scores increased significantly from Day 0 to Day 21, and significant differences were 
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observed at all paired study visits for both the GI and PI (p < .05), except for the PI 
score for Day 0 to Day 35 (p=.091) (Table 4). 
     A series of paired samples t-tests were conducted to determine if significant 
differences existed in the Plaque and Gingival Index scores within both the Colgate 
Total® and Colgate Great Regular Flavor groups (Table 5).  The scores assessed on 
Day 0 and Day 14, Day 0 and 21, Day 0 and Day 35, Day 14 and Day 21, and Day 21 
and Day 35 were paired for comparison.  There was a noted increase in the mean 
difference of both the GI and PI scores from Day 0 to Day 14 and Day 0 to Day 21 in 
both the Colgate Total® and Colgate Great Regular Flavor groups (Table 5). The results 
of the paired samples t-tests demonstrated a significant difference between the GI and 
PI scores in both groups from Day 0 to Day 14, Day 0 to Day 21, Day 14 to Day 21, and 
Day 21 to Day 35 (p < .05) (Table 5).  There was not a significant difference between 
the PI scores from Day 0 to Day 35 in either group; however, the GI score for the 
Colgate Total® group  and the Colgate Great Regular flavor group increased significantly 
(p <.001 and p = .004, respectively) (Table 5). 
4.4A Longitudinal Intergroup Comparisons of Gingival Index and Plaque Index 
Over Time  
    A linear mixed model was used separately for both PI and GI outcomes to combine 
both time and group information into a statistical model that accounts for the dependent 
nature of the data.  During the experimental gingivitis phase, a statistically significant 
increase in both plaque biofilm accumulation (Plaque Index) and gingival inflammation 
(Gingival Index) was noted at each time point compared to Day 0 when controlling for 
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group (Day 14, Day 21, and Day 35) (p <0.05), with the exception of the PI score on 
Day 35 (p=.216) when controlling for group (Table 6).  A statistically significant 
difference between the Colgate Total® and the Colgate Great Regular Flavor groups 
was demonstrated for the PI outcome when controlling for time, with on average the 
Colgate Great Regular Flavor group demonstrating 146 units less PI than the Colgate 
Total Group (p=.031) (Table 6). However, there was not a statistical difference between 
groups for the GI outcome when controlling for time (p=.283) (Table 6).   
4.5 Microbial Pathogen Analysis of Four Pathogens 
     Analysis of four of the forty bacterial microbes analyzed using the checkerboard 
DNA-DNA hybridization technique are depicted in Table 7, with the data classified 
according to dentifrice group, pathogen, and study appointment.  The pathogens 
chosen for analysis include S. mitis, A. israelii, P. nigrescens, and F. nucleatum ss 
polymorphum. S. mitis were chosen because of their inherent association with gingival 
health, and A. israelii, P. nigrescens, and F. nucleatum ss polymorphum are pathogens 
associated with gingivitis.  Quantities of each pathogen taken from the two sites per visit 
were merged and averaged for the data analysis. 
    Relative to the pathogen S. mitis, the Colgate Total® group initially demonstrated a 
mean of 2.61 ± SD 2.09, and the Colgate Great Regular Flavor group revealed a mean 
of 2.02 ± SD1.76 at Day 0 (Table 7).  Both groups increased at Day 14 (Colgate Total® 
group mean 3.40 ± SD 2.63; Colgate Great Regular Flavor group mean 2.62 ± SD 
1.61); however, at Day 21, the Colgate Total® group demonstrated a decrease (mean 
2.98 ± SD 1.95), but the Colgate Great Regular Flavor group continued to increase 
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(mean 2.79 ± SD 1.76) (Table 7). By the Day 35 follow up appointment, both groups 
began to decrease, with the Colgate Total® group mean 2.72 ± SD 2.26, and the 
Colgate Great Regular Flavor group mean 1.69 ± SD 2.03 (Table 7). 
     The pathogen A. israelii showed similar results to S. mitis on Day 0 and 14.  The 
Colgate Total® group’s mean was 2.54 ± SD 1.67, and the Colgate Great Regular Flavor 
group demonstrated a mean of 2.31 ± SD 3.06 at Day 0 (Table 7).  On Day 14, the 
Colgate Total® group increased to a mean pathogen level of 4.90 ± SD 3.40, and the 
Colgate Great Regular Flavor group increased to a mean of 6.81 ± SD 6.57 (Table 7).  
In contrast to the S. mitis pathogen, the Colgate Total® group continued to increase 
(mean 5.67 ± SD 3.85), but the Colgate Great Regular Flavor group level decreased on 
Day 21 (mean 5.89 ± SD 4.83) (Table 7).  By Day 35, both groups markedly decreased, 
with the Colgate Total® group’s mean 2.92 ± SD 2.83, and the Colgate Great Regular 
Flavor group’s mean 2.07 ± SD 2.44 (Table 7). 
     The pathogen P. nigrescens demonstrated an increase from Day 0 to Day 21, and a 
notable decrease at the Day 35 follow up appointment in both groups.  At Day 0, the 
Colgate Total® group had a mean level of 0.94 ± SD 2.21; comparatively, the Colgate 
Great Regular Flavor group had a mean level of 0.54 ± SD 1.03 (Table 7).  The mean 
level of the Colgate Total® group on Day 14 was 3.95 ± SD 4.77, and the Colgate Great 
Regular flavor group mean level was 5.12 ± SD 4.73 (Table 7).  At the Day 21 
appointment, the Colgate Total® group level of P. nigrescens increased more (mean 
7.88 ± SD 6.13) when compared to the Colgate Great Regular flavor group (mean 6.74 
± SD 5.22) (Table 7).  At the Day 35 follow up appointment, both groups demonstrated 
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a distinct decrease, with the Colgate Total® group mean 1.13 ± SD 1.82, and the 
Colgate Great Regular Flavor group mean  0.85 ± SD 1.43 (Table 7).   
     The final pathogen analysis was conducted on F. nucleatum ss polymorphum, and 
the results were similar to P. nigrescens, with both groups increasing from Day 0 to Day 
21, and decreasing by the Day 35 follow up appointment.  On Day 0, the Colgate Total® 
group demonstrated a mean level of 1.75 ± SD 1.85, and the Colgate Great Regular 
Flavor group mean level was 0.99 ± SD 1.33 (Table 7).  The levels increased at Day 14, 
with the Colgate Total® group’s mean 3.55 ± SD 3.45, and the Colgate Great Regular 
Flavor group mean was 2.96 ± SD 2.04 (Table 7).  The levels of both groups further 
increased at Day 21, with the Colgate Total® group mean culminating at 5.98 ± SD 5.42, 
and the Colgate Great Regular Flavor group mean 4.25 ± SD 2.18 (Table 7).  Similar to 
the P. nigrescens pathogen, both groups notably decreased at the Day 35 appointment, 
with the Colgate Total® group mean level of F. nucleatum ss polymorphum measuring at 
1.04 ± SD 0.92, and the Colgate Great Regular Flavor group mean level 1.27 ± SD 1.61 
(Table 7).  
     A series of independent samples t-test were conducted to ascertain if significant 
differences between the two groups exist at each time point for all four pathogens. No 
significant differences were observed between the groups for any of the four pathogens 
at any time point (p > 0.05) (Table 7). 
     Paired samples t-tests were conducted to determine if significant differences existed 
in the four microbial pathogens (Table 8).  The pathogen averages acquired on were 
compared by paired study visit (Day 0 to Day 14, Day 0 to Day 21, Day 0 to Day 35, 
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Day 14 to Day 21, and Day 21 to Day 35 (Table 8).  The results of the paired samples 
test revealed significant differences for all four pathogens from Day 0 to Day 14 (p < 
.05) (Table 8).  In addition, significant differences were noted for A. israelii, P. 
nigrescens, and F. nucleatum ss polymorphum on Day 0 to Day 21 (p <.001); however, 
S. mitis was not significant (p=.179) (Table 8).  The mean difference level of the 
pathogens A. israelii, P. nigrescens, and F. nucleatum ss polymorphum increased from 
Day 0 to Day 21 in both the Colgate Total® and Colgate Great Regular Flavor groups; 
however, the pathogen S. mitis demonstrated an increase from Day 0 to Day 21 solely 
in the Colgate Great Regular group (Table 7).  Although there was an initial increase of 
S. mitis from Day 0 to Day 14 in the Colgate Total® group, the mean difference of the 
level of pathogen decreased from Day 14 to Day 21 (Table 7).  No significant 
differences were noted for any of the four pathogens on the Day 0 to Day 35 
comparison (p >.05) (Table 8).  The Day 14 to Day 21 comparison revealed significant 
differences for P. nigrescens and F. nucleatum polymorphum (p<.05); however, S. mitis 
and A. israelii were not significant (p=.709 and p=.965, respectively) (Table 8).  
Significant differences were noted for all pathogens (p<.001) with the exception of S. 
mitis (p=.135) from Day 21 to Day 35 (Table 8). 
       A series of paired samples t-tests were conducted to determine if significant 
differences existed in the four microbial pathogens within both groups (Table 9).  The 
pathogen averages acquired on Day 0 and Day14, Day 0 and 21, Day 0 and Day 35, 
Day 14 and Day 21, and Day 21 and Day 35 were paired for comparison.   The results 
of the paired samples t-tests demonstrated a significant increase between A. israelii, P. 
nigrescens, and F. nucleatum ss polymorphum in both groups from Day 0 to Day 14 (p 
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< .05) (Table 9); however, S.mitis was significant only in the Colgate Total® group (p= 
.008) (Table 9).  The Day 0 to Day 21 pairing also revealed a significant increase 
between A. israelii, P. nigrescens, and F. nucleatum ss polymorphum in both groups (p 
<.05) (Table 9).  There was not a significant difference with S. mitis in either group 
(p=.512, p= .229) (Table 9).  In addition, there was not a significant difference in any of 
the four pathogens in the Day 0 to Day 35 pairing for either group (Table 9).  However, 
the Day 14 to Day 21 pairing revealed a significant increase with P. nigrescens and F. 
nucleatum ss polymorphum in the Colgate Total® group (p <.05), and the pathogen F. 
nucleatum ss polymorphum was near significance in the Colgate Great Regular Flavor 
group (p=.055); the remaining pathogens were not significant in either group (p>.05) 
(Table 9).  Finally, the Day 21 to 35 pairing revealed significant decreases for all of the 
pathogens in both groups (p <.05) with the exception of S. mitis (p=.547 in the Colgate 
Total® group, and p =.177 in the Colgate Great Regular Flavor group) (Table 9). 
4.6  Microbial Analysis of all Forty Pathogens 
     The forty microbial pathogens evaluated by the previously described DNA-DNA 
Hybridization technique were statistically analyzed, and categorized into the seven 
complexes as previously described by Socransky et al (Figure 4.2).62  Wilcoxon Rank 
Sum and Wilcoxon Signed Rank tests were conducted to ascertain statistical 
significance in each group and between groups.  The bacterial counts of each complex 
for each subject at Baseline were classified by dentifrice group, and are depicted in 
Table 10.  Total bacterial counts increased significantly from baseline to Day 21 and 
decreased significantly from Day 21 to Day 35 (p<0.05) (Figure 4.2).  All microbial 
complexes demonstrated statistically significant increases from Day 0 to Day 21 in both 
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the Colgate Total® and the Colgate Great Regular Flavor Groups (Figure 4.2).  The 
results of the analysis of all forty pathogens revealed limited significant differences 
between groups at certain time points, and the proliferation of certain pathogens was 
noted.  These results prompted further evaluation of all forty pathogens to test the 
hypothesis in this thesis, rather than the sole four pathogens initially chosen. 
4.6a  Microbial Analysis of the Blue (Actinos) Complex 
     There were four pathogens analyzed in the Blue (Actinos) Complex, including 
A.gerencseriae, A.israelli, A.naeslundi, and A.oris.  From Day 0 to Day 14, all four 
pathogens demonstrated significant increases in counts in both groups (p < 0.05), but 
no significant differences were noted between groups (p >0.05) (Table 11).  A.naeslundi  
was near significance (p=0.093), with less microbial growth in the Colgate Total® group 
(Table 11).  In addition, Colgate Total® also demonstrated a tendency to inhibit A. oris 
proliferation (p=0.142) (Table 11). 
     From Day 14 to Day 21, no significant differences were noted in either group (p 
>0.05) (Table 18).  The Colgate Great Regular Flavor group counts decreased for all 
four pathogens, and the A.israelli,  A.naeslundi, A.oris counts were near significance 
(p=0.052, p=0.070, p=0.077, respectively).   Comparatively, the Colgate Total® groups  
counts continued to increase.  In addition, when compared to the Colgate Total® group, 
the Colgate Great Regular Flavor group demonstrated a tendency to inhibit 
A.gerencseriae growth (p=0.101) (Table 18).  
     From Day 0 to Day 21, all four pathogens demonstrated significant increases in 
counts in both groups (p < 0.05), but no significant differences were noted between 
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groups (p >0.05) (Table 25).   When compared to the samples taken on Day 21, the Day 
35 counts revealed significant decreases in both groups (p <0.05), and no significant 
differences were noted between groups (p>0.05) (Table 32). 
4.6b  Microbial Analysis of the Yellow Complex 
     There were five pathogens analyzed in the Yellow Complex, including S.gordonii, 
S.intermedia, S.mitis, S.oralis, and S.sanguinis.  From Day 0 to Day 14, S.gordonii, 
S.intermedia, and S.sanguinis demonstrated significant increases in counts in both 
groups, and S. mitis increased significantly solely in the Colgate Total® group (p < 0.05) 
(Table 12).  S. oralis did not significantly change in either group (Table 12).  No 
significant differences were noted between groups (p >0.05) (Table 12). 
     From Day 14 to Day 21, the Colgate Great Regular Flavor group revealed a 
significant decrease for the S.sanguinis pathogen (p=0.035); S.gordonii was nearly 
significant (p=0.068) (Table 19).  No significant differences were noted in the Colgate 
Total® group, and no significant differences were noted between groups for any of the 
five pathogens (p> 0.05) (Table 19). 
     From Day 0 to Day 21, the S.gordonii increase in the Colgate Total® group was near 
significance (p=0.051), and the S.intermedia counts increased significantly in both 
groups (p=0.035 in the control group and p=0.003 in the test group) (Table 26).  There 
was no significant difference between groups in any of the five pathogens (p>0.05) 
(Table 26). 
     On Day 35, the pathogen counts in each group decreased from the Day 21 amounts 
(Table 33). Significant decreases were noted in S.intermedia in the Colgate Great 
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Regular Flavor group (p=0.004), and the Colgate Total® group was near significance 
(p=0.058) (Table 31).  Both groups exhibited a tendency to prevent S.oralis proliferation 
(p=0.153 in the control group and p=0.159 in the test group) (Table 33).  In addition, 
when compared to the Colgate Total® group, the Colgate Great Regular Flavor group 
demonstrated an inclination to inhibit S.mitis growth (p=0.070) (Table 33). 
4.6c  Microbial Analysis of the Purple Complex 
     There were two pathogens analyzed in the Purple Complex, A.odontolyticus and 
V.parvula.  From Day 0 to Day 14, significant increases were noted for both pathogens 
in both groups (p<0.05); however, there was no significant difference between groups 
(p>0.05) (Table 13).  The quantities of both pathogens continued to increase in the 
Colgate Total® group, and decreased in the Colgate Great Regular Flavor group from 
Day 14 to Day 21 (Table 20).  With the exception of V. parvula in the Colgate Total® 
group which was near significance (p=0.083), these changes were not statistically 
significant (p>0.05) (Table 20).  There were no significant differences between groups 
(p>0.05) (Table 20).   
     Both pathogens in the Purple Complex increased from Day 0 to Day 21, with 
significant increases in A.odontolyticus in both groups (p<0.05); however, the increase 
of the quantity of V.parvula was only significant in the Colgate Total® group (p=0.002) 
(Table 27).  There were no significant differences between groups (p>0.05) (Table 27).  
At Day 35, both pathogens demonstrated a decrease in quantity compared to Day 21, 
with significant decreases for A.odontolyticus in both groups (p<0.05); however the 
decrease of the quantity of V.parvula was only significant in the Colgate Total® group, 
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which was similar to the Day 0 to Day 21 differences (Table 34).  There were no 
significant differences between groups (p>0.05) (Table 34).   
4.6d  Microbial Analysis of the Green Complex 
     There were five pathogens analyzed in the Green Complex, including 
A.actinomycetemcomitans, C.ochracea, C.gingivalis, C.sputige, and E.corrodens.  All of 
the pathogens demonstrated an increase in quantity from Day 0 to Day 14, with the 
exception of A.actinomycetemcomitans in the Colgate Total® group (Table 14).  
Significant increases were noted for C.ochracea and C.gingivalis in both groups 
(p<0.05), and C.sputige significantly increased in the Colgate Total® group (p=0.039), 
and was near significance in the Colgate Great Regular Flavor group (p=0.078) (Table 
14).  The sole significant difference between groups was with 
A.actinomycetemcomitans, with the Colgate Total® dentifrice demonstrating a tendency 
to inhibit A.actinomycetemcomitans proliferation (p=0.012) (Table 14). 
    Analysis of the changes from Day 14 to Day 21 revealed a continual increase in 
A.actinomycetemcomitans and C.ochracea quantities in both groups; an increase in 
C.gingivalis and E.corrodens in the Colgate Great Regular Flavor group, and C.sputige 
in the Colgate Total® group; however, C.gingivalis and E.corrodens decreased in the 
Colgate Total® group, and C.sputige decreased in the Colgate Great Regular Flavor 
group, with no significant differences in either group (p>0.05) (Table 21).  The increase 
of A.actinomycetemcomitans was near significance in the Colgate Total® group 
(p=0.083)(Table 21).  There were no significant differences in the microbial quantity 
increases between the two groups (p>0.05) (Table 21).  With the exception of  
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A.actinomycetemcomitans in the Colgate Total® group, the quantities of pathogen also 
increased from Day 0 to Day 21, with significant increases noted for C.ochracea and 
C.gingivalis in both groups (p<0.05), and C.sputige in the Colgate Total® group 
(p=0.002) (Table 28).  The increase of A.actinomycetemcomitans in the Colgate Great 
Regular Flavor group was near significance (p=0.068) (Table 28).  Similar to the Day 0 
to Day 14 changes, the sole significant difference between groups was with 
A.actinomycetemcomitans, with the Colgate Total® dentifrice demonstrating a tendency 
to inhibit A.actinomycetemcomitans proliferation (p=0.038) (Table 28). 
     At Day 35, all five pathogens demonstrated a decrease in total quantity from Day 21, 
with significant decreases noted in C.ochracea and C.sputige in both groups (p<0.05) 
(Table 35).  C.gingivalis demonstrated a significant decrease in the Colgate Great 
Regular Flavor group (p=0.035), and was near significant in the Colgate Total® group 
(p=0.093) (Table 35).  A.actinomycetemcomitans and E.corrodens were near 
significance in the Colgate Great Regular Flavor group (p= 0.058 and p=0.078, 
respectively), but did not significantly decrease in the Colgate Total® group (p= 0.144 
and p=0.231, respectively) (Table 35).  There were no significant differences between 
groups (p>0.05) (Table 35). 
4.6e  Microbial Analysis of the Orange Complex 
     There were twelve pathogens analyzed in the Orange Complex, including C.gracilis, 
C.rectus, C.showae, E.nodatum, F.nucleatum.ss.nucleatum, 
F.nucleatum.ss.polymorphum, F.nucleatum.ss.vincentii, F.periodonticum, P.micra, 
P.intermedia, P.nigrescens, and S.constellatus.  All pathogens increased in total count 
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from Day 0 to Day 14, and there was a significant increase in both groups for all of the 
pathogen counts (p<0.05) (Table 15).  There were no significant differences between 
groups for any of the twelve pathogens (p>0.05) (Table 15).  However, when comparing 
groups, the Colgate Total® dentifrice did demonstrate a tendency to inhibit proliferation 
of the F. nucleatum.ss.nucleatum, F.nucleatum.ss.vincentii, and P.micra pathogens (p= 
0.131, p=0.154, and p=0.077, respectively) (Table 15).   
     The twelve pathogens continued to increase from Day 14 to Day 21, with the 
exception of C.rectus and C. showae, which decreased solely in the Colgate Great 
Regular Flavor group (Table 22).  Significant increases were noted in both groups for 
the F.nucleatum.ss.nucleatum and F.nucleatum.ss.vincentii pathogens (p<0.05) (Table 
22).  Significant increases were also noted for C.gracilis, E.nodatum, 
F.nucleatum.ss.polymorphum, F.periodonticum, P.micra, P.intermedia, and 
P.nigrescens in the Colgate Total® group (p<0.05) (Table 22).  P. nigrescens, 
F.periodonticum, and F.nucleatum.ss.polymorphum were near significance in the 
Colgate Great Regular Flavor group (p=0.078, p= 0.068, and p=0.091, respectively) 
(Table 22).  The sole significant difference between groups was found in P. nigrescens, 
with the Colgate Great Regular Flavor dentifrice demonstrating a tendency to inhibit P. 
nigrescens proliferation more effectively when compared to Colgate Total® (p=0.034) 
(Table 22).  Similarly, P. intermedia was near significance (p=0.052), with the Colgate 
Great Regular Flavor dentifrice demonstrating a tendency to inhibit P.intermedia growth 
more effectively when compared to Colgate Total® (Table 22).   
     The results from Day 0 to Day 21 mirrored the results from Day 0 to Day 14, with all 
pathogens increasing in total count from Day 0 to Day 21, with a significant increase in 
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both groups for all of the pathogen counts (p<0.05) (Table 29).  There were no 
significant differences between groups for any of the twelve pathogens (p>0.05); 
however, P. micra was near significant, with the Colgate Total® dentifrice demonstrating 
a tendency to inhibit growth (p=0.077) (Table 29).  On Day 35, all pathogens 
demonstrated a decrease in total quantity from Day 21, with significant decreases noted 
in all twelve (p<0.05) (Table 36).  There were no significant differences noted between 
groups (p>0.05) (Table 36.) 
4.6f Microbial Analysis of the Red Complex 
      There were three pathogens analyzed in the Red Complex, including T.forsythia, 
P.gingivalis, and T.denticola.  All pathogens increased in quantity from Day 0 to Day 14, 
with significant increases were noted for all three pathogens in both groups, with the 
exception of P. gingivalis in the Colgate Total® group (p=0.193) (Table 16).  A significant 
difference was noted between groups in regard to the pathogen P.gingivalis, with the 
Colgate Total® dentifrice demonstrating a tendency to inhibit proliferation of this 
pathogen more effectively when compared to Colgate Great Regular Flavor (p=0.006)  
(Table 16).  In addition, T. Forsythia growth was also depressed by the Colgate Total® 
dentifrice when compared to the control, although this difference was not significant 
(p=0.131) (Table 16).   
     The three pathogens continued to increase from Day 14 to Day 21, with significant 
increases solely in the Colgate Total® group for all of the pathogens (p<0.05) (Table 23).  
There was no significant difference noted between the two groups for any of the 
pathogens (p>0.05) (Table 23).  The quantities of these three pathogens also increased 
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from Day 0 to Day 21, with significant increases noted for all pathogens in both groups 
(p<0.05) (Table 30).  There were no significant differences between groups (p>0.05) 
(Table 30).  On Day 35, all pathogens in both groups demonstrated a significant 
decrease (p<0.05), and there were no significant differences between groups (p>0.05) 
(Table 37.) 
4.6g Microbial Analysis of the Grey (Other) Complex 
       There were ten pathogens analyzed in the Grey (Other) Complex, including 
E.saburreum, G.morbillorum, L.bucallis, N.mucosa, P.acnes, P.melaninogenica, 
S.anginosus, S.noxia, T.socranskii, and S.mutans.  All pathogens increased in total 
count from Day 0 to Day 14.  There was a significant or near significant increase in both 
groups for all of the pathogen counts with the exception of N.mucosa (p=0.860 in the 
Colgate Total® group, and p=0.761 in the Colgate Great Regular Flavor group) (Table 
17).  In addition, L.bucallis did not significantly increase in the Colgate Total® group 
(p=0.323), but was near significance in the Colgate Great Regular Flavor group 
(p=0.058) (Table 17).  G.morbillorum increased significantly in the Colgate Total® group 
(p=0.016), and was near significance in the Colgate Great Regular Flavor group 
(p=0.078) (Table 17).  There were no significance differences noted between groups 
(p>0.05) (Table 17). 
     From Day 14 to Day 21, there were significant increases in the counts of T.socranskii 
in both groups (p<0.05), and significant increases in G.morbillorum (p=0.044) and 
S.noxia (p=0.003) solely in the Colgate Total® group (Table 24).  In addition, S. mutans 
and P. melaninogenica were near significance in the Colgate Total® group (p=0.074 and 
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p=0.051, respectively) (Table 24).  The pathogens E.saburreum, P.acnes, and S.noxia 
(Colgate Great Regular Flavor), and L.bucallis and N.mucosa (Colgate Total®) 
demonstrated decreases in pathogen counts; however, these were not significant 
decreases (Table 24).  There were no significant differences between groups, but 
S.noxia was near significance (p=0.085) (Table 24). 
     The comparison between Day 0 and Day 21 revealed all pathogens increased in 
quantity, with significant increases noted in both groups for E.saburreum, P.acnes, 
P.melaninogenica, S.anginosus, S.noxia, T.socranskii, and S.mutans (p<0.05)(Table 
31).   The increase in G.morbillorum was significant in the Colgate Total® group 
(p=0.001) and was near significance in the Colgate Great Regular Flavor Group 
(p=0.068) (Table 31).  The increase in L.bucallis was also near significance in the 
Colgate Great Regular Flavor group (p=0.068), but not in the Colgate Total® group 
(p=0.193) (Table 31).  The increases in N.mucosa were not significant in either group 
(p>0.05) (Table 31).  There were no significant differences noted between groups 
(p>0.05); however, the S.noxia increase was nearly significant, with the Colgate Great 
Regular Flavor group demonstrating the ability to inhibit proliferation of this pathogen  
when compared to Colgate Total® (p=0.085)(Table 31). 
     On Day 35, the ten pathogens demonstrated a decrease in microbial quantity in both 
groups when compared to Day 21, with the exception of N.mucosa, which increased in 
quantity in the Colgate Total® group (Table 38).  The decreases in quantities were 
statistically significant (p<0.05), with the exception of G.morbillorum and L.bucallis in the 
Colgate Great Regular Flavor group (p=0.194 and p=0.455, respectively), and 
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N.mucosa quantities in both groups (p>0.05) (Table 38).  There were no significant 
differences between groups (p>0.05) (Table 38). 
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CHAPTER V 
DISCUSSION 
 
5.1  Study Objective and Aim 
     The aim of this research project was to determine the effect of Colgate Total® 
toothpaste on microbial pathogens in plaque biofilm samples during the controlled 
environment of an experimental gingivitis model in the absence of the mechanical 
interruption of plaque biofilm.  My hypothesis was that Colgate Total® toothpaste, when 
compared to a standard of care toothpaste (Colgate Great Regular Flavor), would be 
more effective at reducing the microbial pathogen load.   
     The inflammatory response from experimental gingivitis is primarily due to microbial 
plaque accumulation. 6,7  The experimental gingivitis model is often chosen for clinical 
research to evaluate the changes in the inflammatory response as the process of 
moving from gingival health to gingivitis occurs.7  Clinical measures (including the 
Gingival and Plaque indices) were evaluated, and microbial plaque samples were 
obtained at Baseline, Day 14, 21 and 35.  Forty microbial pathogens isolated from the 
plaque samples were analyzed using the checkerboard DNA-DNA hybridization 
technique, and the pathogens S. mitis, A. israelii, P. nigrescens, and F. nucleatum ss 
polymorphum were initially chosen for in depth analysis for this thesis.  S. mitis were 
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chosen because of their inherent association with gingival health, and A. israelii, P. 
nigrescens, and F. nucleatum ss polymorphum are pathogens associated with gingivitis. 
The results of the analysis of all forty pathogens revealed significant differences 
between groups at certain time points, and trends were noted to suppress the 
proliferation of certain pathogens.  These results prompted further evaluation of all forty 
pathogens to test the hypothesis in this thesis, rather than solely the four pathogens 
initially chosen. 
5.2  Synthesis of Research Findings – Clinical Measures and Four Pathogens 
     The results of this study revealed that all thirty subjects developed gingivitis, and are 
supported by the statistically significant differences noted in the  Day 0 to Day 21 
Gingival and Plaque Index scores (p <.001, Table 4).  The documented increase in the 
Gingival and Plaque Index scores, combined with the weight of each subject’s unused 
toothpaste, yields evidence that all thirty subjects were compliant with the study protocol 
(Table 39).  Two of the pathogens associated with gingivitis (P. nigrescens and F. 
nucleatum ss polymorphum) increased in quantity in both groups from Day 0 to Day 21, 
and mirrored baseline on Day 35 (Table 7).  The third pathogen associated with 
gingivitis, A. israelii, increased in quantity from Day 0 to Day 21 in the Colgate Total® 
group, however, in the Colgate Great Regular Flavor group, the quantity of A. israelii 
pathogen increased from Day 0 to day 14, then decreased from Day 14 to Day 21 
(Table 7). On Day 35, the quantity of A. israelii mirrored baseline in both groups (Table 
7).  In the Colgate Total® group, the pathogen associated with gingival health, S. mitis, 
increased in quantity from Day 0 to Day 14, then decreased in quantity from Day 14 to 
Day 21, and mirrored baseline on Day 35 (Table 7).  However, S. mitis increased in 
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quantity from Day 0 to Day 21 in the Colgate Great Regular Flavor group, and then 
decreased to a level less than Baseline on Day 35 (Table 7).   
     Statistical analysis of the clinical measures (GI and PI) did not reveal overall 
significant differences among groups with the exception of Day 14, where the Colgate 
Total® group demonstrated significantly more plaque accumulation compared to the 
Colgate Great Regular Flavor group (Table 3) (Figure 4.3).  However, the Linear Mixed 
Model did reveal a significant difference for the PI outcome when controlling for time, 
with on average the Colgate Great Regular Flavor group demonstrating 146 units less 
PI than the Colgate Total Group (p=.031) (Table 6).  In their landmark experimental 
gingivitis studies in the 1960’s, Loe and colleagues used the identical Gingival and 
Plaque Indices uses in this study to evaluate the change in the gingival tissues and 
plaque accumulation in the absence of mechanical plaque removal.50,51  Their results 
demonstrated an increase in both the Gingival and Plaque Index scores from baseline 
to the point where the absence of oral hygiene culminated.50,51  In addition, the scores 
mirrored baseline when oral hygiene resumed, similar to what was revealed in this 
study.50   In 1978, Syed and Loesche used a modified version of the Gingival and 
Plaque indices used in this study in their 21 day experimental gingivitis model 
evaluating the effect of plaque age.55  The results of their study revealed an increase in 
plaque and gingivitis scores during the 21 day period with the absence of oral hygiene, 
although the increase was not as prominent from Day 14 to Day 21, similar to the 
results in this current study.55  Syed and Loesche also evaluated the microbial quantities 
of A. israelii, F. nucleatum, and S. mitis over the 21 day study period, and similar to the 
results in this study, the quantity of S. mitis decreased from Day 14 to Day 21, while the 
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pathogens A. israelii and F. nucleatum quantities increased.55  In 2004, in a repeat trial 
of previous experimental gingivitis participants who were classified as either high or low 
responders, Trombelli and colleagues found similar results, with both the Gingival and 
Plaque Index scores increasing during the 21 day study time period, and no significant 
differences between the two groups.53   
5.2a Synthesis of Research Findings - All Forty Microbial Pathogens 
     In depth analysis of all forty microbial pathogens revealed significant differences in a 
limited number of pathogens, and the inhibition of certain pathogen proliferation was 
observed even though the statistical tests did not detect differences.  The initial 
microbial species to establish growth on acquired pellicle include those from the Blue 
Complex (Actinomyces ) Yellow Complex (Streptococcus), and Purple Complex 
(Veillonella). 18  Small counts of these pathogens have been isolated in healthy gingiva, 
and they co-aggregate with one another for survival and growth.18  In experimental 
gingivitis, Actinomyces are the predominant microbial species, comprising up to fifty 
percent of the total microbial load.27   
     Small amounts of known periodontal pathogens have been detected in healthy 
sulci.18,49,62  In this study, there were diminutive mean counts of known periodontal 
pathogens T. forsythia. P. gingivalis, T. denticola, and A.actinomycetemcomitans 
present at Day 0. With the exception of A. actinomycetemcomitans, the statistical tests 
were unable to detect significant differences between groups among these pathogens; 
however, there were trends noted of the Colgate Total® dentifrice inhibiting proliferation 
of certain known periodontal pathogens early in the experimental gingivitis phase. 
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     Although the counts of the four Actinos Complex pathogens did not achieve 
statistical significance, the Colgate Total® dentifrice had a tendency to inhibit the 
proliferation of A. naeslundi and A. oris from Day 0 to Day 14, which is evident by the 
much lower change in bacterial count when compared to the Colgate Great Regular 
Flavor group (Table 11).  However, the data from Day 14 to 21 of all four pathogens 
reveals a decrease in the Colgate Great Regular flavor group counts, while the Colgate 
Total® group counts continued to increase (Table 18).  Although not significant, the 
results show that the Colgate Great Regular Flavor group had a tendency to depress 
the growth of the Actinos group pathogens from Day 14 to Day 21. By Day 35, all of the 
counts decreased significantly from Day 21; however, with the exception of A. 
gerencseriae and A. israelii in the Colgate Great Regular Flavor group, all of the counts 
were higher when compared to the Day 0 counts (Table 11 and Table 32). 
     The Colgate Great Regular Flavor dentifrice appeared to depress the growth of 
certain pathogens in the Yellow Complex more effectively.  The control toothpaste 
inhibited proliferation of S. mitis from Day 0 to 14 when compared to Colgate Total, ® but 
there were no significant differences between groups (Table 12).  Both dentifrices 
appeared to depress the growth of S. oralis, with no significant differences between 
groups (Table 12).  From Day 14 to Day 21, the counts of S. gordonii and S. sanguinis 
decreased in both groups, with the Colgate Great Regular Flavor dentifrice 
demonstrating a tendency to inhibit growth of these two pathogens when compared to 
the Colgate Total® group, with no significant differences between groups (Table 19).  At 
Day 35, all of the Yellow Complex pathogens decreased; however, when compared to 
the Day 0 counts, the Day 35 counts of the Colgate Great Regular Flavor group 
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demonstrated decreases for all pathogens with the exception of S. gordonii, and the 
Colgate Total® group counts were elevated for all pathogens with the exception of S. 
oralis (Table 12 and 33).  When comparing groups, the Colgate Great Regular flavor 
dentifrice appeared to inhibit S. mitis growth from Day 21 to 35 (Table 33). 
     Neither dentifrice appeared to have a significant effect on the Purple Complex 
pathogens from Day 0 to Day 14 when comparing groups, although the Colgate Total® 
counts increased less (Table 13).  The data from Day 14 to 21 reveals a tendency for 
the Colgate Great Regular Flavor dentifrice to inhibit proliferation of both pathogens, as 
the counts in this group decreased, and the counts in the Colgate Total® group 
increased (Table 20).  At Day 35, the microbial counts of both pathogens decreased in 
both groups, and both pathogen counts were elevated when compared to the Day 0 
counts (Table 13 and Table 34).  The Day 0 to Day 35 comparison counts in the 
Colgate Total® group were higher when compared to the Colgate Great Regular Flavor 
group, especially in regard to V. parvula (Table 13 and Table 34).   
     Analysis of the Green Complex changes from Day 0 to Day 14 revealed that all 
counts increased in both groups for all five pathogens with the exception of A. 
actinomycetemcomitans, which decreased solely in the Colgate Total® group (Table 28).  
This decrease is compelling because A. actinomycetemcomitans is a known periodontal 
pathogen often associated with Localized Aggressive Periodontitis (formerly known as 
Juvenile Periodontitis).86   Significant increases were noted for C.ochracea and 
C.gingivalis in both groups (Table 14).  C.sputige significantly increased in the Colgate 
Total® group, and was near significance in the Colgate Great Regular Flavor group 
(Table 14).  The sole significant difference between groups was with 
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A.actinomycetemcomitans, with the Colgate Total® dentifrice demonstrating a tendency 
to inhibit A.actinomycetemcomitans proliferation (Table 14).   
     This tendency appeared to diminish from Day 14 to Day 21, as data analysis reveals 
that A.actinomycetemcomitans and C.ochracea quantities increased in both groups, 
with the increase of A.actinomycetemcomitans in the Colgate Total® group near 
significance (Table 21). In addition, an increase in C.gingivalis and E.corrodens was 
observed in the Colgate Great Regular Flavor group, and C.sputige increased in the 
Colgate Total® group; however, C.gingivalis and E.corrodens decreased in the Colgate 
Total® group, and C.sputige decreased in the Colgate Great Regular Flavor group, with 
no significant differences in either group or between the two groups (Table 21).   
     At Day 35, all five pathogens demonstrated a decrease in total quantity from Day 21, 
with no significant differences noted between groups; however, when comparing the 
pathogen counts from Day 0 to Day 35, A.actinomycetemcomitans, C.ochracea, and 
C.sputige counts were lower and C.gingivalis were higher in both groups on Day 35 
(Table 14 and 35).  E.corrodens decreased in the Colgate Great Regular Flavor group 
and increased in the Colgate Total® group (Table 14 and Table 35).  The decrease from 
Day 0 and Day 35 in the A.actinomycetemcomitans counts was greater in the Colgate 
Total® group (.18 vs .02) (Table 14 and 35).  The triclosan-copolymer appeared to affect 
the proliferation of this known periodontal pathogen throughout the entire 35 Day study 
period. 
     Analysis of the Day 0 to Day 14 changes in the Orange Complex revealed all 
microbial counts significantly increased in both groups (Table 15).  Although there were 
no significant differences between groups for any of the twelve pathogens, the Colgate 
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Total® dentifrice did demonstrate a tendency to inhibit proliferation of the F. 
nucleatum.ss.nucleatum, F.nucleatum.ss.vincentii, and P.micra pathogens, which is 
evident by the much smaller increase of these pathogen counts (Table 15). 
     It appears that the trends noted from Day 0 to 14 were not as prominent from Day 14 
to Day 21.  The twelve pathogens continued to increase, with the exception of C.rectus 
and C. showae, which decreased solely in the Colgate Great Regular Flavor group 
(Table 22).  Significant increases were noted in both groups for the 
F.nucleatum.ss.nucleatum and F.nucleatum.ss.vincentii pathogens (Table 22). 
Significant increases were also noted for C.gracilis, E.nodatum, 
F.nucleatum.ss.polymorphum, F.periodonticum, P.micra, P.intermedia, and P.nigrescens 
in the Colgate Total® group, and P. nigrescens, F.periodonticum, and 
F.nucleatum.ss.polymorphum were near significance in the Colgate Great Regular 
Flavor group (Table 22).  The sole significant difference between groups was found in P. 
nigrescens, with the Colgate Great Regular Flavor dentifrice demonstrating a tendency 
to inhibit P. nigrescens proliferation more effectively when compared to Colgate Total® 
(Table 22). Similarly, the Colgate Great Regular Flavor dentifrice demonstrated a 
tendency to inhibit P.intermedia growth more effectively when compared to Colgate 
Total® (Table 22).  
     On Day 35, all members of the Orange Complex significantly decreased from Day 21 
(Table 36).  Comparison of the Day 0 to Day 35 differences revealed the Colgate Total® 
group counts decreased from their original numbers, with the exception of P.nigrescens, 
C. gracilis, and S. constellatus (Table 15 and Table 36).  However, the Colgate Great 
Regular Flavor group counts were higher on Day 35 than on Day 0, with the exception 
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of C.gracilis, which increased, and S.constellatus, which returned to its original count 
(Table 15 and Table 36). The differences of F.nucleatum.ss.nucleatum, 
F.nucleatum.ss.polymorphum, F.nucleatum.ss.vincentii, and P. micra pathogens were 
more notable than the rest of the pathogens (Table 15 and Table 36).  A study by 
Socransky and colleagues revealed that the Orange Complex pathogens are late 
colonizers associated with the known periodontal pathogens in the Red Complex.62  
Orange Complex pathogens are also associated with increased pocket depth, and 
establish prior to the Red Complex pathogens.62  These results suggest that the 
triclosan-copolymer formulation may have an effect on the proliferation of the Orange 
Complex pathogens over time, and further research may be warranted. 
     As previously mentioned, the three Red Complex pathogens are closely associated 
with periodontal disease, and are found in increased numbers in both periodontal 
pockets and subjects with high BOP scores.62  All pathogens in the Red Complex 
increased in quantity from Day 0 to Day 14, with significant increases for all three 
pathogens in both groups, with the exception of P. gingivalis in the Colgate Total® group 
(Table 16).  A significant difference was noted between groups in regard to the pathogen 
P.gingivalis, with the Colgate Total® dentifrice demonstrating a tendency to inhibit 
proliferation of this pathogen more effectively when compared to Colgate Great Regular 
Flavor (Table 16).  In addition, T. Forsythia growth was also depressed by the Colgate 
Total® dentifrice when compared to the control, although this difference was not 
significant (Table 16).   
     Analysis of the changes in the Red Complex from Day 14 to Day 21 depict that the 
three pathogens continued to increase in count, with significant increases solely in the 
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Colgate Total® group for all of the pathogens, and there was no significant difference 
noted between the two groups for any of the pathogens (Table 23).  Of the three 
pathogens, only P. gingivalis increased more in the Colgate Total® group when 
compared to the control (Table 23).  Similar to the Orange Complex, it appears that the 
differences noted from Day 0 to 14 were not as prominent from Day 14 to Day 21.   
     At Day 35, all pathogens in both groups demonstrated a significant decrease, and 
there were no significant differences between groups.  When comparing the pathogen 
counts from Day 0 and Day 35, T. forsythia counts were slightly higher in the Colgate 
Great Regular Flavor group, and T.denticola were slightly lower when compared to 
Colgate Total. ®  However, while the P. gingivalis counts in the Colgate Total® group 
returned to their original Day 0 value, the count in the Colgate Great Regular Flavor 
group was .40 units higher (Table 16 and Table 37).  It appears that the triclosan-
copolymer had a continued effect on P.gingivalis during the entire study period.  This 
finding is significant because in the study by Socransky and colleagues, periodontal 
pockets containing P.gingivalis exhibited the greatest depth, regardless if P.gingivalis 
was discovered  alone or with the other members of the Red Complex.62  
     Analysis of the Grey Complex pathogens revealed all pathogens increased from Day 
0 to Day 14, with no significant differences between groups (Table 17).  From Day 14 to 
Day 21, several of the pathogen counts decreased, including E.saburreum, P.acnes, 
and S.noxia (Colgate Great Regular Flavor), and L.bucallis and N.mucosa (Colgate 
Total®); however, these were not significant decreases, and there were no significant 
differences between groups (Table 24).   S.noxia was near significance, with the 
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Colgate Great Regular Flavor dentifrice demonstrating a tendency to inhibit proliferation 
of this pathogen when compared to Colgate Total® (Table 24).   
     On Day 35, all Grey Complex pathogens decreased in count, with the exception of 
N.mucosa in the Colgate Total® group, which increased (though not significantly) (Table 
38).  Analysis of the changes from Day 0 to Day 35 revealed minor differences in 
counts, with the Colgate Total® group counts lower in six of the ten pathogens, and the 
Colgate Great Regular Flavor group higher in seven of the ten pathogens at Day 35 
(Table 17 and Table 38).  The only notable difference was the increase of N.mucosa 
counts in the Colgate Total® group, which was 1.54 units higher on Day 35 than Day 0 
(Table 17 and 38). 
     Based on the findings of this study, it is apparent that the antimicrobial effect of 
triclosan-copolymer is not more effective at reducing gingival inflammation and plaque 
accumulation.  However, Colgate Total® inhibited the proliferation of a limited number of 
known periodontal pathogens when compared to a standard of care fluoride dentifrice in 
the absence of mechanical plaque removal.  Previous studies of Colgate Total® have 
conveyed evidence of the antimicrobial and anti-inflammatory effect of this dentifrice on 
gingivitis reduction, plaque control, and periodontal health.8–12,71,72   However, in this 
study, brushing and flossing was eliminated to determine the sole effect of triclosan-
copolymer formulation on microbial pathogens.  The control group was dispensed 
Colgate Great Regular Flavor toothpaste, which contains the active ingredient sodium 
monofluorophosphate 0.76% (0.15% w/v fluoride ion), and the inactive ingredients 
dicalcium phosphate dihydrate, water, glycerin, sorbitol, sodium lauryl sulfate, cellulose 
gum, flavor, tetrapotassium pyrophosphate, and sodium saccharin.82  The results of this 
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study revealed there was no statistical significance between groups for the clinical 
measures (with the exception of the Day 14 Plaque Index), and the microbial pathogen 
differences were limited; however, the lack of a true control group fails to eliminate the 
possibility that one of the ingredients in the Colgate Great Regular dentifrice is also 
effective at preventing microbial plaque formation and gingivitis.  Colgate Great Regular 
Flavor contains sodium fluoride, and research has shown that sodium fluoride use has 
been effective at reducing microbial pathogen load.87   
The results of this study contribute to the current body of knowledge because it appears 
that the triclosan-copolymer dentifrice has an effect on known periodontal pathogens 
such as those in the Orange Complex group, P.gingivalis, and 
A.actinomycetemcomitans in the absence of mechanical plaque removal.  
     There were several limitations in the research design that could have affected the 
outcome. The time commitment required for participants on Day 14 and Day 21 may 
have narrowed the pool of eligible candidates due to work, school, or familial 
obligations.  The extensive inclusion and exclusion criteria also limited the number of 
qualified subjects, which was evidenced through the high percentage of individuals who 
failed the initial screening appointment (49 percent).  To be eligible for randomization 
into the study, a Probing Pocket Depth of < 4 mm in all sites, a Mean Clinical 
Attachment Level < 2 mm on each tooth, and a BOP score of ≤ to ten percent at 
Baseline was mandatory.  Because of the high prevalence of gingivitis in adults, the 
results from the study participants may not be representative of the entire population.  In 
addition, the composition of plaque during an experimental gingivitis model differs from 
traditional gingivitis, which further limits the ability to generalize the results to the 
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population.   Furthermore, the triclosan copolymer formulation may have been 
ineffective on such exceptionally healthy gingiva, and the three week timeframe of the 
experimental gingivitis model might not have been sufficient for the anti-inflammatory 
properties of Colgate Total® to manifest.   
     The lack of a sample size calculator cannot ensure that there was a large enough 
sample for adequate statistical power.85  Although trends were observed revealing the 
ability of the triclosan – copolymer formulation to inhibit the proliferation of certain 
known periodontal pathogens, the small sample size may have prohibited the detection 
of a statistical difference.  Furthermore, the protocol for placement and removal of the 
stent for the daily brushings created the possibility that the isolated plaque biofilm 
overgrowth may have become dislodged, which could have affected both the Gingival 
and Plaque Indices, and the total microbial quantity.  
      A true control group that did not use any toothpaste in the stent was not included as 
a component of the study protocol, so there is no data to compare a true control with the 
other two dentifrices.  Moreover, all subjects were dispensed Colgate Great Regular 
Flavor dentifrice for use during the “washout” period (Day -14 to Baseline), and resumed 
use of this dentifrice during the recovery phase (Day 21 to Day 35).  It is possible that 
the control group’s use of the same dentifrice for the entire 49 day study may have 
affected the outcome, because the oral flora were already accustomed to the 
ingredients in the Colgate Great Regular Flavor dentifrice.   
     Although all thirty subjects demonstrated compliance based on the weight of 
toothpaste remaining (less than 60 percent), two subjects in the Colgate Total group® 
were close to non-complaint, returning 54 and 55 percent of their toothpaste (Table 39).  
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The highest percentage of toothpaste returned in the Colgate Great Regular Flavor 
group was 41 (Table 39).  The combined average toothpaste returned of both groups 
was 27 percent; however, the Colgate Total® group average was 30.25 percent, and the 
Colgate Great Regular Flavor average was 22.64 percent (Table 39).  The use of more 
toothpaste by the Colgate Great Regular Flavor group may have impacted the study 
outcomes. 
     Although all examiners were calibrated, and every effort was made for the same 
examiner to evaluate the same subjects over the 49 day study period, there were 
instances that this was not possible due to the patient’s schedules and the study 
protocol; therefore, intra-examiner reliability could have affected the significant 
difference in plaque accumulation between groups on the Day 14 study visit. 
5.3 Future Directions 
     The effect of Colgate Total’s® triclosan-copolymer formulation on the development of 
gingivitis has been extensively studied using clinical parameter such as bleeding on 
probing, the Gingival and Plaque Indices, oral fluids such as saliva and gingival 
crevicular fluid, and microbial pathogens.  Although the results of this study revealed 
limited differences in regard to the 40 microbial pathogens analyzed, the known 
periodontal pathogens that did exhibit differences warrant further study on this topic.  
The preponderance of patients incompliant with oral hygiene recommendations 
combined with those with limited dexterity (such as the elderly, arthritic, and 
developmentally disabled) compels the need for evidence-based product 
recommendations that can improve their oral health.   
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     New directions should also be considered for future research studies.  The 
harvesting and analysis of gingival tissue samples could be conducted to determine the 
effect of Colgate Total® toothpaste on gingival tissue morphology and transcriptomes.  
Offenbacher and colleagues used a stent for isolation in an experimental gingivitis 
model to evaluate the change in gene-expression profiles in tissue samples during the 
35 day time period.88  A study by Jönsson and colleagues evaluated the Gingival Index, 
microbial pathogens (using the checkerboard DNA-DNA hybridization method 
previously described by Socransky), and harvested tissue samples to compare 
differences in gene expression at all study time points during an experimental gingivitis 
model.89  Similar studies could be conducted to compare the effect of Colgate Total® 
toothpaste (isolated in a stent) and a true control group (with an empty stent) to 
determine the effect of this dentifrice on gene expression in tissue samples.  A recent 
study by Lee et al was able to classify participants who abstained from oral hygiene as 
either high or low responders based on their inflammatory response, and the clinical 
and microbial changes were similar to previous experimental gingivitis studies.54  
Similarly, an experimental gingivitis study with Colgate Total® toothpaste could be 
conducted to determine the effect of this dentifrice on microbial pathogens in subjects 
classified as having a high response to gingivitis.   
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CHAPTER VI 
 
CONCLUSIONS 
 
     The purpose of this study was to determine the effect of Colgate Total® toothpaste 
(compared to a standard of care fluoride dentifrice) on microbial pathogens in plaque 
biofilm samples during an experimental gingivitis model in the absence of mechanical 
plaque removal.  Oral inflammatory disease is widespread, and the relationship 
between oral health and systemic disease affirms the need to maintain proper oral 
health.1,5  The rationale for this research study was to ascertain if the triclosan-
copolymer formulation in Colgate Total® could benefit patients who are incompliant with 
oral hygiene recommendations, and those with compromised manual dexterity such as 
the elderly, arthritic, or the developmentally disabled through improved oral health.  
     This research study was conducted during a randomized, controlled, clinical trial at 
the University of Michigan Center for Oral Health Research (MCOHR).  This was a pilot 
study, with the goal of acquiring data to support a future study on a larger scale.  The 
total number of subjects enrolled for participation was thirty, with fifteen subjects in each 
arm of the study.   
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     The experimental gingivitis model is often used in clinical research to determine the 
changes in the inflammatory response as the process of moving from gingival health to 
115 
 
gingivitis occurs in a controlled environment.7  The statistical analysis included 
descriptive statistics, independent samples t-tests, paired t-tests, Wilcoxon Signed Rank 
tests, Wilcoxon Rank Sum tests, and a linear mixed model to control all of the variables 
in one model.  The analysis of the data revealed no significant differences between 
groups in regard to the Gingival and Plaque Indices and the four microbial pathogens 
quantities at any time point, with the exception of Day 14,where the Colgate Total® 
group demonstrated significantly more plaque accumulation compared to the Colgate 
Great Regular Flavor group (Table 3) (Figure 4.3).  Further analysis of the 40 microbial 
pathogens revealed limited significant differences between groups in regard to known 
periodontal pathogens such as those in the Orange Complex, P.gingivalis, and 
A.actinomycetemcomitans.  Limited differences were also seen in the Actinos (Blue 
Complex) group from Day 0 to Day 14 (Table 11).  These results warrant further study 
on this topic.   
     Although the examiners and subjects were both blinded to the assignment of study 
arm, there were multiple examiners involved in data collection. Because the Gingival 
and Plaque Indices are subjective, it is possible that this data from this statistically 
significant time point is not truly different.  A single calibrated examiner could improve 
the reliability of the clinical measures such as the Gingival and Plaque indices in future 
studies.  In addition, the use of a true control group could provide additional insight on 
the effect of Colgate Total® and Colgate Great Regular Favor group on gingival 
inflammation, plaque accumulation, and the quantity of microbial pathogens associated 
with gingivitis in oral plaque samples.  Furthermore, it is possible that a true statistical 
difference existed and was not detected because of the small sample size of thirty 
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subjects.  A sample size calculator could determine if the sample size is adequate for 
the necessary statistical power.  Finally, the short duration of the experimental gingivitis 
model may not have been long enough to exhibit changes in subjects with such healthy 
gingiva.   
     Future studies should include new methods such as the harvesting and analysis of 
gingival tissue samples to determine the effect of Colgate Total® toothpaste on gingival 
tissue morphology and transcriptomes, and if subjects that classify as high or low 
responders to gingival inflammation benefit from the triclosan-copolymer formulation or 
other dentifrices.  The aim of future studies should be to provide dental hygienists with 
the ability to make evidence-based product recommendations to improve the oral health 
of patients with limited manual dexterity or inadequate oral hygiene. 
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FIGURE 4.1 
  
 
 
 
580 Interested in Study 
175 Completed Phone Screen 
78 Subjects Were Screened 
38 Failed Screening Visit 
40 Moved to Baseline Visit 
1 Failed to Show at Baseline 
1 Failed to Qualify at Baseline 
2 Failed to Show at Re‐baseline 
6 Failed to Qualify at Re‐baseline 
30 Enrolled In Study 
Control Arm 
N=15 
Treatment Arm 
N=15 
2 Exited Study 
1 Subject Added  1 Subject Added 
30 Subjects Completed Study 
Figure 4.1: Patient Recruitment and Enrollment Chart 
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FIGURE 4.2 
 
 
Figure 4.2: Longitudinal Plot of the Gingival Index for the Colgate Total® and Colgate 
Great Regular Flavor groups during the experimental gingivitis model.  No significant 
differences in the mean GI scores were observed between the two groups. 
 
Blue - Colgate Total® 
Red - Colgate Great Regular Flavor 
 
* †
     * † 
* p <0.001  † p <0.001
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      FIGURE 4.3 
 
 
 
Figure 4.3: Longitudinal Plot of the Plaque Index for both the Colgate Total® and    
Colgate Great Regular Flavor groups during the experimental gingivitis model.  
Significant differences in mean plaque scores were observed between groups at Day 14 
with the Colgate Total® group having significantly more plaque than the Colgate Great 
Regular Flavor group. 
 
        
 
 
 
Blue ‐ Colgate Total® 
Red ‐ Colgate Great Regular Flavor
          
  * † 
  * † 
p=0.017   * p <0.001  † p <0.001 
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FIGURE 4.4 
 
 
 
 
Figure 4.4: Longitudinal Plot of the S. Mitis mean pathogen average during the 
experimental gingivitis model.  No significant differences in the mean S. Mitis quantities 
were noted between groups at any time point. 
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FIGURE 4.5 
 
 
 
Figure 4.5: Longitudinal Plot of the A. israelii mean pathogen average during the 
experimental gingivitis model.  No significant differences in the mean A. israelii 
quantities were noted between groups at any time point. 
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FIGURE 4.6 
 
 
 
Figure 4.6: Longitudinal Plot of the P. nigrescens mean pathogen average during the 
experimental gingivitis model.  No significant differences in the mean P. nigrescens 
quantities were noted between groups at any time point. 
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FIGURE 4.7 
 
 
 
 
Figure 4.7: Longitudinal Plot of the F. nucleatum ss polymorphum mean pathogen 
Average during the experimental gingivitis model.  No significant differences in the 
mean F. nucleatum ss polymorphum quantities were noted between groups at any time 
point. 
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FIGURE 4.8 
      Figure 4.8: Proportions of each bacterial complex as defined by Socransky 
 shown by group over time.  Statistically significant differences in quantities of 
 bacteria within each group were observed between Day 0 and Day 21. 
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FIGURE 4.9 
 
 
 
 Figure 4.9: Mean quantities of each pathogen stratified by group over time. 
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TABLE 1 
Characteristics of Study Participants 
   Colgate Total®  Colgate Great Regular Flavor 
                                   Frequency (%)             Frequency (%)    Fisher’s Exact Test p 
 
Gender       16 (100%)     14 (100%)                      .118 
     Male       7 (43.8%)                  2 (14.3%) 
     Female       9 (56.3%)    12 (85.7%) 
 
Race       16 (100%)                 14 (100%)           1.00 
     African American        1 (6.3%)                    1 (7.1%) 
     Asian       2 (12.5%)      2 (14.3%)   
     Caucasian        11 (68.8%)      9 (64.3%)  
     Hispanic                     1 (6.3%)                    1 (7.1%) 
     Other Race        1 (6.3%)                    1 (7.1%) 
            Colgate Total®              Colgate Great Regular Flavor 
     N          Mean (SD)            N          Mean (SD)     t (df)             p 
   
Age        16    26.06 (5.23)           14       27.07 (5.15)       -.531 (28)       .600 
CAL at Screening (Day -14)     16      0.76 (0.25)           14        0.75 (0.34)         0.87 (28)        .931 
BOP at Screening (Day -14)           16      0.47 (0.11)        14         0.49 (0.13)       -.450 (28)        .656 
BOP at Baseline   (Day 0)              16          0.09 (0.04)           14         0.10 (0.06)        -.497 (28)       .623
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                                                   TABLE 2 
Paired Samples Tests of BOP Scores                                                                                 
   Paired Study Visit         N       Mean Diff. (SD)       t (df)               p             
 
      Day -14 to Day 0  30        .42 (.11)             20.37(29)       <.001 
 
Intergroup Paired Samples Tests of BOP Scores  
         Colgate Total®                                Colgate Great Regular Flavor                                    
   Paired Study Visit        N    Mean Diff. (SD)        t (df)      p   N     Mean Diff. (SD)       t (df)          p       
 
     Day -14 to Day 0 16    .41 (.11)       14.58 (15)    <.001        14      .42 (.12)          13.81 (13)    <.001  
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TABLE 3 
 Analysis of Gingival Index and Plaque Index 
    Colgate Total®            Colgate Great Regular Flavor 
  Study Visit                            N         Mean (SD)     N      Mean (SD)               t (df)               p 
 
    Day 0 
          Gingival Index             16          0.32 (0.13)               14       0.24 (0.16)          1.34 (28)         .192  
          Plaque Index        16          0.44 (0.29)               14       0.38 (0.26)          .607 (28)         .550 
     
    Day 14         
          Gingival Index             16           1.40 (0.29)              14            1.30 (0.25)            .906 (28)          .373 
          Plaque Index        16           1.51 (0.31)    14       1.19 (0.26)          3.02 (28)         .005 
      
     Day 21  
          Gingival Index        16            1.54 (0.30)             14       1.53 (0.30)          .103 (28)         .919 
          Plaque Index               16            1.85 (0.43)   14             1.76 (0.41)          .526 (28)         .603 
     
      Day 35         
           Gingival Index            16                0.48 (0.27)          14              0.40 (0.28)          .739 (28)        .466 
           Plaque Index              16                0.56 (0.19)   14              0.44 (0.24)          1.52 (28)        .140 
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TABLE 4 
Paired Samples Tests of the Gingival Index and Plaque Index for Both Groups Over Time                                        
      Paired Study Visit        N     Mean Diff.(SD)      t (df)            p             
 
   Day 0 – Day 14 
           Gingival Index         30       1.06 (.13)      45.77 (29)     <.001   
           Plaque Index           30       0.95 (.43)      11.99 (29)     <.001       
     
    Day 0 – Day 21 
          Gingival Index           30        1.25 (.16)      44.13 (29)    <.001                                
          Plaque Index      30        1.40 (.53)      14.39 (29)    <.001     
                  
    Day 0 – Day 35       
          Gingival Index           30       .157 (.14)        6.27  (29)   <.001                   
          Plaque Index      30       .095 (.30)        1.75  (29)    .091       
             
   
    Day 14 – 21 
         Gingival Index           30       .187 (.07)        14.56 (29)     <.001 
          Plaque Index     30       .445 (.51)          4.83 (29)     <.001 
 
    Day 21 – 35  
          Gingival Index        30        1. 09 (.06)     98.63 (29)    <.001 
          Plaque Index       30         1.30 (.44)    16. 30 (29)    <.001 
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TABLE 5 
Intergroup Paired Samples Tests of Gingival and Plaque Index Over Time  
                                                           Colgate Total®                                  Colgate Great Regular Flavor       
  Paired Study Visit        N      Mean Diff. (SD)      t (df)         p    N      Mean Diff.(SD)    t (df)           p 
 
    Day 0 – Day 14 
           Gingival Index     16      1.09 (.09)        46.94 (15)   <.001    14     1.03 (.16)     24.84 (13)     <.001 
           Plaque Index       16      1.02 (.43)         9.48  (15)   <.001      14 0.87 (.44)    7.39  (13)      <.001 
     
     Day 0 – Day 21 
          Gingival Index      16       1.27 (.15)       33.87 (15)   <.001       14   1.23 (.16)     28.18 (13)      <.001               
          Plaque Index 16       1.42 (.58)        9.80  (15)   <.001       14   1.37 (.49)     10.40 (13)      <.001 
     Day 0 – Day 35         
          Gingival Index       16       0.17 (.12)         5.47 (15)   <.001       14   0.15 (.16)       3.49 (13)       .004    
          Plaque Index  16       0.12 (.34)         1.39 (15)    .186       14    0.07 (.25)       1.03 (13)       .323 
 
    Day 14 – Day 21 
          Gingival Index 16      0.18 (.07)         10.27 (15)  <.001    14   0.19 (.07)      10.05 (13)       <.001 
          Plaque Index 16      0.40 (.57)          2.76  (15)  .014    14   0.50 (.43)       4.38  (13)         .001 
 
   Day 21 – Day 35 
         Gingival Index 16       1.11(.07)         65.03 (15)  <.001    14  1.08 (.05)        80.32 (13)      <.001 
         Plaque Index 16       1.30 (.46)       11.30 (15)  <.001      14  1.30 (.43)        11.42 (13)      <.001 
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TABLE 6 
Linear Mixed Model for Plaque Index 
Variable                 Coef.    Std. Error        t (df)           p 
 
Intercept    0.480        0.064        7.48(89.89)   .000 
 
Arm: Control   -0.146        0.065        -2.27(28)       .031 
 
Arm: Treatment      Ref           Ref             Ref             Ref 
 
Day 0       Ref           Ref             Ref             Ref 
 
Day 14                  0.951        0.076        12.4(87)       .000 
 
Day 21                  1.396        0.076        18.3 (87)      .000 
  
Day 35                  0.095        0.076        1.25 (87)      .216 
 
 
                           Variance     Std. Error        p 
 
Residual              0.087            0.013          .000 
 
Intercept              0.009            0.009          .304 
 
 
Linear Mixed Model for Gingival Index 
Variable                 Coef..    Std. Error        t (df)           p 
 
Intercept     0.312       0.053        5.83(80.39)  .000 
 
Arm: Control    -0.062       0.057        -1.09(28)      .283 
 
Arm: Treatment      Ref           Ref             Ref             Ref 
 
Day 0       Ref           Ref             Ref             Ref 
 
Day 14                  1.064        0.060        17.67(87)     .000 
 
Day 21                  1.251        0.060        20.79(87)     .000 
 
Day 35                  0.157        0.060          2.62(87)     .011 
 
 
                           Variance     Std. Error        p 
 
Residual             0.054           0.008         .000 
 
Intercept             0.010           0.007         .121  
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TABLE 7 
Analysis of Microbial Pathogens Over Time 
    Colgate Total®                Colgate Great Regular Flavor  
Microbial Pathogen               N               Mean (SD)                 N             Mean (SD)   t (df)         p  
 
S. mitis                
     Day 0         16              2.61 (2.09)       14            2.02 (1.76)         -.821 (28)     .419 
     Day 14         16              3.40 (2.63)       14          2.62 (1.61)         -.962 (28)     .344 
     Day 21         16              2.98 (1.95)       14          2.79 (1.76)         -.274 (28)     .786 
     Day 35         16              2.72 (2.26)       14          1.69 (2.03)       -1.307 (28)     .202 
      
A. israelii                                   
      Day 0                               16  2.54 (1.67)        14           2.31 (3.06)        -.261 (28)       .796                  
      Day 14         16              4.90 (3.40)        14          6.81 (6.57)       1.017 (28)      .318 
      Day 21          16               5.67 (3.85)        14          5.89 (4.83)         .137 (28)       .892 
      Day 35         16              2.92 (2.83)        14           2.07 (2.44)       -.868  (28)       .393 
 
P. nigrescens 
     Day 0         16  0.94 (2.21)                14           0.54 (1.03)        -.617 (28)      .542 
     Day 14         16              3.95 (4.77)        14            5.12 (4.73)         .669 (28)      .509 
     Day 21         16  7.88 (6.13)        14           6.74 (5.22)        -.547 (28)      .589 
     Day 35         16               1.13 (1.82)                14            0.85 (1.43)       -.477 (28)       .637 
 
F. nucleatum ss polymorphum     
     Day 0                                16               1.75 (1.85)         14           0.99 (1.33)       -1.277 (28)     .212 
     Day 14         16                3.55 (3.45)         14           2.96 (2.04)        -.554 (28)      .584 
     Day 21         16                5.98 (5.42)         14           4.25 (2.18)      -1.117 (28)      .274 
     Day 35         16   1.04 (0.92)         14           1.27 (1.61)         .508 (28)      .615 
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TABLE 8 
Paired Samples Tests of Microbial Pathogens Over Time   
  Paired Study Visit                            N       Mean Diff. (SD)     t (df)          p   
 
 Day 0 - Day 14  
    S. mitis                                          30         .71 (1.64)       2.37 (29)     .025              
    A. israelii                                 30       3.36 (5.19)       3.55 (29)     .001     
    P. nigrescens        30        3.74 (4.04)      5.07 (29)   <.001           
    F. nucleatum ss polymorphum      30        1.88 (2.56)      4.04 (29)   <.001        
 Day 0 – Day 21 
     S. mitis                                          30          .56 (2.22)       1.38 (29)   .179           
     A. israelii          30         3.34 (4.28)      4.28 (29)  <.001    
     P. nigrescens         30         6.59 (5.22)      6.91 (29)  <.001     
     F. nucleatum ss polymorphum      30         3.78 (3.89)      5.33 (29)  <.001    
Day 0 – Day 35 
     S. mitis                                          30           .10 (2.19)      .241 (29)    .811               
     A. israelii          30           .10 (2.61)      .200 (29)    .843               
     P. nigrescens                     30           .24 (2.35)      .566 (29)    .576        
     F. nucleatum ss polymorphum      30           .25 (1.94)       .690 (29)   .495 
 Day 14 – Day 21       
     S. mitis                                          30          .150 (2.18)       .397 (29)   .709 
     A. israelii          30          .024 (2.95)      .045 (29)    .965                     
     P. nigrescens                     30          2.85 (3.66)      .668 (29)  <.001        
     F. nucleatum ss polymorphum      30          1.90 (2.93)      .535 (29)    .001  
 Day 21 - Day 35 
     S. mitis                                          30          .654 (2.33)      1.54 (29)     .135        
     A. israelii          30          3.24 (3.03)      .554 (29)   <.001       
     P. nigrescens                    30           6.35 (5.21)       6.67(29)   <.001    
     F. nucleatum ss polymorphum     30           4.03 (4.16)     .759 (29)    <.001 
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TABLE 9 
Intergroup Paired Samples Tests of Microbial Pathogens Over Time 
                                                                     Colgate Total®                         Colgate Great Regular Flavor       
  Paired Study Visit                        N    Mean Diff. (SD)  t (df)        p          N    Mean Diff. (SD)  t (df)       p 
  
 Day 0 - Day 14   
    S. mitis                                      16     .80 (1.04)    3.08 (15)    .008      14    .60 (2.17)     1.04 (13)   .317 
    A. israelii                             16    2.37 (3.41)    2.78 (15)   .014      14   4.50 (6.63)     2.54 (13)  .025  
    P. nigrescens    16    3.01 (3.51)    3.43 (15)   .004      14   4.57 (4.56)     3.76 (13)  .002 
    F. nucleatum ss polymorphum  16    1.80 (3.08)    2.33 (15)   .034      14   1.98 (1.89)     3.91 (13)  .002 
 Day 0 – Day 21 
     S. mitis                                      16     .37 (2.22)      .67 (15)     .512     14   .77 (2.28)     1.26 (13)   .229 
     A. israelii      16    3.13 (3.29)     3.81 (15)   .002     14   3.58 (5.31)   2.52 (13)   .026 
     P. nigrescens     16    6.94 (5.44)     5.10 (15)  <.001    14   6.19 (5.12)   4.52 (13)   .001 
     F. nucleatum ss polymorphum  16    4.24 (4.86)     3.49 (15)   .003    14   3.27 (2.42)    5.05 (13) <.001 
   Day 0 – Day 35 
     S. mitis                                       16     .11 (2.30)       .19 (15)    .849     14   .33 (2.13)      .59 (13)    .567 
     A. israelii       16     .38 (2.81)      .543 (15)   .595     14    .23 (2.42)      .36 (13)   .726 
     P. nigrescens                  16     .19 (2.91)        .26 (15)   .796     14    .30 (1.61)     .70 (13)    .495 
     F. nucleatum ss polymorphum   16      .71 (2.13)      1.33 (15)  .202     14    .29 (1.61)     .67 (13)    .514 
   Day 14 – Day 21 
     S. mitis                                       16        0.43 (2.64)  .646 (15)  .528      14   .167 (1.53)   .408 (13)  .690 
     A. israelii       16        0.76 (2.95)   1.04 (15) .317     14    .925 (2.78)    1.24 (13) .235 
     P. nigrescens                  16        3.93 (3.94)   3.99 (15) .001     14     1.62 (2.99)   2.03 (13) .063 
     F. nucleatum ss polymorphum   16        2.44 (3.38)  2.88 (15)  .011     14     1.29 (2.28)   2.11 (13) .055 
   Day 21 – Day 35 
     S. mitis                                       16       0.26 (1.69)    .616 (15)   .547    14   1.10 (2.89)   1.43 (13)  .177 
     A. israelii       16        2.74 (2.57)   4.28 (15)   .001    14   3.81 (3.50)   4.07 (13)  .001 
     P. nigrescens                  16       6.75 (5.56)    4.85 (15) <.001 14   5.89 (4.95)   4.45 (13)  .001 
     F. nucleatum ss polymorphum   16       4.95 (5.23)    3.78 (15)  .002     14  2.98 (2.18)   5.11 (13) <.001 
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TABLE 10 
Baseline Microbial Data By Complex 
  
Control Group 
Subject ID Blue (Actinos) Orange Red Green Purple Yellow Grey (Other) Total 
3 5.19 0.51 0.38 0.67 0.73 3.61 1.13 12.22 
4 1.74 0.13 0.26 0.08 0.10 0.28 0.30 2.89 
6 4.70 0.23 0.06 0.44 0.31 2.05 0.67 8.44 
7 44.66 25.42 2.96 22.79 11.34 20.27 26.22 153.65
10 43.94 10.76 3.37 19.18 8.97 18.71 17.79 122.72
11 1.00 1.11 0.54 1.49 0.65 2.07 2.61 9.47 
13 2.45 0.88 0.21 2.18 0.98 4.50 2.45 13.66 
15 16.30 10.08 2.13 38.67 3.51 23.41 19.70 113.80
19 4.52 2.37 0.49 1.98 2.70 7.08 2.99 22.13 
24 14.54 8.55 1.61 11.07 8.94 15.96 20.15 80.82 
25 51.08 18.21 2.08 29.03 13.11 16.84 17.58 147.92
26 6.81 0.54 x 0.32 0.42 0.08 0.80 x 
29 14.13 9.60 1.20 21.20 5.72 6.72 21.87 80.43 
31 0.01 0.03 0.08 0.04 0.01 0.04 0.16 0.36 
Mean 15.08 6.31 1.18 10.65 4.11 8.69 9.60 59.12 
Std Dev 4.78 2.11 0.32 3.49 1.24 2.26 2.69 16.42 
Test Group 
Patient ID Blue Orange Red Green Purple Yellow Grey Total 
1 6.24 4.69 0.57 13.71 1.19 8.83 10.21 45.43 
2 17.87 4.66 0.69 7.96 5.83 2.14 5.87 45.01 
5 16.84 1.66 0.82 6.37 2.19 2.40 4.44 34.72 
8 18.38 5.53 2.51 6.50 3.41 14.26 10.86 61.44 
9 23.50 8.76 2.74 13.87 7.25 14.39 14.70 85.20 
12 4.38 2.00 0.95 2.55 0.98 4.75 2.52 18.14 
14 3.58 0.32 0.23 0.91 0.43 2.69 1.18 9.34 
16 8.39 0.27 0.32 0.18 0.88 1.34 0.67 12.05 
18 22.34 4.74 1.64 5.91 8.65 8.02 7.38 58.68 
20 13.03 21.26 3.70 22.66 5.83 30.78 27.38 124.65
21 13.38 35.06 3.24 23.34 4.28 8.50 20.89 108.68
22 41.39 8.69 2.33 9.63 9.72 27.00 13.80 112.56
27 39.37 25.60 3.55 53.18 11.59 21.22 40.28 194.77
28 7.80 15.07 3.07 29.95 2.94 9.37 26.29 94.49 
30 14.09 10.64 1.27 9.70 10.12 12.05 11.02 68.90 
32 20.19 7.17 1.71 13.60 8.01 7.41 10.48 68.56 
Mean 16.92 9.76 1.83 13.75 5.20 10.95 13.00 71.41 
Std Dev 2.76 2.47 0.30 3.35 0.92 2.20 2.72 12.09 
 
Comparison Between Groups 
p-value  0.73 0.31 0.15 0.53 0.48 0.48 0.38 0.54 
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TABLE 11 
Changes in Actinos (Blue) Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from Day 
0 to Day 14 p-value** 
A.gerencseriae Control 2.92 6.51 3.59 0.009
 Test 3.08 5.35 2.27 0.039
 p-value *   0.448  
A.israelli Control 2.31 6.81 4.50 0.002
 Test 2.54 4.90 2.37 0.008
 p-value *   0.552  
A.naeslundi Control 4.57 11.05 6.48 0.000
 Test 4.87 7.80 2.93 0.044
 p-value *   0.093  
A.oris Control 5.29 11.66 6.38 0.004
 Test 6.44 9.09 2.65 0.044
 p-value *   0.142  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
 
TABLE 12 
Changes in Yellow Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
	 	 Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from Day 0 
to Day 14 p-value** 
S.gordonii Control 1.36 2.82 1.46 0.002
 Test 1.90 2.96 1.05 0.006
 p-value *    0.951  
S.intermedia Control 1.30 2.88 1.58 0.025
 Test 1.14 2.07 0.93 0.003
 p-value *    0.400  
S.mitis Control 2.02 2.62 0.60 0.268
 Test 2.60 3.40 0.80 0.011
 p-value *    0.580  
S.oralis Control 1.92 2.51 0.59 0.502
 Test 2.19 2.44 0.25 0.348
 p-value *    0.886  
S.sanguinis Control 2.09 4.51 2.42 0.002
 Test 3.11 4.15 1.04 0.034
 p-value *    0.208  
*	via	Wilcoxon	Rank	Sum	test									**	via	Wilcoxon	Signed	Rank	test	
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TABLE 13 
Changes in Purple Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from Day 
0 to Day 14 p-value** 
A.odontolyticus Control 1.31 3.43 2.11 0.001
 Test 1.78 3.13 1.36 0.003
 p-value *    0.271  
V.parvula Control 2.79 5.60 2.80 0.035
 Test 3.42 5.81 2.39 0.034
 p-value *    0.552  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
 
TABLE 14 
 
Changes in Green Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from 
Day 0 to Day 14 p-value** 
A.actinomycetemcomitans Control 0.29 0.44 0.15 0.153
 Test 0.67 0.43 -0.24 0.144
 p-value *    0.012  
C.ochracea Control 1.93 4.17 2.24 0.035
 Test 2.47 4.94 2.47 0.034
 p-value *    0.854  
C.gingivalis Control 2.24 4.36 2.12 0.030
 Test 2.57 6.80 4.23 0.025
 p-value *    0.608  
C.sputige Control 2.08 3.57 1.49 0.078
 Test 2.34 4.14 1.80 0.039
 p-value *    0.637  
E.corrodens Control 4.11 5.86 1.74 0.326
 Test 5.70 8.47 2.77 0.252
 p-value *    0.951  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 15 
 
Changes in Orange Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from 
Day 0 to Day 14 p-value** 
C.gracilis Control 0.40 1.55 1.14 0.000
 Test 0.40 1.31 0.91 0.001
 p-value *    0.608  
C.rectus Control 0.19 0.78 0.59 0.005
 Test 0.29 0.72 0.42 0.009
 p-value *    0.822  
C.showae Control 0.60 1.84 1.23 0.009
 Test 0.90 2.23 1.33 0.009
 p-value *    0.790  
E.nodatum Control 0.19 0.60 0.40 0.003
 Test 0.29 0.47 0.18 0.006
 p-value *    0.289  
F.nucleatum.ss.nucleatum Control 0.87 2.66 1.79 0.000
 Test 1.46 2.61 1.15 0.011
 p-value *    0.131  
F.nucleatum.ss.polymorphum Control 0.99 2.96 1.98 0.001
 Test 1.75 3.55 1.80 0.009
 p-value *    0.334  
F.nucleatum.ss.vincentii Control 0.57 2.59 2.02 0.001
 Test 1.05 2.01 0.96 0.009
 p-value *    0.154  
F.periodonticum Control 0.82 2.26 1.44 0.000
 Test 1.18 2.17 0.99 0.002
 p-value *    0.275  
P.micra Control 0.35 1.47 1.12 0.001
 Test 0.53 0.82 0.29 0.039
 p-value *    0.077  
P.intermedia Control 0.24 1.93 1.68 0.001
 Test 0.36 1.18 0.82 0.002
 p-value *    0.224  
P.nigrescens Control 0.54 5.12 4.57 0.000
 Test 0.94 3.95 3.01 0.000
 p-value *    0.423  
S.constellatus Control 0.54 1.50 0.95 0.005
 Test 0.61 1.07 0.46 0.004
 p-value *   0.240  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 16 
Changes in Red Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from 
Day 0 to Day 14 p-value** 
T.forsythia Control 0.11 0.54 0.43 0.001
 Test 0.23 0.41 0.18 0.001
 p-value *    0.131  
P.gingivalis Control 0.74 1.84 1.10 0.000
 Test 1.22 1.44 0.22 0.193
 p-value *    0.006  
T.denticola Control 0.30 0.66 0.37 0.002
 Test 0.38 0.59 0.20 0.000
 p-value *    0.275  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 17 
 
Changes in Other (Grey) Complex Microbes from Day 0 to Day 14 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 14
Change from 
Day 0 to Day 14 p-value** 
E.saburreum Control 1.06 2.62 1.56 0.013
 Test 1.54 3.45 1.91 0.001
 p-value *    0.984  
G.morbillorum Control 0.69 1.06 0.37 0.078
 Test 0.88 1.72 0.84 0.016
 p-value *    0.822  
L.bucallis Control 0.62 0.90 0.28 0.058
 Test 1.12 1.40 0.28 0.323
 p-value *    0.294  
N.mucosa Control 3.99 4.67 0.67 0.761
 Test 5.35 5.59 0.24 0.860
 p-value *    0.886  
P.acnes Control 0.29 0.70 0.41 0.005
 Test 0.34 0.65 0.32 0.000
 p-value *    0.822  
P.melaninogenica Control 0.77 1.78 1.01 0.013
 Test 0.51 1.64 1.13 0.000
 p-value *    0.697  
S.anginosus Control 0.63 1.48 0.85 0.007
 Test 0.78 1.52 0.73 0.000
 p-value *    0.951  
S.noxia Control 0.98 3.90 2.92 0.000
 Test 1.50 4.89 3.39 0.000
 p-value *    0.608  
T.socranskii Control 0.15 0.51 0.35 0.011
 Test 0.29 0.52 0.23 0.013
 p-value *    0.552  
S.mutans Control 0.43 0.95 0.52 0.002
 Test 0.67 0.94 0.27 0.002
 p-value *    0.275  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 18 
Changes in Actinos (Blue) Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
A.gerencseriae Control 6.51 6.20 -0.31 0.502 
 Test 5.35 6.30 0.95 0.144 
 p-value *   0.101  
A.israelli Control 6.81 5.89 -0.93 0.241 
 Test 4.90 5.67 0.76 0.175 
 p-value *   0.052  
A.naeslundi Control 11.05 8.40 -2.65 0.153 
 Test 7.80 8.94 1.14 0.105 
 p-value *   0.070  
A.oris Control 11.66 9.97 -1.69 0.194 
 Test 9.09 10.46 1.38 0.159 
 p-value *   0.077  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
TABLE 19 
Changes in Yellow Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
S.gordonii Control 2.82 2.02 -0.80 0.068
 Test 2.96 2.83 -0.13 0.433
 p-value *    0.580  
S.intermedia Control 2.88 2.88 0.01 0.670
 Test 2.07 2.85 0.78 0.464
 p-value *    0.637  
S.mitis Control 2.62 2.79 0.17 0.761
 Test 3.40 2.98 -0.43 0.669
 p-value *    0.473  
S.oralis Control 2.51 2.69 0.18 0.583
 Test 2.44 2.49 0.05 0.940
 p-value *    0.697  
S.sanguinis Control 4.51 3.01 -1.50 0.035
 Test 4.15 4.01 -0.13 0.632
 p-value *    0.377  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 20 
Changes in Purple Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
A.odontolyticus Control 3.43 2.95 -0.47 0.217
 Test 3.14 3.21 0.07 0.348
 p-value *    0.120  
V.parvula Control 5.60 5.45 -0.14 0.502
 Test 5.81 6.96 1.15 0.083
 p-value *    0.110  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
 
TABLE 21 
Changes in Green Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
A.actinomycetemcomitans Control 0.44 0.53 0.09 0.135
 Test 0.43 0.56 0.13 0.083
 p-value *    0.759  
C.ochracea Control 4.17 4.76 0.59 0.391
 Test 4.94 6.65 1.70 0.348
 p-value *    0.886  
C.gingivalis Control 4.36 5.81 1.45 0.104
 Test 6.80 6.09 -0.71 1.000
 p-value *    0.275  
C.sputige Control 3.57 3.26 -0.31 0.855
 Test 4.14 4.62 0.49 0.597
 p-value *    0.886  
E.corrodens Control 5.86 6.18 0.32 0.542
 Test 8.47 8.31 -0.16 0.744
 p-value *    0.552  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 22 
Changes in Orange Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
C.gracilis Control 1.55 1.73 0.18 0.670
 Test 1.31 2.28 0.97 0.016
 p-value *    0.208  
C.rectus Control 0.78 0.77 -0.01 0.626
 Test 0.72 1.04 0.32 0.231
 p-value *    0.790  
C.showae Control 1.84 1.77 -0.07 0.903
 Test 2.23 2.82 0.59 0.252
 p-value *    0.667  
E.nodatum Control 0.60 0.76 0.16 0.241
 Test 0.47 0.74 0.27 0.003
 p-value *    0.552  
F.nucleatum.ss.nucleatum Control 2.66 3.64 0.97 0.045
 Test 2.61 4.79 2.18 0.002
 p-value *    0.271  
F.nucleatum.ss.polymorphum Control 2.96 4.25 1.29 0.091
 Test 3.55 5.98 2.44 0.006
 p-value *    0.637  
F.nucleatum.ss.vincentii Control 2.59 3.86 1.27 0.020
 Test 2.01 3.75 1.74 0.003
 p-value *    0.525  
F.periodonticum Control 2.26 2.98 0.72 0.068
 Test 2.17 3.78 1.61 0.003
 p-value *    0.728  
P.micra Control 1.47 1.96 0.48 0.326
 Test 0.82 1.38 0.57 0.001
 p-value *    0.377  
P.intermedia Control 1.93 2.57 0.64 0.194
 Test 1.18 3.00 1.82 0.001
 p-value *    0.052  
P.nigrescens Control 5.12 6.74 1.62 0.078
 Test 3.95 7.88 3.93 0.001
 p-value *    0.034  
S.constellatus Control 1.50 1.72 0.23 0.626
 Test 1.07 1.48 0.42 0.375
 p-value * 0.790 
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 23 
Changes in Red Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
T.forsythia Control 0.54 0.95 0.41 0.119
 Test 0.41 0.73 0.32 0.008
 p-value *    0.608  
P.gingivalis Control 1.84 2.52 0.68 0.268
 Test 1.44 2.15 0.71 0.003
 p-value *    0.193  
T.denticola Control 0.66 1.16 0.50 0.268
 Test 0.59 1.01 0.42 0.044
 p-value *    0.790  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 24 
Changes in Other (Grey) Complex Microbes from Day 14 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 14 Day 21
Change from Day 
14 to Day 21 p-value** 
E.saburreum Control 2.62 2.29 -0.33 0.761
 Test 3.45 3.92 0.46 0.323
 p-value *    0.608  
G.morbillorum Control 1.06 1.34 0.28 0.391
 Test 1.72 2.45 0.72 0.044
 p-value *    0.525  
L.bucallis Control 0.90 1.01 0.11 0.268
 Test 1.40 1.31 -0.09 0.632
 p-value *    0.552  
N.mucosa Control 4.67 4.69 0.02 0.670
 Test 5.59 5.53 -0.06 0.528
 p-value *    0.854  
P.acnes Control 0.70 0.67 -0.03 0.761
 Test 0.65 0.80 0.14 0.105
 p-value *    0.448  
P.melaninogenica Control 1.78 2.17 0.39 0.463
 Test 1.64 3.78 2.14 0.051
 p-value *    0.355  
S.anginosus Control 1.48 1.66 0.18 0.855
 Test 1.52 1.75 0.23 0.464
 p-value *    0.697  
S.noxia Control 3.90 3.72 -0.19 0.952
 Test 4.89 6.72 1.83 0.003
 p-value *    0.085  
T.socranskii Control 0.51 0.88 0.37 0.042
 Test 0.52 1.02 0.50 0.002
 p-value *    0.759  
S.mutans Control 0.95 1.42 0.47 0.391
 Test 0.94 1.21 0.27 0.074
 p-value *    0.637  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 25 
Changes in Actinos (Blue) Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from Day 
0 to Day 21 p-value** 
A.gerencseriae Control 2.92 6.20 3.28 0.030
 Test 3.08 6.30 3.22 0.000
 p-value *   0.790  
A.israelli Control 2.31 5.89 3.58 0.013
 Test 2.54 5.67 3.13 0.000
 p-value *   0.918  
A.naeslundi Control 4.57 8.40 3.83 0.011
 Test 4.87 8.94 4.07 0.000
 p-value *   0.951  
A.oris Control 5.29 9.97 4.69 0.025
 Test 6.44 10.46 4.03 0.001
 p-value *   0.822  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
TABLE 26 
Changes in Yellow Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from Day 
0 to Day 21 p-value** 
S.gordonii Control 1.36 2.02 0.66 0.241
 Test 1.90 2.83 0.92 0.051
 p-value *    0.951  
S.intermedia Control 1.30 2.88 1.58 0.035
 Test 1.14 2.85 1.71 0.003
 p-value *    0.759  
S.mitis Control 2.02 2.79 0.77 0.241
 Test 2.60 2.98 0.37 0.669
 p-value *    0.608  
S.oralis Control 1.92 2.69 0.77 0.241
 Test 2.19 2.49 0.30 0.348
 p-value *    0.448  
S.sanguinis Control 2.09 3.01 0.92 0.426
 Test 3.11 4.01 0.90 0.298
 p-value *    0.790  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 27 
Changes in Purple Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from Day 
0 to Day 21 p-value** 
A.odontolyticus Control 1.31 2.95 1.64 0.013
 Test 1.78 3.21 1.43 0.001
 p-value *    0.918  
V.parvula Control 2.79 5.45 2.66 0.135
 Test 3.42 6.96 3.54 0.002
 p-value *    0.423  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
 
 
TABLE 28 
Changes in Green Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from Day 
0 to Day 21 p-value** 
A.actinomycetemcomitans Control 0.29 0.53 0.24 0.068
 Test 0.67 0.56 -0.11 0.782
 p-value *    0.038  
C.ochracea Control 1.93 4.76 2.83 0.011
 Test 2.47 6.65 4.17 0.002
 p-value *    0.759  
C.gingivalis Control 2.24 5.81 3.57 0.017
 Test 2.57 6.09 3.52 0.001
 p-value *    0.822  
C.sputige Control 2.08 3.26 1.18 0.358
 Test 2.34 4.62 2.28 0.002
 p-value *    0.854  
E.corrodens Control 4.11 6.18 2.07 0.296
 Test 5.70 8.31 2.61 0.348
 p-value *    0.608  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 29 
Changes in Orange Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from 
Day 0 to Day 21 p-value** 
C.gracilis Control 0.40 1.73 1.33 0.000
 Test 0.40 2.28 1.88 0.000
 p-value *    0.208  
C.rectus Control 0.19 0.77 0.58 0.005
 Test 0.29 1.04 0.74 0.000
 p-value *    0.759  
C.showae Control 0.60 1.77 1.17 0.013
 Test 0.90 2.82 1.92 0.000
 p-value *    0.759  
E.nodatum Control 0.19 0.76 0.56 0.001
 Test 0.29 0.74 0.45 0.000
 p-value *    0.728  
F.nucleatum.ss.nucleatum Control 0.87 3.64 2.76 0.000
 Test 1.46 4.79 3.33 0.000
 p-value *    0.759  
F.nucleatum.ss.polymorphum Control 0.99 4.25 3.27 0.001
 Test 1.75 5.98 4.24 0.000
 p-value *    0.984  
F.nucleatum.ss.vincentii Control 0.57 3.86 3.29 0.000
 Test 1.05 3.75 2.70 0.000
 p-value *    0.423  
F.periodonticum Control 0.82 2.98 2.16 0.001
 Test 1.18 3.78 2.60 0.000
 p-value *    0.525  
P.micra Control 0.35 1.96 1.60 0.001
 Test 0.53 1.38 0.86 0.003
 p-value *    0.193  
P.intermedia Control 0.24 2.57 2.33 0.000
 Test 0.36 3.00 2.64 0.000
 p-value *    0.918  
P.nigrescens Control 0.54 6.74 6.19 0.000
 Test 0.94 7.88 6.94 0.000
 p-value *    0.759  
S.constellatus Control 0.54 1.72 1.18 0.005
 Test 0.61 1.48 0.88 0.009
 p-value *   0.498  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 30 
Changes in Red Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from Day 
0 to Day 21 p-value** 
T.forsythia Control 0.11 0.95 0.83 0.001
 Test 0.23 0.73 0.50 0.000
 p-value *    0.886  
P.gingivalis Control 0.74 2.52 1.78 0.002
 Test 1.22 2.15 0.93 0.000
 p-value *    0.714  
T.denticola Control 0.30 1.16 0.86 0.005
 Test 0.38 1.01 0.62 0.000
 p-value *    0.918  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 31 
 
Changes in Other (Grey) Complex Microbes from Day 0 to Day 21 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 0 Day 21
Change from Day 
0 to Day 21 p-value** 
E.saburreum Control 1.06 2.29 1.23 0.020
 Test 1.54 3.92 2.38 0.000
 p-value *    0.759  
G.morbillorum Control 0.69 1.34 0.65 0.068
 Test 0.88 2.45 1.56 0.001
 p-value *    0.400  
L.bucallis Control 0.62 1.01 0.39 0.068
 Test 1.12 1.31 0.19 0.193
 p-value *    0.275  
N.mucosa Control 3.99 4.69 0.69 0.670
 Test 5.35 5.53 0.18 0.980
 p-value *    0.552  
P.acnes Control 0.29 0.67 0.38 0.007
 Test 0.34 0.80 0.46 0.000
 p-value *    0.728  
P.melaninogenica Control 0.77 2.17 1.40 0.007
 Test 0.51 3.78 3.27 0.000
 p-value *    0.608  
S.anginosus Control 0.63 1.66 1.04 0.013
 Test 0.78 1.75 0.96 0.001
 p-value *    0.822  
S.noxia Control 0.98 3.72 2.74 0.001
 Test 1.50 6.72 5.22 0.000
 p-value *    0.085  
T.socranskii Control 0.15 0.88 0.72 0.002
 Test 0.29 1.02 0.73 0.000
 p-value *    0.918  
S.mutans Control 0.43 1.42 0.99 0.004
 Test 0.67 1.21 0.54 0.001
 p-value *    0.313  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 32 
Changes in Actinos (Blue) Complex Microbes from Day 21 to Day 35 for Dentifrice 
Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from Day 
21 to Day 35 p-value** 
A.gerencseriae Control 6.20 2.75 -3.45 0.000
 Test 6.30 3.51 -2.79 0.001
 p-value *   0.951  
A.israelli Control 5.89 2.07 -3.81 0.000
 Test 5.67 2.92 -2.75 0.001
 p-value *   0.552  
A.naeslundi Control 8.40 4.71 -3.69 0.013
 Test 8.94 5.33 -3.61 0.018
 p-value *   0.667  
A.oris Control 9.97 6.29 -3.69 0.030
 Test 10.46 7.55 -2.92 0.029
 p-value *   0.667  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
TABLE 33 
Changes in Yellow Complex Microbes from Day 21 to Day 35 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from Day 
21 to Day 35 p-value** 
S.gordonii Control 2.02 1.89 -0.13 0.463
 Test 2.83 2.43 -0.40 0.495
 p-value *    0.728  
S.intermedia Control 2.88 1.12 -1.77 0.004
 Test 2.85 1.44 -1.41 0.058
 p-value *    0.580  
S.mitis Control 2.79 1.69 -1.10 0.153
 Test 2.98 2.72 -0.26 0.323
 p-value *    0.070  
S.oralis Control 2.69 1.85 -0.84 0.153
 Test 2.49 2.02 -0.47 0.159
 p-value *    0.240  
S.sanguinis Control 3.01 1.97 -1.05 0.268
 Test 4.01 3.74 -0.27 0.597
 p-value *    0.697  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 34 
Changes in Purple Complex Microbes from Day 21 to Day 35 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from Day 
21 to Day 35 p-value** 
A.odontolyticus Control 2.95 1.53 -1.43 0.005
 Test 3.21 2.13 -1.08 0.011
 p-value *    0.984  
V.parvula Control 5.45 2.89 -2.56 0.173
 Test 6.96 4.40 -2.55 0.011
 p-value *    1.000  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
 
 
TABLE 35 
Changes in Green Complex Microbes from Day 21 to Day 35 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from 
Day 21 to Day 
35 p-value** 
A.actinomycetemcomitans Control 0.53 0.27 -0.26 0.058
 Test 0.56 0.49 -0.08 0.144
 p-value *    0.179  
C.ochracea Control 4.76 1.54 -3.22 0.002
 Test 6.65 1.79 -4.86 0.000
 p-value *    0.377  
C.gingivalis Control 5.81 2.40 -3.41 0.035
 Test 6.09 3.33 -2.76 0.093
 p-value *    0.580  
C.sputige Control 3.26 1.71 -1.55 0.025
 Test 4.62 2.04 -2.58 0.005
 p-value *    1.000  
E.corrodens Control 6.18 2.86 -3.32 0.078
 Test 8.31 5.74 -2.57 0.231
 p-value *    0.608  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 36 
Changes in Orange Complex Microbes from Day 21 to Day 35 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from Day 
21 to Day 35 p-value** 
C.gracilis Control 1.73 0.33 -1.40 0.000
 Test 2.28 0.48 -1.80 0.000
 p-value *    0.240  
C.rectus Control 0.77 0.22 -0.55 0.005
 Test 1.04 0.22 -0.81 0.000
 p-value *    0.667  
C.showae Control 1.77 0.72 -1.06 0.011
 Test 2.82 0.78 -2.03 0.000
 p-value *    0.275  
E.nodatum Control 0.76 0.21 -0.55 0.000
 Test 0.74 0.26 -0.48 0.000
 p-value *    0.854  
F.nucleatum.ss.nucleatum Control 3.64 1.03 -2.61 0.000
 Test 4.79 1.18 -3.61 0.000
 p-value *    0.637  
F.nucleatum.ss.polymorphum Control 4.25 1.27 -2.98 0.000
 Test 5.98 1.04 -4.95 0.000
 p-value *    0.313  
F.nucleatum.ss.vincentii Control 3.86 0.82 -3.04 0.000
 Test 3.75 0.61 -3.14 0.000
 p-value *    0.822  
F.periodonticum Control 2.98 1.00 -1.99 0.001
 Test 3.78 0.92 -2.86 0.000
 p-value *    0.697  
P.micra Control 1.96 0.37 -1.59 0.001
 Test 1.38 0.41 -0.97 0.000
 p-value *    0.525  
P.intermedia Control 2.57 0.36 -2.21 0.000
 Test 3.00 0.30 -2.70 0.000
 p-value *    0.697  
P.nigrescens Control 6.74 0.85 -5.89 0.000
 Test 7.88 1.13 -6.75 0.000
 p-value *    0.790  
S.constellatus Control 1.72 0.54 -1.19 0.007
 Test 1.48 0.72 -0.76 0.008
 p-value *   0.498  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 37 
 
Changes in Red Complex Microbes from Day 21 to Day 35 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from Day 
21 to Day 35 p-value** 
T.forsythia Control 0.95 0.21 -0.74 0.001
 Test 0.73 0.20 -0.54 0.001
 p-value *    0.759  
P.gingivalis Control 2.52 1.14 -1.38 0.025
 Test 2.15 1.22 -0.93 0.003
 p-value *    0.448  
T.denticola Control 1.16 0.29 -0.87 0.007
 Test 1.01 0.40 -0.61 0.005
 p-value *    0.728  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 38 
Changes in Other (Grey) Complex Microbes from Day 21 to Day 35 for Dentifrice Groups  
  Mean (Log Base 2)  
Pathogen Group Day 21 Day 35
Change from Day 
21 to Day 35 p-value** 
E.saburreum Control 2.29 1.07 -1.22 0.020
 Test 3.92 1.46 -2.46 0.002
 p-value *    0.208  
G.morbillorum Control 1.34 0.89 -0.45 0.194
 Test 2.45 0.74 -1.71 0.000
 p-value *    0.240  
L.bucallis Control 1.01 0.92 -0.08 0.455
 Test 1.31 0.75 -0.57 0.003
 p-value *    0.184  
N.mucosa Control 4.69 4.01 -0.68 0.391
 Test 5.53 6.89 1.35 0.782
 p-value *    0.498  
P.acnes Control 0.67 0.20 -0.47 0.001
 Test 0.80 0.33 -0.46 0.000
 p-value *    1.000  
P.melaninogenica Control 2.17 0.43 -1.75 0.001
 Test 3.78 1.06 -2.72 0.000
 p-value *    0.525  
S.anginosus Control 1.66 0.57 -1.09 0.017
 Test 1.75 0.90 -0.85 0.009
 p-value *    0.637  
S.noxia Control 3.72 0.99 -2.73 0.000
 Test 6.72 1.64 -5.08 0.001
 p-value *    0.120  
T.socranskii Control 0.88 0.20 -0.68 0.000
 Test 1.02 0.20 -0.82 0.001
 p-value *    0.728  
S.mutans Control 1.42 0.49 -0.93 0.017
 Test 1.21 0.64 -0.57 0.016
 p-value *    0.822  
* via Wilcoxon Rank Sum test         ** via Wilcoxon Signed Rank test 
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TABLE 39 
Subject compliance and dentifrice usage 
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APPENDIX A 
Study ID: HUM00055445 IRB: IRBMED Date Approved: 11/27/2012 Expiration Date: 11/26/2013 
 
 
UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY 
 
Volunteers needed for a gingivitis research study. This study involves collection of oral 
fluid and plaque samples for measuring markers of gingivitis. 
 
 
Eligible participants will receive free dental cleanings and compensation. 
 
Major inclusion criteria: 
 Age 18-40 
 Must have at least 20 permanent teeth 
 Non-smoker 
 Good general oral health 
 
For more information, please contact: 
Michigan Center for Oral Health Research 
Phone: (734) 998-6721 
E-mail: mcohrclinicalresearch@umich.edu 
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APPENDIX B 
Study ID: HUM00055445 IRB: IRBMED Date Approved: 7/2/2013 Expiration Date: 11/26/2013 
UNIVERSITY OF MICHIGAN 
CONSENT TO BE PART OF A RESEARCH STUDY 
INFORMATION ABOUT THIS FORM 
You may be eligible to take part in a research study.  This form gives you important information 
about the study.  It describes the purpose of the study, and the risks and possible benefits of 
participating in the study.   
Please take time to review this information carefully.  After you have finished, you should talk to 
the researchers about the study and ask them any questions you have.  You may also wish to 
talk to others (for example, your friends, family, or other doctors) about your participation in this 
study.  If you decide to take part in the study, you will be asked to sign this form.  Before you 
sign this form, be sure you understand what the study is about, including the risks and possible 
benefits to you. 
1.  GENERAL INFORMATION ABOUT THIS STUDY AND THE RESEARCHERS 
1.1 Study title:  
Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis 
Model 
 
1.2 Company or agency sponsoring the study:  
Colgate-Palmolive Company 
 
1.3 Names, degrees, and affiliations of the researchers conducting the study: 
Principal Investigator:  Janet Kinney, RDH, MS, MS 
Co-Investigator:  Diana Kott, RDH 
Co-Investigator:  Brooke Pancer, DDS 
Co-Investigator:  William V. Giannobile, DDS, DMSc 
Research Staff: Sara Wesley, RDH, BSDH 
Study Coordinator: Mary Gilson Layher, RDH, BSDH, CCRP 
Study Coordinator: Janet Riggs 
 
2. PURPOSE OF THIS STUDY 
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2.1 Study purpose:  
The overall objective of this proposal is to examine the anti-inflammatory effects of Colgate 
Total® during an experimental gingivitis model.  
 
3. INFORMATION ABOUT STUDY PARTICIPANTS (SUBJECTS) 
Taking part in this study is completely voluntary.  You do not have to participate if you don’t 
want to.  You may also leave the study at any time.  If you leave the study before it is finished, 
there will be no penalty to you, and you will not lose any benefits to which you are otherwise 
entitled.  
3.1 Who can take part in this study? 
If you decide to participate in this study, you will be expected to be present for 5 to 6 
appointments.  The first 2 visits are needed to see if you qualify for the study. 
 
You must meet the following criteria to be considered for the study:  between the ages of 18 to 
40; have at least 20 permanent teeth; be a non-smoker.  At your first visit you must have a 
significant amount of gum inflammation and at your second visit you need to have very little gum 
inflammation. 
 
If you have any of the following you will be excluded:  current smoker, quit smoking less than 
one year ago, or a pack-year history of more than or equal to 10 (pack-years will be calculated 
by multiplying the number of years smoked by the average number of cigarette-packs smoked 
per day), antibiotic therapy within 3 months of baseline or the need for antibiotics for infective 
endocarditis prophylaxis or full joint replacement, chronic medications known to affect the 
periodontal status (calcium antagonists, anticonvulsives, immunosuppressives, anti-
inflammatory medications…), pregnancy or lactating mothers. Women using oral contraceptives 
are eligible, but those who are new oral contraceptives users within 3 months of baseline or are 
planning on starting oral contraceptives during the study will be excluded.  In particular, subjects 
using the Depo-Provera contraceptive injection will be excluded due to emerging evidence of 
increased gingivitis and loss of bone density.  A previous reaction to or oral allergy to any 
ingredient in the study toothpaste; use of any homecare pro ducts to control dental plaque 
formation within 30 days of your baseline visit; current orthodontic treatment or history of 
alcoholism or drug abuse, untreated cavities or defective restorations which could worsen 
during a period of oral hygiene abstinence; and diseases of the immune system or any medical 
condition that may influence the outcome (diabetes, neurologic or psychiatric disorders, 
systemic infections…)  
 
3.2 How many people (subjects) are expected to take part in this study? 
A total of 30 participants will be enrolled in the study. 
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4.  INFORMATION ABOUT STUDY PARTICIPATION 
4.1 What will happen to me in this study?   
 
Visit One  
Day -14 (Screening Visit):  time will be given for you to read the informed consent and ask any 
questions related to the study.  If you sign the informed consent, we will review your medical 
and dental history and note any medications you are taking.  You will receive a dental 
examination and the areas around your teeth and gums will be measured using a small dental 
instrument called a probe.  These measurements must fall into a certain range in order for you 
to qualify.  If you qualify, you will be asked to provide a urine sample.   A urine analysis will 
determine your non-smoking status by measuring your body’s levels of a substance called 
cotinine.  If your urine analysis results are positive, you will not qualify for the study.  An 
impression of your lower teeth will be taken so that a plastic shield can be created to cover the  
lower teeth on one side of your mouth.  You will then receive a dental cleaning, polishing and 
oral hygiene instructions. 
Visit Two 
Day 0 (Baseline Visit):  fourteen days after your screening visit subjects will return for their 
second study visit.  We will review your medical history, ask if there have been any changes to 
any medications you take, and ask if you have had any adverse events since your last study 
visit.  We will then assess the health of your gums to see if they are healthy enough for you to 
participate in the study.  If they are, you will be enrolled in the study.  If your gums are not 
healthy enough, we will review oral hygiene techniques with you and give you an opportunity to 
return in 2 weeks for a second evaluation.  If you return in 2 weeks and your gums are still not 
healthy enough for you to participate in the study, then you will be excluded from participating in 
this trial.  
 
If you qualify, you will be randomly assigned into one of two groups of the study (the control 
group will use a standard of care toothpaste and the test group will use toothpaste with an anti-
bacterial agent called Triclosan (Colgate Total®). Neither you nor the examiners will know which 
group you are in.  You will also be randomly assigned to have either right or left side plastic 
shield made of your lower teeth.  
 
Six intra-oral photos will be taken of your teeth.  We will collect saliva and bacterial plaque 
samples from  2 teeth  and take clinical measures of the amount of plaque you have on your 
teeth and how inflamed your gums are on the sides of your mouth that you are wearing the 
shields.  We will collect a small amount of gum fluid called gingival crevicular fluid from 2 teeth.  
This is done by placing a tiny paper strip between your tooth and gum tissue for 30 seconds.   
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You will be instructed to brush your teeth for two minutes twice a day using the assigned study 
toothpaste.  Before brushing, you need to place 2 ml/2.6 g of the assigned toothpaste into the 
plastic shields and carefully place them in position.  The shields will stay in position while you 
brush the rest of your teeth.  After brushing, you need to carefully remove, rinse and store the 
shields until the next tooth brushing session. 
 
We will give you a toothbrush to use for the duration of the study and instruct you not to use any 
home oral health care products other than those distributed as part of the study protocol. 
 
Call to Participant 
At approximately Day 7 one of the research team members will be contacting by way of a phone 
call or e-mail to ask how you are doing following the study procedures and to inquire if you are 
having any problems.   
 
Visit Three 
Day 14 Study Visit:  you will return after having refrained from tooth brushing your teeth for 10-
12 hours before the appointment. We will review your medical history, ask if there have been 
any changes to any medications you take, and ask if you have had any adverse events since 
your last study visit.  We will take photos of your teeth, collect saliva, bacterial plaque from 2 
teeth , collect gingival crevicular fluid from 2 teeth , and assess the amount of plaque and gum 
inflammation you have on the teeth in the area of the plastic shield.  After these measurements 
have been made, you will put the plastic shield into position with the toothpaste inside of the 
shield and brush your teeth for 2 minutes.  Gingival crevicular fluid samples will be collected 
again from the same 2 teeth  at approximately 1, 2, 4, and 6 hours post-brushing.   
 
We will remind you to continue at-home study tooth brushing procedures until next study visit. 
You will receive $100 incentive payment. 
 
Visit Four 
Day 21 Study Visit:  you will return after having refrained from tooth brushing your teeth for 10-
12 hours before the appointment. We will review your medical history, ask if there have been 
any changes to any medications you take, and ask if you have had any adverse events since 
your last study visit.  We will take photos of your teeth, collect saliva, bacterial plaque from  2 
teeth , collect gingival crevicular fluid from 2 teeth, and assess the amount of plaque and gum 
inflammation you have on the teeth in the area of the plastic shield.  After these measurements 
have been made, you will put the plastic shield into position with the toothpaste inside of the 
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shield and brush your teeth for 2 minutes.  Gingival crevicular fluid samples will be collected 
again from the same 2 teeth at approximately 1, 2, 4, and 6 hours post-brushing.   
 
You will receive a full-mouth dental cleaning.   
 
We will collect your plastic shields and any unused toothpaste. A quantity of more than 60% will 
be considered lack of compliance with the study protocol and grounds for dismissal from the 
study.   
  
You will receive $100 incentive payment. 
 
Visit Five 
Day 35 Study Visit:  you will return after having refrained from tooth brushing your teeth for 10-
12 hours before the appointment. We will review your medical history, ask if there have been 
any changes to any medications you take, and ask if you have had any adverse events since 
your last study visit.  We will take photos of your teeth, collect saliva, bacterial plaque from  2 
teeth, collect gingival crevicular fluid from  2 teeth , and assess the amount of plaque and gum 
inflammation you have on the teeth in the area of the plastic shield.  
 
You will receive $300 incentive payment. 
 
4.2 How much of my time will be needed to take part in this study?   
Your participation in this study will last for approximately 7 ½ weeks.  There are 5 to 6 study 
visits involved in this project.  Your visit today should take about 2 hours.  The second study visit 
will take approximately 1 hour.  Study visits three and four will take about 7 hours.  At these two 
visits you will have flexibility to leave the research facility as long as you return 1,2,4,6 hours 
post-brushing.  Your final study visit should last about 1 ½ hours.  
 
4.3 When will my participation in the study be over?  
Your participation in the study will end after your final study visit. 
 
5.  INFORMATION ABOUT RISKS AND BENEFITS 
166 
 
5.1 What risks will I face by taking part in the study?  What will the researchers do to 
protect me against these risks? 
There are minimal risks or discomforts associated with collection of saliva and dental plaque 
samples. 
The known or expected risks are: 
Risks associated with dental cleanings are small.  Possible risks include minimal discomfort and 
bleeding associated with scaling of the teeth.   
Overall, these types of studies have been proven to be safe with relatively minimal adverse side 
effects. Adverse effects include bleeding of the gums, plaque accumulation and bad breath.  
Studies have shown that these effects are completely reversible when oral hygiene is resumed 
after 21 days.  Subjects are expected to reverse back to a state of oral health within 7 days 
when the oral hygiene is resumed. 
In cases of existing dental conditions (e.g. cavities, untreated gum diseases), the disease can 
worsen if the oral hygiene is discontinued.  For this reason, such subjects will be excluded from 
the study. 
The researchers will try to limit these risks by:  closely monitoring you for the duration of the 
study and providing a full mouth dental cleaning at the beginning of the study and at Day 21.  
As with any research study, there may be additional risks that are unknown or unexpected. 
 
5.2 What happens if I get hurt, become sick, or have other problems as a result of this 
research? 
The researchers have taken steps to minimize the risks of this study.  Even so, you may still 
have problems or side effects, even when the researchers are careful to avoid them. Please tell 
the researchers listed in Section 10 about any injuries, side effects, or other problems that you 
have during this study.  You should also tell your regular doctors. 
 
5.3 If I take part in this study, can I also participate in other studies? 
Being in more than one research study at the same time, or even at different times, may 
increase the risks to you.  It may also affect the results of the studies.  You should not take part 
in more than one study without approval from the researchers involved in each study.   
 
5.4 How could I benefit if I take part in this study?  How could others benefit?   
You may not receive any personal benefits from being in this study. Future patients may 
benefit as a result of this research due to dentists being able to more easily assess 
patients’ oral health. 
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5.5 Will the researchers tell me if they learn of new information that could change my 
willingness to stay in this study? 
Yes, the researchers will tell you if they learn of important new information that may change 
your willingness to stay in this study. If new information is provided to you after you have joined 
the study, it is possible that you may be asked to sign a new consent form that includes the new 
information. 
6.  OTHER OPTIONS 
6.1 If I decide not to take part in this study, what other options do I have? 
If you decide not to participate in this study you have the option of returning to your private 
dental practice for ongoing oral health care needs. 
 
7.  ENDING THE STUDY 
7.1 If I want to stop participating in the study, what should I do? 
You are free to leave the study at any time.  If you leave the study before it is finished, there will 
be no penalty to you. You will not lose any benefits to which you may otherwise be entitled.  If 
you choose to tell the researchers why you are leaving the study, your reasons for leaving may 
be kept as part of the study record. If you decide to leave the study before it is finished, please 
tell one of the persons listed in Section 10 “Contact Information” (below). 
7.2 Could there be any harm to me if I decide to leave the study before it is finished?  
No, there will be no harm to you if you decide to leave the study before it is finished, but we 
would like to schedule a final visit to ensure your teeth and gums are healthy before you leave. 
 
7.3 Could the researchers take me out of the study even if I want to continue to 
participate? 
Yes. There are many reasons why the researchers may need to end your participation in the 
study.  Some examples are: 
 The researcher believes that it is not in your best interest to stay in the study. 
 You become ineligible to participate. 
 Your condition changes and you need treatment that is not allowed while you are taking 
part in the study. 
 You do not follow instructions from the researchers. 
 The study is suspended or canceled. 
 
 8.  FINANCIAL INFORMATION 
 
8.1 Who will pay for the costs of the study? Will I or my health plan be billed for any 
costs of the study?   
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The study will pay for research-related items or services that are provided only because you are 
in the study.  If you are not sure what these are, see Section 4.1 above or ask the researchers 
for a list.  If you get a bill you think is wrong, call the researchers’ number listed in section 10.1. 
You or your health plan will pay for all the things you would have paid for even if you were not in 
the study, like: 
 Health care given during the study as part of your regular care 
 Items or services needed to give you study drugs or devices 
 Monitoring for side effects or other problems 
 Deductibles or co-pays for these items or services. 
If you do not have a health plan, or if you think your health plan may not cover these costs 
during the study, please talk to the researchers listed in Section 10 below or call your health 
plan’s medical reviewer. 
By signing this form, you do not give up your right to seek payment if you are harmed as a result 
of being in this study. 
8.2 Will I be paid or given anything for taking part in this study? 
Yes, you will be paid $500 for your participation in the study.  Eligible subjects will receive $100 
at Day 14, $100 at Day 21, $300 at Day 35. 
 
8.3 Who could profit or financially benefit from the study results? 
The company whose product is being studied:  Colgate-Palmolive Company 
 
9. CONFIDENTIALITY OF SUBJECT RECORDS AND AUTHORIZATION TO RELEASE 
YOUR PROTECTED HEALTH INFORMATION 
The information below describes how your privacy and the confidentiality of your research 
records will be protected in this study. 
9.1 How will the researchers protect my privacy? 
If you qualify for the study you will be given a study number.  We will use your study number 
along with your initials on any samples we take and on all of our data collection systems. 
 
9.2 What information about me could be seen by the researchers or by other people?  
Why?  Who might see it? 
Signing this form gives the researchers your permission to obtain, use, and share information 
about you for this study, and is required in order for you to take part in the study.  Information 
about you may be obtained from any hospital, doctor, and other health care provider involved in 
your care, including: 
 Hospital/doctor’s office records, including test results (X-rays, blood tests, urine tests, 
etc.) 
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 All records relating to your condition, the treatment you have received, and your 
response to the treatment 
 Billing information 
There are many reasons why information about you may be used or seen by the researchers or 
others during or after this study.  Examples include: 
 The researchers may need the information to make sure you can take part in the study.   
 The researchers may need the information to check your test results or look for side 
effects.   
 
 University, Food and Drug Administration (FDA), and/or other government officials may 
need the information to make sure that the study is done in a safe and proper manner.    
 
 Study sponsors or funders, or safety monitors or committees, may need the information 
to:  
o Make sure the study is done safely and properly 
o Learn more about side effects  
o Analyze the results of the study  
 The researchers may need to use the information to create a databank of information 
about your condition or its treatment. 
 Information about your study participation may be included in your regular UMHS 
medical record. 
 If you receive any payments for taking part in this study, the University of Michigan 
accounting department may need your name, address, social security number, payment 
amount, and related information for tax reporting purposes.  
 Federal or State law may require the study team to give information to government 
agencies. For example, to prevent harm to you or others, or for public health reasons. 
The results of this study could be published in an article, but would not include any information 
that would let others know who you are.  
A description of this clinical trial will be available on www.ClinicalTrials.gov, as required by US 
law. This website will not include information that can identify you. At most, the website will 
include a summary of the results. You can search this website at any time. 
9.3 What happens to information about me after the study is over or if I cancel my 
permission? 
As a rule, the researchers will not continue to use or disclose information about you, but will 
keep it secure until it is destroyed.  Sometimes, it may be necessary for information about you to 
continue to be used or disclosed, even after you have canceled your permission or the study is 
over.   
Examples of reasons for this include: 
 To avoid losing study results that have already included your information  
 To provide limited information for research, education, or other activities  (This 
information would not include your name, social security number, or anything else that 
could let others know who you are.)  
 To help University and government officials make sure that the study was conducted 
properly 
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As long as your information is kept within the University of Michigan Health System, it is 
protected by the Health System’s privacy policies.  For more information about these policies, 
ask for a copy of the University of Michigan “Notice of Privacy Practices”.  This information is 
also available on the web at http://www.med.umich.edu/hipaa/npp.htm. Note that once your 
information has been shared with others as described under Question 9.2, it may no longer be 
protected by the privacy regulations of the federal Health Insurance Portability and 
Accountability Act of 1996 (HIPAA).   
 
9.4 When does my permission expire?   
Your permission expires at the end of the study, unless you cancel it sooner. You may cancel 
your permission at any time by writing to the researchers listed in Section 10 “Contact 
Information” (below).   
10. CONTACT INFORMATION 
10.1 Who can I contact about this study? 
Please contact the researchers listed below to: 
 Obtain more information about the study 
 Ask a question about the study procedures or treatments 
 Talk about study-related costs to you or your health plan  
 Report an illness, injury, or other problem (you may also need to tell your regular 
doctors) 
 Leave the study before it is finished 
 Express a concern about the study 
Principal Investigator:  Janet Kinney, RDH, MS, MS 
Mailing Address:  24 Frank Lloyd Wright Dr, Lobby M, Box 442, Ann Arbor, MI  48106 
Telephone:  (734) 998-1468 
 
Research Core Staff 
Michigan Center for Oral Health Research (MCOHR)  
Mailing Address:  24 Frank Lloyd Wright Drive, Lobby M, Box 442, Ann Arbor, MI  48106 
Telephone:  (734) 998-6721 
 
You may also express a concern about a study by contacting the Institutional Review Board 
listed below. 
University of Michigan Medical School Institutional Review Board (IRBMED) 
2800 Plymouth Road 
Building 200, Room 2086 
Ann Arbor, MI 48109-2800 
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Telephone: 734-763-4768  (For International Studies:  US Country Code: 001) 
Fax: 734-763-1234 
e-mail: irbmed@umich.edu  
If you are concerned about a possible violation of your privacy or concerned about a study you 
may contact the University of Michigan Health System Compliance Help Line at 1-866-990-
0111. 
When you call or write about a concern, please provide as much information as possible, 
including the name of the researcher, the IRBMED number (at the top of this form), and details 
about the problem.  This will help University officials to look into your concern.  When reporting 
a concern, you do not have to give your name unless you want to. 
11.  RECORD OF INFORMATION PROVIDED 
11.1 What documents will be given to me? 
Your signature in the next section means that you have received copies of all of the following 
documents: 
 This “Consent to be Part of a Research Study” document.  (Note: In addition to the copy 
you receive, copies of this document will be stored in a separate confidential research 
file and may be entered into your regular University of Michigan medical record.) 
 Other (specify):   
 
12.  SIGNATURES 
Photographs 
I understand that photographs will be taken as part of the study procedures on Days 0, 14, 21, 
and 35.  Reasonable efforts will be made to conceal any features that would disclose or reveal 
my identity.  I understand that these photographs may be published for educational and 
scientific purposes.  I have indicated below if I am willing to allow my photographs to be 
published for educational and scientific purposes. 
  YES, I DO consent to photographs of my oral and facial structures being 
published for educational and scientific purposes.   
  NO, I DO NOT consent to photographs of my oral and facial structures being 
published for educational and scientific purposes.  
Research Subject: 
I understand the information printed on this form.  I have discussed this study, its risks and potential benefits, and 
my other choices with ___________________.  My questions so far have been answered.  I understand that if I 
have more questions or concerns about the study or my participation as a research subject, I may contact one of 
the people listed in Section 10 (above).  I understand that I will receive a copy of this form at the time I sign it and 
later upon request.  I understand that if my ability to consent for myself changes, either I or my legal 
representative may be asked to re-consent prior to my continued participation in this study. 
 
Name (print legal name):  
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Signature of Subject:  
 
Date of signature:  
 
Patient ID:   Date of Birth (mm/dd/yyyy):  
 
Principal Investigator (or Designee): 
I have given this research subject (or his/her legally authorized representative, if applicable) information about this 
study that I believe is accurate and complete.  The subject has indicated that he or she understands the nature of 
the study and the risks and benefits of participating. 
 
Name:  
 
Title:   
 
Signature:  
 
Date of Signature:  
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APPENDIX C 
Study ID: HUM00055445 IRB: IRBMED Date Approved: 11/27/2012 Expiration Date: 11/26/2013 
Experimental Gingivitis Phone Script 
Hello, my name is_________. I am calling from Michigan Center for Oral Health 
Research (MCOHR) regarding the dental study that you are interested in. Do you have a few 
minutes to discuss the study? 
 
This research study is being done to measure the levels of certain proteins and bacteria 
related to gingivitis (inflammation of the gums). Previous studies have shown that these 
substances are found at higher levels in areas of inflammation. We are recruiting 30 
patients for this study. This study will include 5 to 6 visits and last approximately 2 
months. Most of the study visits will last between 1-2 hours, but two of the study visits 
will last about 7 hours. 
 
If you are eligible, we will take an impression of your lower teeth for the preparation of a 
plastic shield you will need to wear twice a day when you brush your teeth. You must 
wear the shield every time you brush your teeth. You will also have a dental cleaning. 
 
You will return to the clinic on days 14, 21, and 35. We will take photos of your mouth 
and measure the levels of gum inflammation. Saliva, bacterial samples, and gum tissue 
fluid samples will be collected. You will be asked to place a small amount of toothpaste 
into the plastic shield and then brush the rest of your teeth for 2 minutes. On days 14 and 21 we 
will repeat taking gum tissue fluid samples 12, 4, and 6 hours after you brush.These study visits 
will last approximately 7 hours. You will not need to stay in the dentalclinic for the entire time, 
but will need to return to the dental clinic at the previously 
mentioned times so that the oral fluids can be collected at the appropriate time intervals. 
At Day 21, you will receive a thorough dental cleaning and can resume your normal oral 
health care routine. 
 
You will return on day 35 for your last study visit. We will collect all of the same 
samples, measure the amount of inflammation in your gum tissues and check to make 
sure that your gums have returned to their pre-study levels of health. 
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Study ID: HUM00055445 IRB: IRBMED Date Approved: 11/27/2012 Expiration Date: 11/26/2013 
If enrolled, you will receive $500 for a total of 5 to 6 visits. You will receive $100 at 
your Day 14 Study Visit, $100 at your Day 21 Study Visit, and $300 at your Day 35 
Study Visit. 
 
I would like to go over some preliminary inclusion criteria with you. I will be asking you 
questions about your personal health and child bearing potential. Please only answer 
questions that you want to answer. Answering is optional, and you can tell me to stop 
asking these questions at any time. The purpose of these questions is to pre-screen 
subjects to see if they are likely to qualify for the study. We will make notes in our 
subject database as to whether or not you appear to qualify for the study. This 
information will be used to search for potential subjects for future studies. Would you 
like me to continue? 
 Are you between 18 and 40 years old? (must be 40 for the duration of the 
patient’s involvement in the study) 
 Do you have at least 20 permanent teeth? 
 Do you have good general oral health? 
 Are you a non-smoker? 
 If you quit smoking less than a year ago, you are excluded from the study 
 Have you smoked in the past? If so, how much and for how long? if a previous 
smoker – must have quit smoking over 1 year and have a pack-year history equal or less than 
10 (pack-years is calculated by multiplying the number of years smoked by the average number 
of packs per day) 
o We will be verifying your non-smoking status by urinalysis should you 
decide to screen for the study. 
o Reminder: Nicorette gum and marijuana use in the last year will also 
exclude patient; In case patient does provide this information. 
 Have you been on antibiotic therapy within 3 months of baseline, need antibiotics 
for infective endocarditis prophylaxis or total joint replacement? 
 Are you taking medications known to affect periodontal status (calcium 
antagonists, anticonvulsives, immunosuppressives, or anti-inflammatory 
medications)? 
 Are you pregnant or lactating? 
 Are you currently receiving orthodontic or periodontal treatment? 
 Do you have history of alcohol or drug abuse? 
 Do you have untreated cavities? 
 Do you have any systemic infections or immune system disorders (diabetes, 
neurologic, psychiatric disorders....)? 
 If using oral or other hormonal contraceptives (ex: the pill, patch, NuvaRing), 
must be on for more than 3 months 
175 
 
Study ID: HUM00055445 IRB: IRBMED Date Approved: 11/27/2012 Expiration Date: 11/26/2013 
 Are you using Depo-Provera injections? 
 If you are a pre-menopausal woman you or your male partner must be surgically 
sterile or you must be using reliable birth control (ie prescription oral 
contraceptives, contraceptive injections, intrauterine device, double-barrier 
method, contraceptive patch) now and throughout the study or abstain from sex 
throughout the study 
 Do you have an active oral infection, including periodontitis? 
 Do you have a known reaction to or oral allergy to any ingredient in the study 
toothpaste? 
 Have you used an antiseptic homecare oral product to control dental plaque 
formation? (must not be within 30 days prior to the baseline visit) 
 
If patient does not qualify: 
Would you like to hear about the other studies at our center? 
If yes, continue with description of other studies. 
If no, continue to last 2 paragraphs of this script. 
If patient does qualify: 
If you are interested, I would like to schedule a screening appointment for you. 
 
Are you a patient at the University of Michigan Dental School? If so, when were you last 
seen there? If you are not a U of M dental school patient, we will need to enter your 
information into our scheduling system now. Open axiUm and enter patient 
information 
 
Do you know where Domino’s Farms is located? We are in Lobby M on the second 
floor. Come through the glass doors and the receptionist will greet you there. Do you 
need a map? 
 
Since we schedule an individual appointment for each screening patient, please let us 
know within 24 hours if you are unable to keep your appointment so we can schedule 
another person for that time. Our number is (734) 998-6721. 
 
Please plan on the screening appointment taking up to 2 hours. Please arrive 15 minutes 
early to your visit to fill out paperwork. If you are more than 20 minutes late to the 
scheduled visit, you will not be seen due to time constraints. 
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Study ID: HUM00055445 IRB: IRBMED Date Approved: 11/27/2012 Expiration Date: 11/26/2013 
As a reminder, the information we discussed today will be stored in our research subject 
database. It will remain there so we can easily find subjects to screen for future studies. 
Your personal contact information is also kept in the dental school scheduling database. 
Do you have any questions regarding how your personal information is handled? 
 
Thank you very much for your interest in MCOHR studies. 
End if patient did not qualify for any studies. 
 
Continue if patient qualified for a study. 
Thank you, and we will see you on ___________ 
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APPENDIX D 
Day 7                                                                                                          Examiner: 
 
 
Dear _________________,  
 
This is _______________ from the Michigan Center for Oral Health Research (MCOHR).  I am 
calling/writing to see how things are going for you with the experimental gingivitis study you are enrolled 
in.  Do you have any questions about wearing the plastic shield?  Have you been following the 
instructions for using the plastic shields when brushing your teeth?  Do you have any concerns about 
your participation in the study at this time?  Have you been brushing twice a day? 
 
You are scheduled for your Day 14 study visit on _______________________.  Please remember not to 
brush your teeth for 10 to 12 hours before your appointment.  Also, please remember that at this visit will 
last approximately 7 hours.  We will be sampling oral fluids 1, 2, 4, and 6 hours after you brush your teeth, 
so if you decide to leave MCOHR between sampling times, you return on time so that we are able to 
collect the oral fluids according to the study protocol. 
 
Once again, thank you for participating in the study.  You can call us at 734-998-6712 if you have any 
questions or concerns. 
 
We look forward to seeing you again in a week. 
 
*Reminder*  - Ask subject to bring in stent and toothpaste at next appointment. 
ADVERSE EVENTS 
Have there been any adverse events?  
(if “Yes” complete AE form) 
YES NO 
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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APPENDIX E 
Randomization List 
 
 
 
 
Patient ID Stent
1 Right 31D 30M 31M 28M 30D 29M 28D 29D
2 Left 19D 18D 20D 18M 21M 20M 21D 19M
3 Left 20M 18D 19M 18M 21D 21M 20D 19D
4 Right 29D 30D 28D 30M 31D 31M 28M 29M
5 Left 21D 18M 20D 21M 18D 20M 19D 19M
6 Left 21M 20D 20M 19D 19M 18M 18D 21D
7 Right 30D 29M 29D 31M 31D 30M 28M 28D
8 Right 31D 29D 30M 28M 31M 28D 30D 29M
9 Right 31D 30D 28D 30M 29M 28M 31M 29D
10 Left 18D 18M 19M 21M 20M 20D 19D 21D
11 Right 29M 29D 28M 31M 30D 30M 28D 31D
12 Left 20D 21M 18D 20M 19D 19M 21D 18M
13 Left 18D 21D 20D 18M 20M 19D 21M 19M
14 Right 30D 29M 30M 31D 31M 28D 28M 29D
15 Right 30D 28D 28M 30M 31D 31M 29M 29D
16 Left 19D 20D 21D 21M 19M 20M 18D 18M
17 Left 21D 21M 19M 18D 18M 20M 20D 19D
18 Right 30D 29D 31D 28M 31M 28D 29M 30M
19 Right 31D 29D 30M 29M 31M 28M 30D 28D
20 Left 18D 20M 21D 19M 21M 18M 19D 20D
21 Left 18M 21D 20M 19M 18D 21M 20D 19D
22 Right 28M 30D 29D 31D 29M 31M 30M 28D
23 Right 28M 30M 31D 29M 31M 29D 28D 30D
24 Left 20D 20M 21D 19M 18M 21M 19D 18D
25 Right 28D 30D 28M 31M 30M 31D 29D 29M
26 Left 18D 20M 21D 21M 18M 20D 19D 19M
27 Left 18D 20D 20M 19D 21M 21D 19M 18M
28 Right 28M 31M 29M 30D 29D 31D 30M 28D
29 Left 18M 19M 19D 21M 21D 20D 18D 20M
30 Right 31M 28M 31D 29D 30M 29M 28D 30D
31 Right 29D 28D 30D 30M 28M 31M 31D 29M
32 Left 19D 19M 21D 18M 18D 21M 20M 20D
33 Right 31M 29M 30D 31D 29D 28M 28D 30M
34 Left 21M 19M 20D 18M 19D 20M 21D 18D
35 Right 28D 30M 31M 29M 29D 28M 30D 31D
36 Left 21D 19M 20D 19D 21M 20M 18M 18D
37 Left 21D 21M 18D 20M 20D 19D 19M 18M
38 Right 31M 28D 30M 30D 31D 29D 29M 28M
39 Left 20M 20D 19M 18M 21M 19D 21D 18D
40 Right 29M 28M 29D 31M 30D 30M 31D 28D
Day 0 Day 14 Day 21 Day 35
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APPENDIX F 
 
Dear Previous MCHOR Research Patient: 
  
We are writing to invite you to participate in a research study for inflammation of the gums 
(gingivitis). The purpose of this research study is to examine the anti-inflammatory effects of 
Colgate Total during an experimental gingivitis model. The study will require 5 to 6 visits and will 
last for approximately 2 months. Over the course of the study, you will be compensated for your 
participation. 
  
You May be eligible if: 
  
 You are between the ages of 18 and 40 
 You have at least 20 teeth 
 You do NOT have an allergy to Colgate Total 
 You do NOT need to take antibiotics before dental treatment 
 You have NOT taken any antibiotics in the last 3 months 
 You have NOT had periodontal treatment in the last 6 months (regular cleanings are 
acceptable) 
 You have NOT used tobacco products in the past year, such as cigarettes, cigars, chew 
 You do NOT have any of the following medical conditions: diabetes, HIV infection, AIDS 
 You are NOT pregnant, lactating or breastfeeding 
  
If you think you may be interested in our new study, please call us at (734) 998 – 1468 so that 
we may provide you with additional information and/or carry out a phone screening at your 
convenience. Thank you for your interest in our clinical research at the Michigan Center for Oral 
Health Research (MCOHR)! 
  
  
Kindest Regards, 
  
  
  
Janet Riggs 
Michigan Center for Oral Health Research (MCOHR) 
University of Michigan 
24 Frank Lloyd Wright Drive 
Lobby M, Box 422 
Ann Arbor, MI 48106 
janetrig@umich.edu 
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APPENDIX G 
* All events should be resolved or noted as ongoing at the time of subjects discontinuation in the study (i.e. study 
complete, subject withdrawal, death) 
** Report all adverse events in accordance with UMMS IRB Policy : http://med.umich.edu/irbmed/ae_orio/ae_report.htm 
Original:  Regulatory File               Copy:  As Needed 
 
Revised 01Sep2010
 
COLGATE 
ADVERSE EVENT TRACKING LOG 
IRB Protocol #: 
HUM00055445 
Study Title: Study of the Anti-Inflammatory Effects of Colgate Total® During an 
Experimental Gingivitis Model 
Investigator Name: 
Janet Kinney 
Study Coordinator Name: Jan Riggs 
 Subject ID 
Start Date 
of Event 
End Date 
(indicate if 
ongoing)* 
Event ** Date 
Report 
sent 
to 
IRB 
 
Date Report sent 
to Sponsor 
(if applicable) Description Severity Relationship Outcome 
1 01 
 
 
30/Mar/13 06/Apr/13 Aphthous ulcer Mild 
Possible; 
may be 
related to 
taking stent 
in & out of 
mouth 
Resolved   
2 03 07/Apr/13 26/Apr/13 Tissue Sloughing Mild Possible Resolved 
  
3 11 05/Aug/13 Unknown Aphthous ulcer Mild Possible Resolved 
  
4 16 14/Aug/13 19/Aug/13 Left TMJ soreness Mild Unknown Resolved 
  
5 17 09/Aug/13 Unknown Decay #18 Mild Unrelated Unknown   
6 21A 04/Sept/13 Ongoing Tingling in tongue Mild Possible Resolved 
  
7 21B 25/Aug/13 Unknown Aphthous Ulcer Mild Possible Resolved 
  
8 22 Unknown Ongoing Toothbrush trauma Mild Unrelated Resolving 
  
9 30 05/Nov/13 12/Nov/13 Herpetic lesion Mild Possibly Resolved 
  
10 27 06/Oct/13 21/Oct/13 Aphthous ulcer Mild Possibly Resolved 
  
11 28 28/Oct/13 04/Nov/13 Herpetic lesion Mild Possibly Resolved 
  
12 31 26/Nov/13 30/Nov/13 Tissue sloughing Mild Possibly Resolved 
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APPENDIX H 
Screening (Day -14) Examination Form 
 
 
 
 
 
Informed	Consent	  
Was	the	informed	consent	form	signed?	 							 								 							Yes	 									 No	 Initials	______	
	
Was	the	informed	consent	documented	in	the	 								 							Yes	 								 No	 Initials	______	
treatment	record?	
	
Was	a	copy	given	to	the	patient?								 	 	 							Yes	 								 No	 Initials	______	 	 	
	
General	Inclusion	Criteria:	 	 	 	 	 	 	 	 	Yes	 										No	
	
1.	Is	the	subject	aged	18	through	40	years?	
	
	
2.	Does	the	subject	willing	to	follow	all	study	procedures?	
	
	
3.	Does	the	subject	have	a	minimum	of	20	permanent	teeth?	
	
	
4.	Does	the	subject	have	probing	pocket	depths	<	4mm	on	all	sites?	
	
	
5.	Does	the	subject	have	a	mean	clinical	attachment	level	of	<	2mm?	
	
	
6.	Does	the	subject	have	a	mean	score	of	<	1	in	both	the	plaque	and		
				gingival	indices?	
	
	
7.	Does	the	subject	have	a	BOP	score	≥	30	percent?	
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General	Exclusion	Criteria:	 	 	 	 	 	 	 Yes	 										No	
	
1. Is	the	subject	a	current	smoker,	quit	smoking	less	than	one	year	ago,	
or	have	a	pack‐year	history	of	more	than	or	equal	to	10	(pack‐years		
will	be	calculated	by	multiplying	the	number	of	years	smoked	by	the	
average	number	of	cigarette	packs	smoked	per	day)?	
	
Pack‐year	History	Calculation:	
	
______	packs	of	cigarettes	smoked	per	day		(times)		____	number	of	years	smoked	=			_________	
	 								 	 	 	 	 	 	 	 	 	 	 Pack‐year	
History	
	
2. Has	the	subject	had	antibiotic	therapy	within	3	months	of	the	baseline	
visit	or	need	antibiotics	for	infective	endocarditis	prophylaxis?	
	
3. Does the subject take chronic medications known to affect the periodontal 
status (calcium antagonists, anticonvulsives, immunosuppressives,  
anti-inflammatory medications….)? 
	
4. Is the subject pregnant or lactating? 
 
5. Is the subject currently in active orthodontic or periodontal treatment? 
	
6. Does the subject have a history of alcoholism or drug abuse? 
 
7. Does the subject have any untreated carious lesions or defective restorations        
which could exacerbate during a period of oral hygiene abstinence? 
 
8. Does the subject have any disease of the immune system or any medical          
condition that may influence the outcome (diabetes, neurologic, psychiatric    
disorders, systemic infections…)? 
 
9. Is the subject a new oral contraceptive user (within 3 months of baseline) or plan to 
start taking oral contraceptives during the study? 
 
10. Does the subject use Depo-Provera contraceptive injections? 
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General	Information 
	 	
	
Date	of	Birth	
MON/DD/YY	
/										/	
	
	
	
																																																																							
																																																																				
Medical/Oral	History	
	 	 Was	the	medical/oral	history	recorded?	 	 	 						Yes						 	 No						
	 	 	
Oral	Soft	Tissue	Examination	
Was	oral	soft	tissue	exam	performed?	 	 	 						Yes				 	 No						
	 	
Laboratory	
Was	a	urine	analysis	taken?		 	 	 	 						Yes									 											 No						
	
 
Clinical	
Was	a	prophylaxis	preformed?																			 	 	 						Yes				 													No						
	
	
Was	the	subject	given	OHI?																																								 	 						Yes																					 No						
	
Impression	
	 	
Was	a	mandibular	impression	taken	for	stent?							 						Yes																			 No						
			
	 	
	 	 _________________________________	 	 	 ________________________	
	
	 	 Investigator	Signature	 	 	 	 	 Date	
Gender	
M										F	
Date of Screening Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
African Native
American AmericanRace: Caucasian Asian Hispanic Other
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CLINICAL	(Calculation	on	mean	on	page	11)	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
FGM                      
PD                      
CAL                      
BOP                      
BUCCAL 
 
  2    3    4    5    6    7    8  
FGM                      
PD                      
CAL                      
BOP                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
	
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
FGM                      
PD                      
CAL                      
BOP                      
LINGUAL  
 15 
  
14 
  
13 
  
12 
  
11 
  
10 
  
9 
 
FGM                      
PD                      
CAL                      
BOP                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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CLINICAL	(Calculation	on	mean	on	page	11)	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
FGM                      
PD                      
CAL                      
BOP                      
BUCCAL 
 
 18   19   20   21   22   23   24  
FGM                      
PD                      
CAL                      
BOP                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
	
Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
FGM                      
PD                      
CAL                      
BOP                      
LINGUAL 
 
 31   30   29   28   27   26   25  
FGM                      
PD                      
CAL                      
BOP                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
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Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
PLAQUE	INDEX	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
PI                      
    2    3    4    5    6    7    8  
PI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
PI                      
  15   14   13   12   11   10   9  
PI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
PI                      
  18   19   20   21   22   23   24  
PI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
PI                      
  31   30   29   28   27   26   25  
PI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
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Mean	PLAQUE	INDEX	for	Patient:	
		 Total		÷		Number	of	Sites		=		MEAN		
	
											__________		÷		__________		=		__________	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
Scores	 Criteria	
0	 No	plaque	
1	 A	film	of	plaque	adhering	to	free	gingival	margin	and	adjacent	area	
of	 tooth.	 	The	plaque	may	be	seen	 in	situ	only	after	application	of	
disclosing	solution	or	by	using	the	probe	on	the	tooth	surface.	
2	 Moderate	accumulation	of	soft	deposits	within	the	gingival	pocket,	
or	 on	 the	 tooth	 and	 gingival	margin,	which	 can	 be	 seen	with	 the	
naked	eye.	
3	 Abundance	of	soft	matter	within	the	gingival	pocket	and/or	on	the	
tooth	and	gingival	margin	
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GINGIVAL	INDEX	
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
GI                      
   2    3    4    5    6    7    8  
GI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
GI                      
  15   14   13   12   11   10   9  
GI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
GI                      
  18   19   20   21   22   23   24  
GI                      
LINGUAL  d  l  m  d  L  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
GI                      
  31   30   29   28   27   26   25  
GI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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Mean	GINGIVAL	INDEX	for	Patient:	
Total		÷		Number	of	Sites		=	MEAN	
	
__________			÷			__________				=		__________	
	
	
Scores	 Criteria	 Bleeding	
0	 Absence	of	inflammation	 No	bleeding	on	probing	
1	 Mild	inflammation		
Slight	change	in	color	and	texture	
No	bleeding	on	probing	
2	 Moderate	 inflammation,	 glazing,	
redness,	edema	and	hypertrophy		
Bleeding	on	probing	
3	 Severe	inflammation,	redness	and	
hypertrophy.	Ulceration.	
Tendency	 to	 spontaneous	
bleeding	
	
	
	
Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
	
	
	
	
Percentage	BLEEDING	ON	PROBING	SCORE	for	Patient:	
								Number	of	BOP	Sites		÷		Total	Number	of	Sites	x	100	=		PERCENTAGE	
	
__________		÷		__________		x	100	=		__________	
 
 
 
	
	
	
	 	 	
Score Criteria 
0 No bleeding upon probing 
1 Presence of bleeding upon probing 
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Experimental	Gingivitis	Model	for	the	Study	of	Anti‐Inflammatory	Effects	of	Colgate	Total®	‐	a	Pilot	Investigation	
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
CALCULATIONS:	
	
Mean	Clinical	Attachment	 	
	
		Total	÷	Number	of	sites	=	MEAN							__________		÷		__________		=	__________	
	
	
RESULTS:	
	
1)	Mean	CLINICAL	ATTACHMENT		 	 	 =	 __________	
	
	
2)	Mean	PLAQUE	INDEX																																				 =							__________	
	
	
3)	Mean	GINGIVAL	INDEX																												 	 =							__________	
	
	
4)	Percentage	BLEEDING	ON	PROBING	SCORE	 =						__________	
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APPENDIX I 
Baseline (Day 0) Examination Form 
	
ADVERSE	EVENTS	
Have	there	been	any	adverse	events?		
(if	“Yes”	complete	AE	form)	 YES	 NO	
	
Medical/Oral	History		 	 	 	 	 	 	 	 				Yes																			No	
Was	the	medical/oral	history	updated?	 																																															 															
	
Oral	Soft	Tissue	Exam	
Were	photographs	taken?	 	 	 																							 	 	 	 			
	
Was	an	oral	soft	tissue	exam	performed?	 	 	 	 	 	 			
			
Bleeding	on	Probing	
	 Did	the	subject	have	a	BOP	score	≤	10	percent	(If	answered	“No”,			
subject	needs	to	return	in	two	weeks	for	a	second	assessment	visit.)?	
Qualification					 	 	 	 	 	 	 	 	 				Yes															No	
	 Does	the	subject	qualify	for	the	study?	
	
Study	Procedures	
Whole	Saliva																																							 	 	 	 	 	 				Yes																			No																										
Was	whole	saliva	collected?																																																																																										
	
__________	ml	collected	in	__________	minutes	(max.	15)	
	
Plaque	Index	
Was	the	Plaque	Index	(PI)	completed?			 	 																																																			
The	mean	PI	was	_______	
Gingival	Index	
Was	the	Gingival	Index	(GI)	completed?																																																																						
	 	
The	mean	GI	was	_______	
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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	 Gingival	Crevicular	Fluid	 	 	 	 	 	 Yes																			No																																					
Was	a	gingival	crevicular	fluid	sample	collected	pre‐brushing?																																				 	 			
	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
Plaque	Biofilm																											 	 	 	 	 	 					
Was	sub‐gingival	plaque		and	GCF	samples	collected?																																																
	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
Oral	Hygiene	
	
Was	the	subject	instructed	to	brush	their	teeth	in	the	non‐stent	area	
for	two	minutes	twice	a	day	using	the	assigned	study	toothpaste?	
	
Was	the	subject	instructed	to	place	2ml/2.6g	of	assigned	toothpaste		
into	the	stent	before	brushing?	
	
Was	the	subject	instructed	to	keep	the	stent	in	position	while	the	rest		
of	the	mouth	is	cleaned?	
	
Was	the	subject	instructed	to	carefully	remove,	rinse	and	store	the		
stent	after	brushing?	
	
Was	the	subject	instructed	not	to	use	any	home	oral	health	care		
products	other	than	those	distributed	as	part	of	the	study?	
	
	
	 	
	
	
	
_________________________________	 	 	 			______________	
												Investigator	Signature	 	 	 	 	 Date
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
 194 
 
PLAQUE	INDEX	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
PI                      
   2    3    4    5    6    7    8  
PI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
PI                      
  15   14   13   12   11   10   9  
PI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
PI                      
  18   19   20   21   22   23   24  
PI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
PI                      
  31   30   29   28   27   26   25  
PI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
	
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
Mean	PLAQUE	INDEX	for	Patient:	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Scores	 Criteria	
0	 No	plaque	
1	 A	film	of	plaque	adhering	to	free	gingival	margin	and	adjacent	area	
of	 tooth.	 	The	plaque	may	be	seen	 in	situ	only	after	application	of	
disclosing	solution	or	by	using	the	probe	on	the	tooth	surface.	
2	 Moderate	accumulation	of	soft	deposits	within	the	gingival	pocket,	
or	 on	 the	 tooth	 and	 gingival	margin,	which	 can	 be	 seen	with	 the	
naked	eye.	
3	 Abundance	of	soft	matter	within	the	gingival	pocket	and/or	on	the	
tooth	and	gingival	margin	
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GINGIVAL	INDEX	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
GI                      
   2    3    4    5    6    7    8  
GI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
GI                      
  15   14   13   12   11   10   9  
GI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
GI                      
  18   19   20   21   22   23   24  
GI                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
GI                      
  31   30   29   28   27   26   25  
GI                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
	
	
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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Mean	GINGIVAL	INDEX	for	Patient:	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
Scores	 Criteria	 Bleeding	
0	 Absence	of	inflammation	 No	bleeding	on	probing	
1	 Mild	inflammation		
Slight	change	in	color	and	texture	
No	bleeding	on	probing	
2	 Moderate	 inflammation,	 glazing,	
redness,	edema	and	hypertrophy		
Bleeding	on	probing	
3	 Severe	inflammation,	redness	and	
hypertrophy.	Ulceration.	
Tendency	 to	 spontaneous	
bleeding	
	
	
	
	
	 	
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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BLEEDING	ON	PROBING	SCORE	
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
BOP                      
   2    3    4    5    6    7    8  
BOP                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
BOP                      
  15   14   13   12   11   10   9  
BOP                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m
BOP                      
  18   19   20   21   22   23   24  
BOP                      
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m
	
LINGUAL  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m  d  l  m 
BOP                      
  31   30   29   28   27   26   25  
BOP                      
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
	 	
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
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Percentage	BLEEDING	ON	PROBING	SCORE	for	Patient:	
								Number	of	BOP	Sites		÷		Total	Number	of	Sites	x	100		=		PERCENTAGE	
	
__________		÷		__________		x	100		=		__________	
 
 
 
 
 
 
 
 
 
 
 
 
 
	
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
Score Criteria 
0 No bleeding upon probing 
1 Presence of bleeding upon probing 
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APPENDIX J 
Power Point Instructions For At-Home Use of Dentifrice and Stent During Experimental 
Gingivitis Phase 
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APPENDIX K 
Take Home Instructions Sheet for At-Home Use of Dentifrice and Stent During 
Experimental Gingivitis Phase 
	
						
Experimental	Ginvigitis	Study	
1. Remove	plunger	from	syringe	tube	
2. Squeeze	assigned	toothpaste	into	syringe	tube	such	that	the	tube	evenly	fills	up	
from	the	end	to	the	5cc	mark	
3. Place	plunger	back	in	end	of	syringe	tube	and	push	forward	until	black	stopper	
reaches	the	toothpaste	
4. Verify	that	the	toothpaste	is	filled	to	the	2cc	mark	(the	black	stopper	should	end	at	
that	line	too)	
a. If	there	is	excess	toothpaste	in	the	syringe	(i.e.	the	toothpaste	and	black	
stopper	end	closer	to	the	plunger	end	than	the	2cc	line)‐	squeeze	out	the	
excess	toothpaste	into	the	assigned	toothpaste	tube	by	pushing	the	plunger	
forward	until	it	stops	at	the	2cc	mark	
b. If	there	is	insufficient	toothpaste	in	the	syringe	(i.e.	the	toothpaste	and	black	
stopper	end	closer	to	the	nozzle	tip	than	the	2cc	line)‐	remove	the	plunger	
from	the	syringe,	squeeze	the	desired	amount	of	toothpaste	into	the	syringe	
such	that	when	the	plunger	is	replaced	and	pushed	forward,	the	black	
stopper	stops	at	the	desired	2cc	mark	
5. Hold	the	stent	with	you	non‐dominant	hand	with	the	open	end	facing	you	
6. With	your	dominant	hand,	push	the	plunger	forward	to	as	to	squeeze	the	assigned	
toothpaste	into	the	stent	first	starting	at	the	very	base,	filling	it	as	evenly	as	possible	
on	the	bottom,	then	moving	on	to	fill	the	side	walls	of	the	stent.	Fill	the	stent	such	
that	all	the	toothpaste	is	expelled	into	the	stent	
7. Before	placing	the	stent	in	the	assigned	area	of	the	mouth,	place	it	aside	on	a	flat	
counter	top	with	the	open	end	facing	the	ceiling		
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8. With	your	assigned	toothbrush,	slightly	wet	it	to	soften	the	bristles.	Place	a	ribbon	of	
the	assigned	toothpaste	along	the	length	of	the	bristles	in	an	even	manner	
9. Set	the	toothbrush	aside	on	a	flat	countertop	
10. Have	your	timer	ready	
11. Place	the	stent	in	the	assigned	area	of	your	mouth	and	push	down	all	the	way	until	it	
is	seated	comfortably	
12. Carefully	wipe	off	any	excess	toothpaste	that	expelled	out	of	the	stent	onto	your	
gums	with	a	piece	of	tissue		
13. Turn	the	time	over	so	as	to	start	the	2	minute	hygiene	session	
14. Brush	the	remaining	3	quadrants	of	your	mouth	(not	the	area	of	the	mouth	with	the	
stent)	using	a	circular	scrub	technique	as	instructed	earlier	
15. When	2	minutes	has	elapsed	as	indicated	by	the	timer,	remove	the	toothbrush	and	
stent	from	your	mouth	
16. Gently	rinse	your	mouth	with	water	to	remove	any	remaining	toothpaste	
17. Rinse	the	toothbrush,	stent,	and	disassembled	syringe	with	warm	water.	Do	not	use	
hot	water	for	this	process	as	it	can	melt	the	plastics.	The	toothbrush	can	also	be	
used	to	remove	any	remaining	toothpaste	from	the	stent	
18. 	Place	the	clean	stent	in	the	case	provided.	Place	the	assigned	toothpaste,	stent,	and	
toothbrush	in	the	bag	provided	for	safekeeping	
19. *Do	not	use	dental	floss,	any	interproximal	cleaning	devices	(such	as	a	Waterpik®,	
ProxaBrush®,	toothpick	etc…),	or	mouthwash	anywhere	in	your	mouth	throughout	
the	duration	of	the	study*	
20. *No	home	oral	health	care	products	other	than	those	distributed	as	part	of	the	study	
protocol	may	be	used	(only	the	assigned	toothpaste	and	toothbrush	may	be	used)*	
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APPENDIX L 
Day 14 Examination Form 
	
	
	
Tooth	Brushing															 	 	 	 	 	 	 					Yes	 	 						No	
	 Has	the	subject	refrained	from	brushing	their	teeth	for	the		
last	10‐12	hours?	
	
Medical/Oral	History	
Was	the	medical/oral	history	updated?	 																																										
	
Oral	Soft	Tissue	Exam	
	 Were	photographs	taken?	 	 	 	 	 	 	 			
	
Was	an	oral	soft	tissue	exam	performed?	 	 	 																											
			
Whole	Saliva																																																																
Was	whole	saliva	collected?																																																																														
	
__________	ml	collected	in	__________	minutes	(max.	15)	
	 	
Plaque	Index	
Was	the	Plaque	Index	(PI)	completed?		 																																																			
	
The	mean	PI	was	_______	
	
Gingival	Index	
Was	the	Gingival	Index	(GI)	completed?																																																									
	 	
The	mean	GI	was	_______	
ADVERSE	EVENTS	
Have	there	been	any	adverse	events?	
(if	“Yes”	complete	AE	form)	 YES	 NO	
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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Gingival	Crevicular	Fluid	(Pre‐brushing)	 	 	 	 			Yes		 						 						No	
Was	a	gingival	crevicular	fluid	sample	collected	pre‐brushing?																																				 	 			
	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
Plaque	Biofilm																																																																																																																						
Were	sub‐gingival	plaque	samples	collected?																																					 			
	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
Gingival	Crevicular	Fluid	(Post‐brushing)	 	 	 	 	 					
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	1	hour	post‐brushing?																														
							 	 			
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	2	hours	post‐brushing?																																				 	 			
	 	
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	4	hours	post‐brushing?		
																																			 	 			
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	6	hours	post‐brushing?																																				 	 			 	
	
Oral	Hygiene	
Was	the	subject	instructed	to	continue	oral	hygiene	practices?																								
	
Payment	
	 Was	the	subject	given	$100	compensation?																																																								
	
	
	
_________________________________	 	 ______________	
Investigator	Signature	 	 														Date
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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PLAQUE	INDEX	
	
BUCCAL  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m  d  b  m 
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   2    3    4    5    6    7    8  
PI                      
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Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
Mean	PLAQUE	INDEX	for	Patient:	
	
	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Scores	 Criteria	
0	 No	plaque	
1	 A	film	of	plaque	adhering	to	free	gingival	margin	and	adjacent	area	
of	 tooth.	 	 The	 plaque	may	 be	 seen	 in	 situ	only	 after	 application	 of	
disclosing	solution	or	by	using	the	probe	on	the	tooth	surface.	
2	 Moderate	accumulation	of	 soft	deposits	within	 the	gingival	pocket,	
or	 on	 the	 tooth	 and	 gingival	 margin,	 which	 can	 be	 seen	 with	 the	
naked	eye.	
3	 Abundance	of	soft	matter	within	the	gingival	pocket	and/or	on	the	
tooth	and	gingival	margin	
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Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
	
	
Mean	GINGIVAL	INDEX	for	Patient:	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Scores	 Criteria	 Bleeding	
0	 Absence	of	inflammation	 No	bleeding	on	probing	
1	 Mild	inflammation		
Slight	change	in	color	and	texture	
No	bleeding	on	probing	
2	 Moderate	 inflammation,	 glazing,	
redness,	edema	and	hypertrophy		
Bleeding	on	probing	
3	 Severe	 inflammation,	redness	and	
hypertrophy.	Ulceration.	
Tendency	 to	 spontaneous	
bleeding	
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APPENDIX M 
Day 21 Examination Form 
	
	
Tooth	Brushing															 	 	 	 	 	 	 					Yes	 	 						No	
	 Has	the	subject	refrained	from	brushing	their	teeth	for	the		
last	10‐12	hours?	
	
Medical/Oral	History	
Was	the	medical/oral	history	updated?	 																																										
	
Oral	Soft	Tissue	Exam	
	 Were	photographs	taken?	 	 	 	 	 	 	 			
	
Was	an	oral	soft	tissue	exam	performed?	 	 	 																											
			
Whole	Saliva																																																																
Was	whole	saliva	collected?																																																																														
	
__________	ml	collected	in	__________	minutes	(max.	15)	
	 	
Plaque	Index	
Was	the	Plaque	Index	(PI)	completed?		 																																																			
The	mean	PI	was	_______	
	
Gingival	Index	
Was	the	Gingival	Index	(GI)	completed?																																																									
The	mean	GI	was	_______	
	
Gingival	Crevicular	Fluid	(Pre‐brushing)	 	 	 	 	 					
Was	sub‐gingival	plaque	samples	collected	pre‐brushing?																																				 	 			
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
ADVERSE	EVENTS	
Have	there	been	any	adverse	events?	
(if	“Yes”	complete	AE	form)	 YES	 NO	
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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Plaque	Biofilm																																												 	 	 	 	 					Yes									No																																										
Were	sub‐gingival	plaque	samples	collected?																																					 			
	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
Gingival	Crevicular	Fluid	(Post‐brushing)	 	 	 	 	 					
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	1	hour	post‐brushing?																														
							 	 			
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	2	hours	post‐brushing?																																				 	 			
	 	
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	4	hours	post‐brushing?		
																																			 	 			
Was	a	gingival	crevicular	fluid	sample	collected	from	the	same		
teeth	6	hours	post‐brushing?																																				 	 			
Pr	
ophylaxis	
Did	the	subject	receive	a	full‐mouth	prophylaxis?	
	
Was	subject	given	OHI?																								
	
Compliance	
	 Were	all	stents	collected?	
	
	 Was	remaining	product	collected	(A	quantity	of	more	than	60%		
remaining	will	indicate	lack	of	study	compliance	and	grounds	for		
dismissal	from	the	study)?	
	
Payment	
	 Was	the	subject	given	$100	compensation?																																																								
	
	
	
_________________________________	 	 	 			______________	
Investigator	Signature	 	 																																					Date
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
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Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
Mean	PLAQUE	INDEX	for	Patient:	
	
	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Scores	 Criteria	
0	 No	plaque	
1	 A	film	of	plaque	adhering	to	free	gingival	margin	and	adjacent	area	
of	 tooth.	 	 The	 plaque	may	 be	 seen	 in	 situ	only	 after	 application	 of	
disclosing	solution	or	by	using	the	probe	on	the	tooth	surface.	
2	 Moderate	accumulation	of	 soft	deposits	within	 the	gingival	pocket,	
or	 on	 the	 tooth	 and	 gingival	 margin,	 which	 can	 be	 seen	 with	 the	
naked	eye.	
3	 Abundance	of	soft	matter	within	the	gingival	pocket	and/or	on	the	
tooth	and	gingival	margin	
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GINGIVAL	INDEX	
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(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
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Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
	
	
Mean	GINGIVAL	INDEX	for	Patient:	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
Scores	 Criteria	 Bleeding	
0	 Absence	of	inflammation	 No	bleeding	on	probing	
1	 Mild	inflammation		
Slight	change	in	color	and	texture	
No	bleeding	on	probing	
2	 Moderate	 inflammation,	 glazing,	
redness,	edema	and	hypertrophy		
Bleeding	on	probing	
3	 Severe	 inflammation,	redness	and	
hypertrophy.	Ulceration.	
Tendency	 to	 spontaneous	
bleeding	
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APPENDIX N 
Day 35 Examination Form  
	
ADVERSE	EVENTS	
Have	there	been	any	adverse	events?		
(if	“Yes”	complete	AE	form)	 YES	 NO	
	
Tooth	Brushing																																																																																																																						
	 Has	the	subject	refrained	from	brushing	their	teeth	for	the																	 		Yes	 	 No	
last	10‐12	hours?	
	
Medical/Oral	History	
Was	the	medical/oral	history	updated?	 																																								 																Yes	 	 		No	
	
Oral	Soft	Tissue	Exam	
	 Were	photographs	taken?	 	 	 	 	 	 	 		Yes	 	 		No	
	
Was	an	oral	soft	tissue	exam	performed?	 	 	 																													Yes																				No	
			
Whole	Saliva																																																																
Was	whole	saliva	collected?																																																																																 	 	 	
	 	 	 	 	 	 	 	 	 	 	 	 		Yes																				No	
__________	ml	collected	in	__________	minutes	(max.	15)	
	
Plaque	Index	
Was	the	Plaque	Index	(PI)	completed?			 	 																																												Yes	 															No	
The	mean	PI	was	_______	
	
Gingival	Index	
Was	the	Gingival	Index	(GI)	completed?		 	 	 	 															Yes																				No	
The	mean	GI	was	_______	
	
Gingival	Crevicular	Fluid	
Was	a	gingival	crevicular	fluid	sample	collected?																																				 Yes	 	 No	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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Plaque	Biofilm																																																																																																																						
Were	sub‐gingival	plaque	samples	collected?																																																																					Yes																		
No	
	 	
Which	teeth	were	sampled?			_____					_____					_____					_____	
	 				
	
Payment	
	 Was	the	subject	given	$300	compensation?																																																																						Yes																	
No	
	
	
	
	
	
	
_________________________________	 	 	 			______________	
Investigator	Signature	 	 																																					Date
Date Patient Number Patient Initials
(MON/DD/YY)
 /          /
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of 
Colgate Total® - a Pilot Investigation
University of Michigan
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(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
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Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
	
Mean	PLAQUE	INDEX	for	Patient:	
	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Scores	 Criteria	
0	 No	plaque	
1	 A	film	of	plaque	adhering	to	free	gingival	margin	and	adjacent	area	
of	 tooth.	 	The	plaque	may	be	seen	 in	situ	only	after	application	of	
disclosing	solution	or	by	using	the	probe	on	the	tooth	surface.	
2	 Moderate	accumulation	of	soft	deposits	within	the	gingival	pocket,	
or	 on	 the	 tooth	 and	 gingival	margin,	which	 can	 be	 seen	with	 the	
naked	eye.	
3	 Abundance	of	soft	matter	within	the	gingival	pocket	and/or	on	the	
tooth	and	gingival	margin	
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GINGIVAL	INDEX	
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Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
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Mean	GINGIVAL	INDEX	for	Patient:	
Total		÷		Number	of	Sites		=		MEAN	
	
__________		÷		__________		=		__________	
	
	
	
Experimental Gingivitis Model for the Study of Anti-Inflammatory Effects of Colgate Total® - a Pilot Investigation 
University	of	Michigan	
Date	
(MM	/	DD	/	YY)	
Patient	Number	 Patient	Initials	
	 	
/																	/	
Scores	 Criteria	 Bleeding	
0	 Absence	of	inflammation	 No	bleeding	on	probing	
1	 Mild	inflammation		
Slight	change	in	color	and	texture	
No	bleeding	on	probing	
2	 Moderate	 inflammation,	 glazing,	
redness,	edema	and	hypertrophy		
Bleeding	on	probing	
3	 Severe	inflammation,	redness	and	
hypertrophy.	Ulceration.	
Tendency	 to	 spontaneous	
bleeding	
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